• Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow.
    • Kinney AY, Walters ST, Lin Y, Lu SE, Kim A, Ani J, Heidt E, Le Compte CJG, O'Malley D, Stroup A, Paddock LE, Grumet S, Boyce TW, Toppmeyer DL, McDougall JA.
    • J Clin Oncol. 2023 Feb 14:JCO2200751. doi: 10.1200/JCO.22.00751. Epub ahead of print.

    Related:

    •• Identifier: NCT03326713: Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project (GRACE). (ClinicalTrials.gov . Accessed 2023 Feb 14.)

    • Mainstream genetic testing for high-grade ovarian, tubal and peritoneal cancers: A tertiary referral centre experience.
    • Srinivasa S, Bowman M, Titterton L, Harnett P, Brand A, Kirk J, Ragunathan A.
    • Aust N Z J Obstet Gynaecol. 2023 Feb 13. doi: 10.1111/ajo.13650. Epub ahead of print.
    • Implementing digital systems to facilitate genetic testing for hereditary cancer syndromes: An observational study of four clinical workflows.
    • Wang C, Lu H, Bowen DJ, Xuan Z.
    • Genet Med. 2023 Feb 10:S1098-3600(23)00815-8. doi: 10.1016/j.gim.2023.100802. Epub ahead of print.
    • Socioeconomic Factors Are Associated With Disparities in Germline Testing in Pancreatic Cancer.
    • King D, Scott R.
    • OncLive. 2023 Feb 5.
    • Proactive breast cancer risk assessment in primary care: a review based on the principles of screening.
    • Usher-Smith JA, Hindmarch S, French DP, Tischkowitz M, Moorthie S, Walter FM, Dennison RA, Stutzin Donoso F, Archer S, Taylor L, Emery J, Morris S, Easton DF, Antoniou AC.
    • Br J Cancer. 2023 Feb 3:1–11. doi: 10.1038/s41416-023-02145-w. Epub ahead of print.
    • Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology.
    • Ray T.
    • Precision Oncology News. 2023 Feb 1.
    • News
    • Testing for Inherited Susceptibility to Breast Cancer.
    • Robson M.
    • Hematol Oncol Clin North Am. 2023 Feb;37(1):17-31. doi: 10.1016/j.hoc.2022.08.003.
    • Review
    • Dr. King on Delays in Access to Germline Testing in Pancreatic Cancer.
    • King D.
    • OncLive. OncLive TV. 2023 Jan 31.
    • Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer.
    • Heitz F, Ataseven B, Staniczok C, Denkert C, Rhiem K, Hahnen E, Heikaus S, Moubarak M, Welz J, Dagres T, Vrentas V, Bommert M, Schneider S, Concin N, Harter P.
    • Cancers (Basel). 2023 Jan 29;15(3):818. doi: 10.3390/cancers15030818.
    • Financial toxicity in BRCA1 and BRCA2 carriers.
    • Proussaloglou EM, Rosenthal AE, Raker CA, Wilbur JS, Stuckey AR, Robison KM.
    • Gynecol Oncol. 2023 Jan 24;170:160-166. doi: 10.1016/j.ygyno.2023.01.007. Epub ahead of print.
    • Disparities in the uptake of cascade genetic testing among family members of mutation-positive lynch and HBOC syndrome patients. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Namey E, Dudley B, Horton C, Carraway C, Zhou J, Hatton W, Komala T, Milliard C, Namey T, Karloski E, Brand R.
    • Fam Cancer. [O-05: Research Categories» Lynch syndrome.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Development of an EHR-integrated electronic tool for the identification of individuals at-risk for an inherited cancer syndrome. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Singh V, Rafter T, Sharbatji M, Brierley K, Healy C, Liu J, Brown Q, Xicola R, Kashyap N, Llor X.
    • Fam Cancer. [O-06: Research Categories» Lynch syndrome.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Importance of timely genetics services and critical evaluation of diagnosis and reported family history when assessing for hereditary cancer syndromes. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Malca S.
    • Fam Cancer. [P-08: Case Reports» Case Series on any topic.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract, Case report
    • Actionable pathogenic germline variants discovered by panel-based hereditary cancer testing in families with previously identified pathogenic variants. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Neumann C, Mcsweeny M, Rainey K, Campbell H, Nguyen C, Hall M.
    • Fam Cancer. [P-13: Research Categories » Counseling, Behavioral Health, Psychosocial, and Survivorship.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Innovative approaches to expanding cancer genetic testing in Michigan (project might). [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Stoffel EM, Austin S, Koeppe E, Hanson EN, Delacroix E, Rizzo E, Griggs JJ, Resnicow K.
    • Fam Cancer. [P-17: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Implementation of a multi modal best practice bundle to improve genetic testing referral for pancreatic cancer patients. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Blazey M, Lee T, Hendershot A, Bartell N, Marino D.
    • Fam Cancer. [P-20: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Attitudes about sharing genetic test results in families with hereditary cancer syndromes. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Guivatchian E, Koeppe E, Stoffel EM.
    • Fam Cancer. [P-22: Research Categories » Other.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Oncologist knowledge of cost of genetic testing. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Weiner S, Austin SE, Carr G, Kidwell KM, Resnicow K, Martinez Stoffel E, Griggs J.
    • Fam Cancer. [P-23: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Decreased time from diagnosis to referral of PDAC patients: a quality improvement effort. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Cohen SA, Doran W, Harshbarger C, Nixon DM, Lichtenberg E, Cantafio A.
    • Fam Cancer. [P-24: Research Categories» Delivery of Care and Alternative Models.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Pairing tumor testing with germline sequencing increases the number of pathogenic germline variants identified. [2022 CGA-IGC Annual Meeting: The collaborative group of the Americas on Inherited Gastrointestinal Cancer November 11–13, 2022.]
    • Nefeli Dimopoulos C, Brierly K, Gibson J, Walther Z, Llor X.
    • Fam Cancer. [P-32: Research Categories» Gastric cancer-related syndromes.] 2023 Jan 23. doi: 10.1007/s10689-022-00324-x. Epub ahead of print.
    • Conference abstract
    • Genetic Testing for Cancer Risk and Perceived Importance of Genetic Information Among US Population by Race and Ethnicity: a Cross-sectional Study.
    • Hong YR, Yadav S, Wang R, Vadaparampil S, Bian J, George TJ, Braithwaite D.
    • J Racial Ethn Health Disparities. 2023 Jan 23. doi: 10.1007/s40615-023-01526-4. Epub ahead of print.
    • Genetic Testing Challenges in Oncology: Patient With Pending Bill Has BRCA1 Result Withheld.
    • Ray T.
    • Precision Oncology News. 2023 Jan 23.
    • Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan.
    • Nomura H, Abe A, Fusegi A, Yoshimitsu T, Misaka S, Murakami A, Matsumoto T, Tsumura S, Kanno M, Aoki Y, Netsu S, Omi M, Tanigawa T, Okamoto S, Omatsu K, Yunokawa M, Kanao H, Habano E, Arakawa H, Kaneko K, Ueki A, Haruyama Y, Inari H, Ueno T.
    • Sci Rep. 2023 Jan 19;13(1):1018. doi: 10.1038/s41598-023-28304-w.
    • Racial Differences in Germline Genetic Testing for Prostate Cancer: A Systematic Review.
    • Briggs LG, Steele GL, Qian ZJ, Subbana S, Alkhatib KY, Labban M, Langbein BJ, Nguyen DD, Cellini J, Kilbridge K, Kibel AS, Trinh QD, Rana HQ, Cole AP.
    • JCO Oncol Pract. 2023 Jan 12:OP2200634. doi: 10.1200/OP.22.00634. Epub ahead of print.
    • Review

    Related:

    •• Commentary:

    Germline Testing in Prostate Cancer: Implementation and Disparities of Care.

    • Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer.
    • Kwon DH, Gordon KM, Tong B, Borno HT, Beigh M, Fattah D, Schleicher A, Aggarwal RR, Blanco AM, Small EJ, Dhawan M.
    • JCO Oncol Pract. 2023 Jan 12:OP2200638. doi: 10.1200/OP.22.00638. Epub ahead of print.

    Related:

    •• Commentary:

    Germline Testing in Prostate Cancer: Implementation and Disparities of Care.

    • Assessing Breast and Ovarian Cancer Risk Prior to Gender-Affirming Surgery.
    • Cortina CS.
    • JAMA Surg. 2023 Jan 11. doi: 10.1001/jamasurg.2022.5447. Epub ahead of print.
    • Commentary
    • January 2023: Awareness of genetic testing – results and analysis from the 2020 Health Information National Trends Survey.
    • Mechanic L, Helzlsouer K.
    • Genet Med. GenePOD. 2023 Jan 9.

    Related:

    •• Original research:

    Awareness and use of genetic testing: An analysis of the Health Information National Trends Survey 2020.

    • Adding a genetic counseling assistant improves efficiency of hereditary cancer genetic counseling without impacting patient experience.
    • Cohen SA, Nixon DM, Lichtenberg E.
    • J Genet Couns. 2023 Jan 8. doi: 10.1002/jgc4.1671. Epub ahead of print.
    • Breast Cancer Advances in 2022 Showcase a Shifting Landscape.
    • Sparano JA.
    • OncLive. 2023 Jan 6.
    • Missed opportunities in the real-world genetic testing in BRCA gene variant carriers with cancers meeting NCCN criteria.
    • Lee SS, Rajeev P, Finning S, Oh C, Pothuri B.
    • Gynecol Oncol. 2023 Jan 5;170:32-37. doi: 10.1016/j.ygyno.2022.12.015. Epub ahead of print.
    • Current Issues in the Management of Patients With Newly Diagnosed Advanced-Stage High-Grade Serous Carcinoma of the Ovary.
    • Penn CA, Alvarez RD.
    • JCO Oncol Pract. 2023 Jan 5:OP2200461. doi: 10.1200/OP.22.00461. Epub ahead of print.
    • Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention.
    • Seibert TM, Garraway IP, Plym A, Mahal BA, Giri V, Jacobs MF, Cheng HH, Loeb S, Helfand BT, Eeles RA, Morgan TM.
    • Eur Urol. 2023 Jan 4:S0302-2838(22)02870-6. doi: 10.1016/j.eururo.2022.12.021. Epub ahead of print.
    • Review
    • Internet-Based Germline Genetic Testing for Men With Metastatic Prostate Cancer.
    • Cheng HH, Sokolova AO, Gulati R, Bowen D, Knerr SA, Klemfuss N, Grivas P, Hsieh A, Lee JK, Schweizer MT, Yezefski T, Zhou A, Yu EY, Nelson PS, Montgomery B.
    • JCO Precis Oncol. 2023 Jan;7:e2200104. doi: 10.1200/PO.22.00104.
    • Outcomes of Universal Point-of-Care Genetic Testing in Diverse Patients With Pancreatic Ductal Adenocarcinoma.
    • Drogan CM, Kindler HL, Gao G, Kupfer SS.
    • JCO Precis Oncol. 2023 Jan;7:e2200196. doi: 10.1200/PO.22.00196.
    • Genetic Testing in the Latinx community: Impact of acculturation and provider relationships.
    • Ioffe YJ, Hong L, Joachim-Célestin M, Soret C, Montgomery S, Unternaehrer JJ.
    • Gynecol Oncol. 2022 Dec 26;169:125-130. doi: 10.1016/j.ygyno.2022.12.001. Epub ahead of print.
    • Development of a comprehensive approach to adult hereditary cancer testing in Ontario.
    • Bell KA, Kim R, Aronson M, Gillies B, Ali Awan A, Chun K, Hart J, Healey R, Kim L, Klaric G, Panabaker K, Sabatini PJB, Sadikovic B, Selvarajah S, Smith AC, Stockley TL, Vaags AK, Eisen A, Pollett A, Feilotter H.
    • J Med Genet. 2022 Dec 23:jmg-2022-108945. doi: 10.1136/jmg-2022-108945. Epub ahead of print.
    • Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study.
    • Taji T, Odan N, Kataoka Y, Ikeda M, Yamaguchi A, Suzuki E, Suwa H.
    • Breast Cancer. 2022 Dec 22. doi: 10.1007/s12282-022-01424-3. Epub ahead of print.
    • Genetic testing in privately insured women with surgically treated breast cancer.
    • Dinan MA, Pitafi S, Greenup RA, Long JB, Gross CP.
    • Breast Cancer Res Treat. 2022 Dec 21. doi: 10.1007/s10549-022-06829-4. Epub ahead of print.
    • Development and Psychometric Evaluation of Healthcare Access Measures among Women with Ovarian Cancer.
    • Akinyemiju T, Joshi A, Deveaux A, Wilson LE, Chen D, Meernik C, Bevel M, Gathings J, Fish L, Barrett N, Worthy V, Boyce X, Martin K, Robinson C, Pisu M, Liang M, Potosky A, Huang B, Ward K, Schymura MJ, Berchuck A, Reeve BB.
    • Cancers (Basel). 2022 Dec 19;14(24):6266. doi: 10.3390/cancers14246266.
    • Evaluation of out-of-pocket pay genetic testing in a publicly funded healthcare system.
    • Grant P, Cook CB, Langlois S, Nuk J, Mung S, Zhang Q; GenCOUNSEL Study, Lynd LD, Austin J, Elliott AM.
    • Clin Genet. 2022 Dec 11. doi: 10.1111/cge.14276. Epub ahead of print.
    • Understanding cancer genetic risk assessment motivations in a remote tailored risk communication and navigation intervention randomized controlled trial.
    • Le Compte CG, Lu SE, Ani J, McDougall J, Walters ST, Toppmeyer D, Boyce TW, Stroup A, Paddock L, Grumet S, Lin Y, Heidt E, Kinney AY.
    • Health Psychol Behav Med. 2022 Dec 9;10(1):1190-1215. doi: 10.1080/21642850.2022.2150623.

    Related:

    •• Identifier: NCT03326713: Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project (GRACE). (ClinicalTrials.gov . Accessed 2022 Dec 16.)

    • Cancer Moonshot 2.0, health equity and BRCA1/2 testing.
    • Sorscher S.
    • J Cancer Policy. 2022 Dec 8:100379. doi: 10.1016/j.jcpo.2022.100379. Epub ahead of print.
    • Letter
    • Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients.
    • Matsubayashi H, Todaka A, Kawakami T, Hamauchi S, Yokota T, Higashigawa S, Kiyozumi Y, Harada R, Kado N, Nishimura S, Ishiwatari H, Sato J, Niiya F, Ono H, Sugiura T, Sasaki K, Yasui H, Yamazaki K.
    • J Hum Genet. 2022 Dec 8. doi: 10.1038/s10038-022-01097-y. Epub ahead of print.
    • Patient uptake of updated genetic testing following uninformative BRCA1 and BRCA2 results.
    • Macklin-Mantia SK, Clift KE, Maimone S, Hodge DO, Riegert-Johnson D, Hines SL.
    • J Genet Couns. 2022 Dec 7. doi: 10.1002/jgc4.1665. Epub ahead of print.
    • Does mainstream BRCA testing affect surgical decision-making in newly-diagnosed breast cancer patients?
    • Ain Q, Richardson C, Mutebi M, George A, Kemp Z, Rusby JE.
    • Breast. 2022 Dec 6:S0960-9776(22)00193-X. doi: 10.1016/j.breast.2022.12.001. Epub ahead of print.
    • Sociodemographic, Clinical, and Variation Outcomes for Breast Cancer and Breast Cancer-Related Mutations in a Ten-Year Cohort From Neiva, Huila, Colombia.
    • Olaya J, Sanjuan J, Torres-Lopez D, Olaya L, Gutierrez-Vargas M, Olaya G, Olaya JD.
    • Cureus. 2022 Dec 6;14(12):e32257. doi: 10.7759/cureus.32257.
    • Awareness and use of genetic testing: An analysis of the Health Information National Trends Survey 2020.
    • Tiner JC, Mechanic LE, Gallicchio L, Gillanders EM, Helzlsouer KJ.
    • Genet Med. 2022 Dec;24(12):2526-2534. doi: 10.1016/j.gim.2022.08.023. Epub 2022 Sep 22.

    Related:

    •• Podcast: January 2023: Awareness of genetic testing – results and analysis from the 2020 Health Information National Trends Survey. (Genetics in Medicine GenePOD)

    • A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot.
    • Torr B, Jones C, Choi S, Allen S, Kavanaugh G, Hamill M, Garrett A, MacMahon S, Loong L, Reay A, Yuan L, Valganon Petrizan M, Monson K, Perry N, Fallowfield L, Jenkins V, Gold R, Taylor A, Gabe R, Wiggins J, Lucassen A, Manchanda R, Gandhi A, George A, Hubank M, Kemp Z, Evans DG, Bremner S, Turnbull C.
    • J Med Genet. 2022 Dec;59(12):1179-1188. doi: 10.1136/jmg-2022-108655. Epub 2022 Jul 22.

    Related:

    •• Trial registration number: ISRCTN87845055: BRCA-DIRECT- Is digitally delivered information about genetic testing feasible, effective and acceptable to women with breast cancer?. (ISRCTN registry)

    •• Press: UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer. (GenomeWeb)

    • Management of patients with advanced prostate cancer in Japan: 'real-world' consideration of the results from the Advanced Prostate Cancer Consensus Conference.
    • Fujita K, Suzuki H, Hinata N, Miura Y, Edamura K, Tabata KI, Arai G, Matsubara N, Yasumizu Y, Kosaka T, Oya M, Sugimoto M.
    • Transl Androl Urol. 2022 Dec;11(12):1771-1785. doi: 10.21037/tau-22-396.

    Related:

    •• Commentary:

    Assessment of real-world application of advanced prostate cancer management in Japan.

    • Referral, Genetic Counselling, and BRCA Testing in the Manitoba High-Grade Serous Ovarian Cancer Population, 2004–2019.
    • Winchar K, Lambert P, McManus KJ, Chodirker B, Kean S, Serfas K, Decker K, Nachtigal MW, Altman AD.
    • Curr Oncol. 2022 Nov 30;29(12):9365-9376. doi: 10.3390/curroncol29120735.
    • BRCAShare-Assessment of an animated digital message for intrafamilial communication of pathogenic variant positive test results: A feasibility study.
    • Aeilts AM, Carpenter KM, Hovick SR, Byrne L, Shoben AB, Senter L.
    • J Genet Couns. 2022 Nov 25. doi: 10.1002/jgc4.1656. Epub ahead of print.
    • UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer.
    • [No author given]
    • GenomeWeb. The Scan. 2022 Nov 23.

    Related:

    •• Original research:

    A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot.

    • Four-in-Five Eligible Breast Cancer Patients Not Informed of Genomic Testing Options.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Nov 21.
    • Fatalism and metaphor in Confucianism: A qualitative study of barriers to genetic testing among first-degree relatives of hereditary cancer patients from China.
    • Jiang C, Liu L, Wang Y, Wu L, Zhang W, Wu X.
    • Psychooncology. 2022 Nov 15. doi: 10.1002/pon.6068. Epub ahead of print.
    • Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate Cancer.
    • Hollasch M, Antonarakis ES.
    • OncLive. 2022 Nov 11.
    • Testing a deliberative democracy method with citizens of African ancestry to weigh pros and cons of targeted screening for hereditary breast and ovarian cancer risk.
    • Guan Y, Pathak S, Ballard D, Veluswamy JK, McCullough LE, McBride CM, Gornick MC.
    • Front Public Health. 2022 Nov 8;10:984926. doi: 10.3389/fpubh.2022.984926.
    • Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.
    • Clark NM, Roberts EA, Fedorenko C, Sun Q, Dubard-Gault M, Handford C, Yung R, Cheng HH, Sham JG, Norquist BM, Flanagan MR.
    • Ann Surg Oncol. 2022 Nov 5. doi: 10.1245/s10434-022-12755-y. Epub ahead of print.
    • BRCA1/2 Mutation Testing in Patients with HER2-Negative Advanced Breast Cancer: Real-World Data from the United States, Europe, and Israel.
    • Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP.
    • Cancers (Basel). 2022 Nov 2;14(21):5399. doi: 10.3390/cancers14215399.
    • Disparities in cancer genetics care by race/ethnicity among pan-cancer patients with pathogenic germline variants.
    • Liu YL, Maio A, Kemel Y, Salo-Mullen EE, Sheehan M, Tejada PR, Trottier M, Arnold AG, Fleischut MH, Latham A, Carlo MI, Murciano-Goroff YR, Walsh MF, Mandelker D, Mehta N, Bandlamudi C, Arora K, Zehir A, Berger MF, Solit DB, Aghajanian C, Diaz LA Jr, Robson ME, Brown CL, Offit K, Hamilton JG, Stadler ZK.
    • Cancer. 2022 Nov 1;128(21):3870-3879. doi: 10.1002/cncr.34434. Epub 2022 Aug 30.
    • The first Chinese National Union of Real-world Gynaecological Oncology Research and Patient Management Platform: A retrospective study.
    • Zeng S, Chi J, Liu J, Jiao X, Liu X, Yu Y, Li R, Huo Y, Ma G, Zhao Y, Wang L, Zhou Q, Zou D, Cheng X, Li Q, Wang J, Yao S, Zhao W, Xia B, Chen Y, Fan J, Wang W, Hong L, Guo R, Liu Z, Gao Y, Li J, Zhang B, Yu J, Hu T, Zhang W, Shan W, Peng Z, Li M, Xie X, Ma D, Gao Q.
    • BJOG. 2022 Nov;129 Suppl 2:60-69. doi: 10.1111/1471-0528.17328.
    • Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.
    • Mahtani R, Niyazov A, Lewis K, Rider A, Massey L, Arondekar B, Lux MP.
    • Adv Ther. 2022 Oct 28. doi: 10.1007/s12325-022-02302-2. Epub ahead of print.
    • Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
    • Zang B, Helms M, Besch L, Kalmbach N, Stegen S, Blohmer JU, Speiser D.
    • Arch Gynecol Obstet. 2022 Oct 28. doi: 10.1007/s00404-022-06819-3. Epub ahead of print.
    • What happens in the long term: Uptake of cancer surveillance and prevention strategies among at-risk relatives with pathogenic variants detected via cascade testing.
    • Frey MK, Ahsan MD, Badiner N, Lin J, Narayan P, Nitecki R, Rauh-Hain JA, Moss H, Fowlkes RK, Thomas C, Bergeron H, Christos P, Levi SR, Blank SV, Holcomb K, Cantillo E, Sharaf RN, Lipkin S, Offit K, Chapman-Davis E.
    • Cancer. 2022 Oct 27. doi: 10.1002/cncr.34482. Epub ahead of print.
    • Latinx attitudes, barriers, and experiences with genetic counseling and testing: A systematic review.
    • Dron HA, Bucio D, Young JL, Tabor HK, Cho MK.
    • J Genet Couns. 2022 Oct 27. doi: 10.1002/jgc4.1632. Epub ahead of print.
    • From the patient to the population: Use of genomics for population screening.
    • Mighton C, Shickh S, Aguda V, Krishnapillai S, Adi-Wauran E, Bombard Y.
    • Front Genet. 2022 Oct 24;13:893832. doi: 10.3389/fgene.2022.893832.
    • Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO.
    • Hoffman TL, Kershberg H, Goff J, Holmquist KJ, Haque R, Alvarado M.
    • Fam Cancer. 2022 Oct 20. doi: 10.1007/s10689-022-00317-w. Epub ahead of print.
    • Uptake of BRCA1/BRCA2 predictive genetic testing in an Irish population is low: a missed opportunity.
    • O'Reilly DE, Dooley L, Watson GA, Clarke R, Nolan A, Nolan C, Berkeley E, Farrell M, McDevitt T, Rogers M, Clabby C, Gallagher DJ.
    • Ir J Med Sci. 2022 Oct 19. doi: 10.1007/s11845-022-03176-7. Epub ahead of print.
    • Relatives from Hereditary Breast and Ovarian Cancer and Lynch Syndrome Families Forgoing Genetic Testing: Findings from the Swiss CASCADE Cohort.
    • Sarki M, Ming C, Aceti M, Fink G, Aissaoui S, Bürki N, Graffeo R, Heinimann K, Zufferey MC, Monnerat C, Rabaglio M, Zürrer-Härdi U, Chappuis PO, Katapodi MC.
    • J Pers Med. 2022 Oct 19;12(10):1740. doi: 10.3390/jpm12101740.
    • Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications.
    • Bhardwaj PV, Abdou YG.
    • Curr Oncol Rep. 2022 Oct 18. doi: 10.1007/s11912-022-01340-x. Epub ahead of print.
    • Review
    • Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study.
    • Shirota H, Komine K, Takahashi M, Takahashi S, Miyauchi E, Niizuma H, Tada H, Shimada M, Niihori T, Aoki Y, Sugiyama I, Kawamura M, Yasuda J, Suzuki S, Iwaya T, Saito M, Saito T, Shibata H, Furukawa T, Ishioka C.
    • Cancer Med. 2022 Oct 17. doi: 10.1002/cam4.5349. Epub ahead of print.
    • Proband-mediated interventions to increase disclosure of genetic risk in families with a BRCA or Lynch syndrome condition: a systematic review.
    • Young AL, Imran A, Spoelma MJ, Williams R, Tucker KM, Halliday J, Forrest LE, Wakefield CE, Butow PN.
    • Eur J Hum Genet. 2022 Oct 17. doi: 10.1038/s41431-022-01200-z. Epub ahead of print.
    • An Accessible Communication System for Population-Based Genetic Testing: Development and Usability Study.
    • Coffin T, Bowen D, Swisher E, Lu K, Rayes N, Norquist B, Blank S, Levine D, Bakkum-Gamez J, Fleming G, Olopade O, D'Andrea A, Nebgen D, Peterson C, Munsell M, Gavin K, Lechner R, Crase J, Polinsky D, Romero I.
    • JMIR Form Res. 2022 Oct 17;6(10):e34055. doi: 10.2196/34055.
    • Hereditary Breast and Ovarian Cancer Service in Sparsely Populated Western Pomerania.
    • Felbor U, Bülow R, Schmutzler RK, Rath M.
    • Healthcare (Basel). 2022 Oct 13;10(10):2021. doi: 10.3390/healthcare10102021.
    • Interest in genetic testing and risk-reducing behavioral changes: results from a community health assessment in New York City.
    • Lima SM, Nazareth M, Schmitt KM, Reyes A, Fleck E, Schwartz GK, Terry MB, Hillyer GC.
    • J Community Genet. 2022 Oct 13. doi: 10.1007/s12687-022-00610-2. Epub ahead of print.
    • Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome?
    • Kahn RM, Ahsan MD, Chapman-Davis E, Holcomb K, Nitecki R, Rauh-Hain JA, Fowlkes RK, Tubito F, Pires M, Christos PJ, Tkachuk K, Krinsky H, Sharaf RN, Offit K, Lipkin S, Frey MK.
    • Fam Cancer. 2022 Oct 8. doi: 10.1007/s10689-022-00316-x. Epub ahead of print.
    • Provider discussion of genetic counseling among high-risk Spanish-preferring Latina breast cancer survivors.
    • Conley CC, Rivera Rivera JN, Castro-Figueroa EM, Moreno L, Dutil J, García JD, Ricker C, Quinn GP, Soliman H, Vadaparampil ST.
    • Transl Behav Med. 2022 Oct 7;12(9):900-908. doi: 10.1093/tbm/ibac031.
    • Temporal Patterns and Adoption of Germline and Somatic BRCA Testing in Ovarian Cancer.
    • Huepenbecker SP, Wright JD, Downer MK, Incerti D, Luhn P, Dolado I, Bastiere-Truchot L, Lin YG, Chan JK, Meyer LA.
    • Obstet Gynecol. 2022 Oct 6. doi: 10.1097/AOG.0000000000004958. Epub ahead of print.
    • Genetic testing for patients at risk of hereditary breast and ovarian cancer.
    • DeTroye A, Gabbett K, Yi C, Judice M, Luu V, Nelson B, Gregory T.
    • JAAPA. 2022 Oct 1;35(10):48-52. doi: 10.1097/01.JAA.0000873796.81961.da.
    • Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer.
    • Ip E, Young AL, Scheinberg T, Harrison M, Beale P, Goodwin A.
    • Asia Pac J Clin Oncol. 2022 Oct;18(5):e414-e419. doi: 10.1111/ajco.13741. Epub 2022 Jan 30.
    • Use of eConsult to enhance genetics service delivery in primary care: A multimethod study.
    • Carroll JC, Liddy C, Afkham A, Keely E, Goh ES, Graham GE, Permaul JA, Allanson J, Heisey R, Makuwaza T, Manca DP, O'Brien MA, Grunfeld E; CanIMPACT.
    • Genet Med. 2022 Oct;24(10):2034-2041. doi: 10.1016/j.gim.2022.07.003. Epub 2022 Aug 10.
    • Mainstream germline genetic testing for patients with epithelial ovarian cancer leads to higher testing rates and a reduction in genetics-related healthcare costs from a healthcare payer perspective.
    • Bokkers K, Frederix GWJ, Velthuizen ME, van der Aa M, Gerestein CG, van Dorst EBL, Lange JG, Louwers JA, Koole W, Zweemer RP, Ausems MGEM.
    • Gynecol Oncol. 2022 Oct;167(1):115-122. doi: 10.1016/j.ygyno.2022.08.011. Epub 2022 Aug 26.
    • BRCA1/2 Variants Identified Through Tumor Genomic Profiling: Assessing Genetic Counseling Outcomes.
    • Harriman JW, Espinel WF, Vagher J, Gammon A.
    • JCO Precis Oncol. 2022 Oct;6:e2100375. doi: 10.1200/PO.21.00375.
    • Prenatal genetic counseling practices regarding recommendations for cancer genetic counseling: A retrospective chart review from two academic institutions.
    • Saba LF, Sullivan CM, Solomon T, Huguenard S, Nassef SA.
    • J Genet Couns. 2022 Oct;31(5):1062-1070. doi: 10.1002/jgc4.1577. Epub 2022 Apr 18.
    • Attitudes and training needs of oncologists and surgeons in mainstreaming breast cancer genetic counseling in a low-to-middle income Asian country.
    • Lee YQ, Yoon SY, Hassan T, Padmanabhan H, Yip CH, Keng WT, Thong MK, Ahmad Annuar MA, Mohd Taib NA, Teo SH.
    • J Genet Couns. 2022 Oct;31(5):1080-1089. doi: 10.1002/jgc4.1579. Epub 2022 Apr 28.
    • Use of a chatbot to increase uptake of cascade genetic testing.
    • Schmidlen T, Jones CL, Campbell-Salome G, McCormick CZ, Vanenkevort E, Sturm AC.
    • J Genet Couns. 2022 Oct;31(5):1219-1230. doi: 10.1002/jgc4.1592. Epub 2022 May 26.
    • Cancer screening and breast cancer family history in Spanish-speaking Hispanic/Latina women in California.
    • Tamayo LI, Perez F, Perez A, Hernandez M, Martinez A, Huang X, Zavala V, Ziv E, Neuhausen S, Carvajal-Carmona LG, Duron Y, Fejerman L.
    • Front Oncol. 2022 Sep 28;12:940162. doi: 10.3389/fonc.2022.940162.
    • Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients.
    • Culver JO, Freiberg Y, Ricker C, Comeaux JG, Chang EY, Banerjee V, Sturgeon D, Solomon I, Kagey J, Dobre MG, Carey J, Carr A, Cho S, Lu J, Kang IM, Patel K, Terando A, Ye JC, Li M, Lerman C, Spicer D, Nelson M.
    • Ann Surg Oncol. 2022 Sep 26. doi: 10.1245/s10434-022-12595-w. Epub ahead of print.
    • Using Social Media to Facilitate Communication About Women's Testing: Tool Validation Study.
    • Coffin T, Bowen D, Lu K, Swisher EM, Rayes N, Norquist B, Blank SV, Levine DA, Bakkum-Gamez JN, Fleming GF, I Olopade O, Romero I, D'Andrea A, Nebgen DR, Peterson C, Munsell MF, Gavin K, Crase J, Polinsky D, Lechner R.
    • JMIR Form Res. 2022 Sep 26;6(9):e35035. doi: 10.2196/35035.

    Related:

    Identifier: NCT02993068: Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible). (ClinicalTrials.gov)

    • Genetic Tests Create Treatment Opportunities and Confusion for Breast Cancer Patients.
    • Andrews M.
    • KHN [Kaiser Health News]. 2022 Sep 21.

    Related:

    Press: Genetic Tests Create Treatment Opportunities and Confusion for Breast Cancer Patients. (Medscape)

    • Implementation and outcome evaluations of a multi-site improvement program in cancer genetics.
    • Bednar EM, Harper B, Walsh MT Jr, Rechis R, Bilbao M, Carr RL, Eppolito AL, Goedde T, Levin B, Mattie K, Morman NA, Rath K, Russ P, Siettmann JM, Warshal D, Wise E, Yobbi C, Lu KH.
    • J Genet Couns. 2022 Sep 19. doi: 10.1002/jgc4.1633. Epub ahead of print.
    • Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer.
    • Esplin ED, Nielsen SM, Bristow SL, Garber JE, Hampel H, Rana HQ, Samadder NJ, Shore ND, Nussbaum RL.
    • JCO Precis Oncol. 2022 Sep [2022 Sep 15];6:e2100516. doi: 10.1200/PO.21.00516.
    • Biomarker Test Access for Precision Oncology Varies Widely in Europe, ESMO Survey Finds.
    • Hopkins C.
    • Precision Oncology News. 2022 Sep 14.
    • Conference News
    • Screening for Individuals at Risk for Hereditary Breast and Ovarian Cancer: A Statewide Initiative, Georgia, 2012-2020.
    • Veitinger JK, Kerber AS, Gabram-Mendola SGA, Liu Y, Durham LM, Durrence D, Berzen AK, Shin JY, Snyder C, Bellcross CA, Guan Y.
    • Am J Public Health. 2022 Sep;112(9):1249-1252. doi: 10.2105/AJPH.2022.306932. Epub 2022 Jul 21.
    • Primary care physician referral practices regarding BRCA1/2 genetic counseling in a major health system.
    • Linfield DT, Rothberg MB, Pfoh ER, Noss R, Cassard L, Powers JC, Lipold L, Martinez KA.
    • Breast Cancer Res Treat. 2022 Sep;195(2):153-160. doi: 10.1007/s10549-022-06523-5. Epub 2022 Jul 16.
    • Uptake of genetic counseling and testing in a clinic-based population of women with breast cancer.
    • Wehbe A, Manning M, Assad H, Purrington KS, Simon MS.
    • Cancer Med. 2022 Sep;11(17):3304-3311. doi: 10.1002/cam4.4684. Epub 2022 Mar 23.
    • Implementing universal upfront multi-gene panel testing in endometrial cancer: From cost to practical considerations.
    • Levine MD, Barrington DA, Hampel H, Goodfellow PJ, Cohn DE.
    • Gynecol Oncol. 2022 Sep;166(3):538-542. doi: 10.1016/j.ygyno.2022.07.016. Epub 2022 Jul 21.
    • Leveraging an Informatics Approach to Identify an Unmet Clinical Need for BRCA1/2 Testing Among Patients With Ovarian Cancer.
    • Gray SW, Ottesen RA, Currey M, Cristea M, Nikowitz J, Shehayeb S, Lozano V, Hom J, Kilburn J, Lopez LN, Wing S, Sosa E, Shen J, Morris M, Dilsizian B, Joseph T, Shen J, Adeimy C, Phillips T, Bahadini B, Niland JC.
    • JCO Clin Cancer Inform. 2022 Sep;6:e2200034. doi: 10.1200/CCI.22.00034.
    • Current status of hereditary breast and ovarian cancer practice among gynecologic oncologists in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO).
    • Kobayashi Y, Masuda K, Hiraswa A, Takehara K, Tsuda H, Watanabe Y, Oda K, Nagase S, Mandai M, Okamoto A, Yaegashi N, Mikami M, Enomoto T, Aoki D, Katabuchi H; Working Group on Clinical Practice for Cancer Genomic Medicine and HBOC, Japan Society of Gynecologic Oncology.
    • J Gynecol Oncol. 2022 Sep;33(5):e61. doi: 10.3802/jgo.2022.33.e61. Epub 2022 Jul 18.
    • Call for action: expanding global access to hereditary cancer genetic testing.
    • Bychkovsky B, Rana HQ, Ademuyiwa F, Plichta J, Anderson K, Nogueira-Rodrigues A, Santa-Maria CA, Coffman LG, Marquez C, Das A, Taghian A, Koeller DR, Sandoval RL, Park BH, Dizon DS.
    • Lancet Oncol. 2022 Sep;23(9):1124-1126. doi: 10.1016/S1470-2045(22)00378-3.
    • Commentary
    • Disparities in germline testing among racial minorities with prostate cancer.
    • Weise N, Shaya J, Javier-Desloges J, Cheng HH, Madlensky L, McKay RR.
    • Prostate Cancer Prostatic Dis. 2022 Sep;25(3):403-410. doi: 10.1038/s41391-021-00469-3. Epub 2021 Nov 13.
    • Experience with a nurse-driven genetic counseling pathway of Italian women with uninformative BRCA test result.
    • Blondeaux E, Lambertini M, Buzzatti G, Bruzzone C, Baraga M, Pisani R, Del Mastro L, Pronzato P, Varesco L, Bonelli L.
    • J Genet Couns. 2022 Aug 29. doi: 10.1002/jgc4.1630. Epub ahead of print.
    • A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
    • McVeigh TP, Sweeney KJ, Brennan DJ, McVeigh UM, Ward S, Strydom A, Seal S, Astbury K, Donnellan P, Higgins J, Keane M, Kerin MJ, Malone C, McGough P, McLaughlin R, O'Leary M, Rushe M, Barry MK, MacGregor G, Sugrue M, Yousif A, Al-Azawi D, Berkeley E, Boyle TJ, Connolly EM, Nolan C, Richardson E, Giffney C, Doyle SB, Broderick S, Boyd W, McVey R, Walsh T, Farrell M, Gallagher DJ, Rahman N, George AJ.
    • Fam Cancer. 2022 Aug 27. doi: 10.1007/s10689-022-00313-0. Epub ahead of print.
    • Eligibility, uptake and response to germline genetic testing in women with DCIS.
    • Turza L, Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE.
    • Front Oncol. 2022 Aug 26;12:918757. doi: 10.3389/fonc.2022.918757.
    • Investigating disparity in access to Australian clinical genetic health services for Aboriginal and Torres Strait Islander people.
    • Luke J, Dalach P, Tuer L, Savarirayan R, Ferdinand A, McGaughran J, Kowal E, Massey L, Garvey G, Dawkins H, Jenkins M, Paradies Y, Pearson G, Stutterd CA, Baynam G, Kelaher M.
    • Nat Commun. 2022 Aug 24;13(1):4966. doi: 10.1038/s41467-022-32707-0.
    • Disparities in Biomarker Testing in Ovarian Cancer: A Real-World Analysis.
    • Bodurtha Smith AJ, Alvarez R, Heintz J, Haggerty A, Ko EM.
    • Am J Obstet Gynecol. 2022 Aug 22:S0002-9378(22)00686-X. doi: 10.1016/j.ajog.2022.08.043. Epub ahead of print.
    • Estimating lifetime risk for breast cancer as a screening tool for identifying those who would benefit from additional services among women utilizing mobile mammography.
    • Wetmore JB, Otarola L, Paulino LJ, Henry BR, Levine AF, Kone D, Ulloa J, Jandorf L, Margolies L, Vang S.
    • J Cancer Policy. 2022 Aug 19:100354. doi: 10.1016/j.jcpo.2022.100354. Epub ahead of print.
    • Changing patterns of referral into a family history clinic and detection of ovarian cancer: a retrospective 10-year review.
    • Smallwood KG, Crockett S, Huang V, Cullimore V, Davies J, Satti G, Phillips A.
    • J Obstet Gynaecol. 2022 Aug 18:1-7. doi: 10.1080/01443615.2022.2111253. Epub ahead of print.
    • Dana-Farber Educating Black, Latinx Patients Hoping to Boost Pancreatic Cancer Genetic Risk Testing.
    • Kanski A.
    • Precision Oncology News. Disease Areas. 2022 Aug 18.
    • News
    • Oncologists Consider Germline Testing in Lung Cancer Patients Amid New Data Showing High Prevalence.
    • Hopkins C.
    • Precision Oncology News. Disease Areas. 2022 Aug 17.
    • Conference report
    • Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis.
    • Frey MK, Ahsan MD, Bergeron H, Lin J, Li X, Fowlkes RK, Narayan P, Nitecki R, Rauh-Hain JA, Moss HA, Baltich Nelson B, Thomas C, Christos PJ, Hamilton JG, Chapman-Davis E, Cantillo E, Holcomb K, Kurian AW, Lipkin S, Offit K, Sharaf RN.
    • J Clin Oncol. 2022 Aug 12:JCO2200303. doi: 10.1200/JCO.22.00303. Epub ahead of print.
    • Meta-Analysis
    • Evaluating the Effectiveness of a Telehealth Cancer Genetics Program: A BRCA Pilot Study.
    • Rose E, Hardy MW, Gates R, Stanislaw C, Meisel J, Grinzaid KA.
    • Public Health Genomics. 2022 Aug 9:1-14. doi: 10.1159/000525658. Epub ahead of print.
    • Training promotores to lead virtual hereditary breast cancer education sessions for Spanish-speaking individuals of Latin American heritage in California.
    • Reyna M, Almeida R, Lopez-Macha A, Fuller S, Duron Y, Fejerman L.
    • BMC Womens Health. 2022 Aug 8;22(1):336. doi: 10.1186/s12905-022-01902-y.
    • A qualitative reflexive thematic analysis into the experiences of being identified with a BRCA1/2 gene alteration: "So many little, little traumas could have been avoided".
    • Warner NZ, Groarke A.
    • BMC Health Serv Res. 2022 Aug 6;22(1):1007. doi: 10.1186/s12913-022-08372-w.
    • Impact of BRCA1/2 cascade testing on anxiety, depression, and cancer worry levels among unaffected relatives in a multiethnic Asian cohort.
    • Padmanabhan H, Mariapun S, Lee SY, Hassan NT, Lee DS, Meiser B, Wong SW, Lee YQ, Yip CH, Teo SH, Thong MK, Taib NAM, Yoon SY.
    • J Genet Couns. 2022 Aug 1. doi: 10.1002/jgc4.1619. Epub ahead of print.
    • A Woman Needs to Know She Is a BRCA Carrier Before She Develops Breast Cancer.
    • Hughes KS, Yin K.
    • Ann Surg Oncol. 2022 Aug;29(8):4667-4669. doi: 10.1245/s10434-022-11860-2. Epub 2022 May 12.

    Related:

    Original research:

    Comparison of Outcomes Between BRCA Pathogenic Variant Carriers Undergoing Breast-Conserving Surgery Versus Mastectomy.

    • Health equity in the implementation of genomics and precision medicine: A public health imperative.
    • Khoury MJ, Bowen S, Dotson WD, Drzymalla E, Green RF, Goldstein R, Kolor K, Liburd LC, Sperling LS, Bunnell R.
    • Genet Med. 2022 Aug;24(8):1630-1639. doi: 10.1016/j.gim.2022.04.009. Epub 2022 Apr 28.
    • Review
    • Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer.
    • Goh JCH, Gourley C, Tan DSP, Nogueira-Rodrigues A, Elghazaly H, Edy Pierre M, Giornelli G, Kim BG, Morales-Vasquez F, Tyulyandina A.
    • Gynecol Oncol Rep. 2022 Jun 17 [eCollection 2022 Aug];42:101028. doi: 10.1016/j.gore.2022.101028.
    • Relatively Speaking: COVID-19’s Impact on Cancer Screenings and Genetic Counseling Services.
    • Haidle JL.
    • Inside Precision Medicine. 2022 Aug 16 [2022 Aug];9(4).
    • Challenges and opportunities in the establishment of a hereditary breast cancer clinic at an academic medical center in a low-middle income country.
    • Ehsan L, Waheed MT, Akbar F, Siddiqui Z, Sattar AK, Kirmani S.
    • J Genet Couns. 2022 Aug;31(4):998-1002. doi: 10.1002/jgc4.1555. Epub 2022 Jan 31.
    • Adapting a Theoretically-Based intervention for underserved clinical populations at increased risk for hereditary Cancer: Lessons learned from the BRCA-Gist experience.
    • Hurtado-de-Mendoza A, Reyna VF, Wolfe CR, Gómez-Trillos S, Sutton AL, Brennan A, Sheppard VB.
    • Prev Med Rep. 2022 Jul 5 [eCollection 2022 Aug];28:101887. doi: 10.1016/j.pmedr.2022.101887.
    • Attitudes towards and sociodemographic determinants of genetic test usage in the USA; data from the Health Information National Trend Survey, 2020.
    • Swoboda CM, Wijayabahu AT, Fareed N.
    • J Genet Couns. 2022 Jul 31. doi: 10.1002/jgc4.1620. Epub ahead of print.
    • Association between Health Insurance Type and Genetic Testing and/or Counseling for Breast and Ovarian Cancer.
    • Mansur A, Zhang F, Lu CY.
    • J Pers Med. 2022 Jul 31;12(8):1263. doi: 10.3390/jpm12081263.
    • Impact of comprehensive family history and genetic analysis in the multidisciplinary pancreatic tumor clinic setting.
    • Everett JN, Dettwyler SA, Jing X, Stender C, Schmitter M, Baptiste A, Chun J, Kawaler EA, Khanna LG, Gross SA, Gonda TA, Beri N, Oberstein PE, Simeone DM.
    • Cancer Med. 2022 Jul 30. doi: 10.1002/cam4.5059. Epub ahead of print.
    • The Communication Chain of Genetic Risk: Analyses of Narrative Data Exploring Proband–Provider and Proband–Family Communication in Hereditary Breast and Ovarian Cancer.
    • Pedrazzani C, Aceti M, Schweighoffer R, Kaiser-Grolimund A, Bürki N, Chappuis PO, Graffeo R, Monnerat C, Pagani O, Rabaglio M, Katapodi MC, Caiata-Zufferey M.
    • J Pers Med. 2022 Jul 29;12(8):1249. doi: 10.3390/jpm12081249.
    • Genetic counselors' experience with reimbursement and patient out-of-pocket cost for multi-cancer gene panel testing for hereditary cancer syndromes.
    • Weldon CB, Trosman JR, Liang SY, Douglas MP, Scheuner MT, Kurian A, Schaa KL, Roscow B, Erwin D, Phillips KA.
    • J Genet Couns. 2022 Jul 28. doi: 10.1002/jgc4.1614. Epub ahead of print.
    • Survey on implementation of molecular testing in ovarian cancer and PARP inhibitor: a national North-Eastern German Society of Gynecologic Oncology/Young Academy of Gynecologic Oncology/Arbeitsgemeinschaft Gynäkologische Onkologie intergroup analysis.
    • Nguyen-Sträuli BD, Baum J, Meyer-Wilmes P, Kreklau A, Buschmann C, El Ouardi N, Fotopoulou C, Hummel M, Chekerov R, Braicu E, Sehouli J, Pietzner K.
    • Int J Gynecol Cancer. 2022 Jul 27:ijgc-2022-003637. doi: 10.1136/ijgc-2022-003637. Epub ahead of print.
    • Lessons Learned from the Pilot Phase of a Population-Wide Genomic Screening Program: Building the Base to Reach a Diverse Cohort of 100,000 Participants.
    • Allen CG, Lenert L, Hunt K, Jackson A, Levin E, Clinton C, Clark JT, Garrison K, Gallegos S, Wager K, He W, Sterba K, Ramos PS, Melvin C, Ford M, Catchpole K, McMahon L, Judge DP.
    • J Pers Med. 2022 Jul 27;12(8):1228. doi: 10.3390/jpm12081228.
    • An Electronic Health Record Tool Increases Genetic Counseling Referral of Individuals at Hereditary Cancer Risk: An Intervention Study.
    • Wurtmann EJ, Baldinger S, Olet S, Daley A, Swenson KK.
    • Public Health Genomics. 2022 Jul 27:1-7. doi: 10.1159/000525447. Epub ahead of print.
    • Public Interest in Population Genetic Screening for Cancer Risk.
    • Roberts MC, Foss KS, Henderson GE, Powell SN, Saylor KW, Weck KE, Milko LV.
    • Front Genet. 2022 Jul 22;13:886640. doi: 10.3389/fgene.2022.886640.
    • Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial.
    • Kukafka R, Pan S, Silverman T, Zhang T, Chung WK, Terry MB, Fleck E, Younge RG, Trivedi MS, McGuinness JE, He T, Dimond J, Crew KD.
    • JAMA Netw Open. 2022 Jul 18;5(7):e2222092. doi: 10.1001/jamanetworkopen.2022.22092.

    Related:

    Identifier: NCT03470402: Decision Support for BRCA Testing in Ethnically Diverse Women. (ClinicalTrials.gov)

    • Women's thoughts on receiving and sharing genetic information: Considerations for genetic counseling.
    • Pfledderer CD, Gren LH, Frost CJ, Andrulis IL, Chung WK, Genkinger J, Glendon G, Hopper JL, John EM, Southey M, Terry MB, Daly MB.
    • J Genet Couns. 2022 Jul 6. doi: 10.1002/jgc4.1599. Epub ahead of print.
    • Understanding Cancer Genetic Risk Assessment Intentions in a Tailored Risk Communication Intervention Randomized Controlled Trial.
    • LeCompte CG, McDougall J, Walters ST, Toppmeyer D, Boyce TW, Lu S, Stroup A, Paddock L, Grumet S, Lin Y, Ani J, Heidt E, Kinney AY.
    • Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1513-1514. doi: 10.1158/1055-9965.EPI-22-0482.
    • Conference abstract
    • Genetic medicine is accelerating in Japan.
    • Hayashi S, Kubo M, Kaneshiro K, Kai M, Yamada M, Morisaki T, Takao Y, Shimazaki A, Shikada S, Nakamura M.
    • Breast Cancer. 2022 Jul;29(4):659-665. doi: 10.1007/s12282-022-01342-4. Epub 2022 Feb 21.
    • BRCA1/2 testing among young women with breast cancer in Massachusetts, 2010-2013: An observational study using state cancer registry and All-Payer claims data.
    • Pace LE, Ayanian JZ, Wolf RE, Knowlton R, Gershman ST, Hawkins SS, Keating NL.
    • Cancer Med. 2022 Jul;11(13):2679-2686. doi: 10.1002/cam4.4648. Epub 2022 Mar 21.
    • Identification of women at risk of hereditary breast-ovarian cancer among participants in a population-based breast cancer screening.
    • Bonelli L, Valle I, Rebora I, Ricci P, Biocchi L, Bruschi G, Parodi S, Bruzzone C, Varesco L.
    • Fam Cancer. 2022 Jul;21(3):309-318. doi: 10.1007/s10689-021-00281-x. Epub 2021 Oct 20.
    • Patient ethnicity and cascade genetic testing: a descriptive study of a publicly funded hereditary cancer program.
    • Braley EF, Bedard AC, Nuk J, Hong Q, Bedard JEJ, Sun S, Schrader KA.
    • Fam Cancer. 2022 Jul;21(3):369-374. doi: 10.1007/s10689-021-00270-0. Epub 2021 Jul 7.
    • Outcomes of retesting in patients with previously uninformative cancer genetics evaluations.
    • Dettwyler SA, Koeppe ES, Jacobs MF, Stoffel EM.
    • Fam Cancer. 2022 Jul;21(3):375-385. doi: 10.1007/s10689-021-00276-8. Epub 2021 Sep 21. Erratum in: Fam Cancer. 2021 Oct 28.
    • Evaluating Costs Associated With Genetic Counseling Among Commercially Insured US Patients With Cancer From 2013 to 2019.
    • Roberson ML, Padi-Adjirackor NA, Hooker G, Pal T.
    • JAMA Health Forum. 2022 Jul 29 [eCollection 2022 Jul];3(7):e222260. doi: 10.1001/jamahealthforum.2022.2260.

    Related:

    Research news: Genetic Counseling for Cancer Often Costs Patients Nothing. (Medscape Oncology)

    • Germline Pathogenic Variant Prevalence Among Latin American and US Hispanic Individuals Undergoing Testing for Hereditary Breast and Ovarian Cancer: A Cross-Sectional Study.
    • Ossa Gomez CA, Achatz MI, Hurtado M, Sanabria-Salas MC, Sullcahuaman Y, Chávarri-Guerra Y, Dutil J, Nielsen SM, Esplin ED, Michalski ST, Bristow SL, Hatchell KE, Nussbaum RL, Pineda-Alvarez DE, Ashton-Prolla P.
    • JCO Glob Oncol. 2022 Jul;8:e2200104. doi: 10.1200/GO.22.00104.
    • Can Automated Alerts in the Electronic Health Record Encourage Referrals for Genetic Counseling and Testing Among Patients at High Risk for Hereditary Cancer Syndromes?
    • Zorn KK, Simonson ME, Faulkner JL, Carr CL, Acuna J, Hall TL, Jenkins JF, Drummond KL, Curran GM.
    • JCO Oncol Pract. 2022 Jul;18(7):e1219-e1224. doi: 10.1200/OP.21.00641. Epub 2022 Mar 22.
    • Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention.
    • Tindale LC, Zhantuyakova A, Lam S, Woo M, Kwon JS, Hanley GE, Knoppers B, Schrader KA, Peacock SJ, Talhouk A, Dummer T, Metcalfe K, Pashayan N, Foulkes WD, Manchanda R, Huntsman D, Stuart G, Simard J, Dawson L.
    • Curr Oncol. 2022 Jun 30;29(7):4632-4646. doi: 10.3390/curroncol29070368.
    • High Number of Familial Breast Cancer Cases in the Arabian Gulf Countries: Investigating the Reasons.
    • Mohammed EM.
    • Breast Cancer (Auckl). 2022 Jun 28;16:11782234221107121. doi: 10.1177/11782234221107121.
    • Pilot study of a culturally sensitive intervention to promote genetic counseling for breast cancer risk.
    • Henderson V, Madrigal JM, Kendall LC, Parekh P, Newsome J, Chukwudozie IB, Comer-Hagans L, Coffey V, Grumbach G, Spencer S, Rodgers C, Kaur R, Balay L, Maga T, Ramamonjiarivelo Z, Balthazar C, Winn R, Watson K, Odoms-Young A, Hoskins KF.
    • BMC Health Serv Res. 2022 Jun 25;22(1):826. doi: 10.1186/s12913-022-08193-x.

    Related:

    Identifier: NCT04082117: Uptake of Genetic Counseling Among African American Women. (ClinicalTrials.gov)

    • TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
    • Delahunty R, Nguyen L, Craig S, Creighton B, Ariyaratne D, Garsed DW, Christie E, Fereday S, Andrews L, Lewis A, Limb S, Pandey A, Hendley J, Traficante N, Carvajal N, Spurdle AB, Thompson B, Parsons MT, Beshay V, Volcheck M, Semple T, Lupat R, Doig K, Yu J, Chen XQ, Marsh A, Love C, Bilic S, Beilin M, Nichols CB, Greer C, Lee YC, Gerty S, Gill L, Newton E, Howard J, Williams R, Norris C, Stephens AN, Tutty E, Smyth C, O'Connell S, Jobling T, Stewart CJR, Tan A, Fox SB, Pachter N, Li J, Ellul J, Mir Arnau G, Young MA, Gordon L, Forrest L, Harris M, Livingstone K, Hill J, Chenevix-Trench G, Cohen PA, Webb PM, Friedlander M, James P, Bowtell D, Alsop K; Australian Ovarian Cancer Study, Ovarian Cancer Prognosis and Lifestyle Study and the TRACEBACK Study.
    • J Clin Oncol. 2022 Jun 20;40(18):2036-2047. doi: 10.1200/JCO.21.02108. Epub 2022 Mar 9.
    • Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake.
    • Ramsey ML, Tomlinson J, Pearlman R, Abushahin L, Aeilts A, Chen HZ, Chen Y, Compton A, Elkhatib R, Geiger L, Hays J, Jeter J, Jin N, Malalur P, Roychowdhury S, Ruple J, Prebish J, Stanich PP, Hampel H.
    • Fam Cancer. 2022 Jun 17. doi: 10.1007/s10689-022-00300-5. Epub ahead of print.
    • Nine Myths About Men and Hereditary Cancer.
    • [No author given]
    • My Gene Counsel. Genetic Journal blog. 2022 Jun 15.
    • A systematic literature review of the management, oncological outcomes and psychosocial implications of male breast cancer.
    • Rutherford CL, Goodman D, Lannigan A.
    • Eur J Surg Oncol. 2022 Jun 10:S0748-7983(22)00488-7. doi: 10.1016/j.ejso.2022.06.004. Epub ahead of print.
    • Review
    • Literacy-adapted, electronic family history assessment for genetics referral in primary care: patient user insights from qualitative interviews.
    • Mittendorf KF, Lewis HS, Duenas DM, Eubanks DJ, Gilmore MJ, Goddard KAB, Joseph G, Kauffman TL, Kraft SA, Lindberg NM, Reyes AA, Shuster E, Syngal S, Ukaegbu C, Zepp JM, Wilfond BS, Porter KM.
    • Hered Cancer Clin Pract. 2022 Jun 10;20(1):22. doi: 10.1186/s13053-022-00231-3.

    Related:

    Identifier: NCT03426878: Cancer Health Assessments Reaching Many (CHARM). (ClinicalTrials.gov)

    • Medicaid Expansions: Probing Medicaid's Filling of the Cancer Genetic Testing and Screening Space.
    • Modell SM, Schlager L, Allen CG, Marcus G.
    • Healthcare (Basel). 2022 Jun 8;10(6):1066. doi: 10.3390/healthcare10061066.
    • African American Prostate Cancer Patients Get More VUS, Fewer Actionable Results, Studies Show.
    • Anderson A.
    • GenomeWeb. Disease Areas. Cancer. 2022 Jun 7.
    • Healthcare Predictors of Information Dissemination About Genetic Risks.
    • Henderson V, Strayhorn SM, Bergeron NQ, Strahan DC, Ganschow PS, Khanna AS, Watson K, Hoskins K, Molina Y.
    • Cancer Control. 2022 Jan-Dec [First Published 2022 Jun 6];29:10732748221104666. doi: 10.1177/10732748221104666.
    • Development, Implementation and Initial Results of CDSS Recommendations for Patients at Risk of Hereditary Breast Cancer.
    • Rosa J, Tajerian M, Zin Y, Brunner M, Lopez N, Gaiera A, Butti M, Menazzi S, Chanfreau H, Luna D, Rubin L, Benitez S.
    • Stud Health Technol Inform. 2022 Jun 6;290:340-344. doi: 10.3233/SHTI220092.
    • Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.
    • Bychkovsky BL, Li T, Sotelo J, Tayob N, Mercado J, Gomy I, Chittenden A, Kane S, Stokes S, Hughes ME, Kim JS, Umeton R, Awad MM, Konstantinopoulos PA, Yurgelun MB, Wolpin BM, Taplin ME, Newmark RE, Johnson BE, Lindeman NI, MacConaill LE, Garber JE, Lin NU.
    • Clin Cancer Res. 2022 Jun 1;28(11):2349-2360. doi: 10.1158/1078-0432.CCR-21-2861.
    • Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort.
    • Bajpai J, Kashyap L, Vallathol DH, Das A, Singh M, Pathak R, Rath S, Sekar A, Mohanta S, Reddy A, Joshi S, Nandhana R, Ravind R, Wadasadawala T, Nair N, Ghosh J, Parmar V, Gulia S, Desai S, Shet T, Thakur M, Patil A, Sarin R, Gupta S, Badwe R.
    • Breast. 2022 Jun;63:77-84. doi: 10.1016/j.breast.2022.03.011. Epub 2022 Mar 19.
    • Helping Patients Understand and Cope with BRCA Mutations.
    • Makhnoon S, Arun B, Bedrosian I.
    • Curr Oncol Rep. 2022 Jun;24(6):733-740. doi: 10.1007/s11912-022-01254-8. Epub 2022 Mar 18.
    • Interventions to improve delivery of cancer genetics services in the United States: A scoping review.
    • Bednar EM, Nitecki R, Krause KJ, Rauh-Hain JA.
    • Genet Med. 2022 Jun;24(6):1176-1186. doi: 10.1016/j.gim.2022.03.002. Epub 2022 Apr 7.
    • Review
    • Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access.
    • Amendola LM, Shuster E, Leo MC, Dorschner MO, Rolf BA, Shirts BH, Gilmore MJ, Okuyama S, Zepp JM, Kauffman TL, Mittendorf KF, Bellcross C, Jenkins CL, Joseph G, Riddle L, Syngal S, Ukaegbu C, Goddard KAB, Wilfond BS, Jarvik GP; CHARM Study.
    • Genet Med. 2022 Jun;24(6):1196-1205. doi: 10.1016/j.gim.2022.02.006. Epub 2022 Mar 16.
    • Integrating Medical Genetics Into Precision Oncology Practice in the Veterans Health Administration: The Time Is Now.
    • Scott A, Mohan A, Austin S, Amini E, Raupp S, Pannecouk B, Kelley MJ, Narla G, Ramnath N.
    • JCO Oncol Pract. 2022 Jun;18(6):e966-e973. doi: 10.1200/OP.21.00693. Epub 2022 Mar 8.
    • Programmatic Efforts Increase Adoption of Genomic Precision Medicine in Cancer Care in a Community Cancer Center.
    • Darabi S, Braxton D, Homer J, Brodie T, Holnagel D, Eisenberg B, Demeure MJ.
    • JCO Precis Oncol. 2022 Jun;6:e2200090. doi: 10.1200/PO.22.00090.
    • Advocating for equitable management of hereditary cancer syndromes.
    • Caffrey RG.
    • J Genet Couns. 2022 Jun;31(3):584-589. doi: 10.1002/jgc4.1548. Epub 2022 Jan 14.
    • Commentary
    • Utilization of genetic testing: Analysis of 4,499 prior authorization requests for molecular genetic tests at four US regional health plans.
    • Bajguz D, Danylchuk NR, Czarniecki M, Selig JP, Sutphen R, Kaylor J.
    • J Genet Couns. 2022 Jun;31(3):771-780. doi: 10.1002/jgc4.1543. Epub 2021 Dec 23.
    • Transgender patients' perspectives on their cancer genetic counseling experiences.
    • Rolle L, Zayhowski K, Koeller D, Chiluiza D, Carmichael N.
    • J Genet Couns. 2022 Jun;31(3):781-791. doi: 10.1002/jgc4.1544. Epub 2021 Dec 28.
    • Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study.
    • Pace LE, Tung N, Lee YS, Hamilton JG, Gabriel C, Revette A, Raja S, Jenkins C, Braswell A, Morgan K, Levin J, Block J, Domchek SM, Nathanson K, Symecko H, Spielman K, Karlan B, Kamara D, Lester J, Offit K, Garber JE, Keating NL.
    • J Gen Intern Med. 2022 Jun;37(8):1862-1869. doi: 10.1007/s11606-021-06970-8. Epub 2021 Jun 25.

    Related:

    Identifier: NCT03351803: BRCA Founder OutReach (BFOR) Study. (ClinicalTrials.gov)

    • Present status of germline findings in precision medicine for Japanese cancer patients: issues in the current system.
    • Higashigawa S, Matsubayashi H, Kiyozumi Y, Kado N, Nishimura S, Oishi T, Sugino T, Fushiki K, Shirasu H, Yasui H, Mamesaya N, Fukuzaki N, Kunitomo K, Horiuchi Y, Kenmotsu H, Serizawa M.
    • Jpn J Clin Oncol. 2022 May 31;52(6):599-608. doi: 10.1093/jjco/hyac046.
    • Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013-2018.
    • Acharya M, Zorn KK, Simonson ME, Bimali M, Moore GW, Peng C, Martin BC.
    • Hered Cancer Clin Pract. 2022 May 23;20(1):19. doi: 10.1186/s13053-022-00226-0.
    • UC Davis Looks to Expand Genetic Breast Cancer Risk Education, Outreach for Hispanic Women.
    • Kanski A.
    • Precision Oncology News. Technology. 2022 May 19.
    • News
    • Differences in Willingness to Undergo BRCA1/2 Testing and Risk Reducing Surgery among the General Public, Cancer Patients, and Healthcare Professionals: A Large Population-Based Survey.
    • Chang YJ, Cho S, Joo J, Ryu KH, Lee S, Cho J, Lim MC, Jung SY, Han JH, Lee ES, Kong SY.
    • J Pers Med. 2022 May 18;12(5):818. doi: 10.3390/jpm12050818.
    • Healthcare professionals' perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups.
    • Witjes VM, Braspenning JCC, Hoogerbrugge N, Smolders YHCM, Hermkens DMA, Mourits MJE, Ligtenberg MJL, Ausems MGEM, de Hullu JA.
    • Fam Cancer. 2022 May 16. doi: 10.1007/s10689-022-00294-0. Epub ahead of print.
    • Understanding the Experience of Canadian Women Living with Ovarian Cancer through the Every Woman Study™.
    • Tone A, Boghosian T, Ross A, Baugh E, Altman AD, Dawson L, Reid F, Crawford C.
    • Curr Oncol. 2022 May 5;29(5):3318-3340. doi: 10.3390/curroncol29050271.
    • African American Women Need to Know More About High-Risk Breast Cancer.
    • Johnson F.
    • FORCE. Blog. 2022 May 2.

    Related:

    Video: Felicia's Story: Genetic Testing Sheds Light on a Family's Cancer History. (YouTube / Breastcancer.org)

    • Assessing Breast Cancer Risks to Improve Care for an Increased-Risk Population within Eastern North Carolina.
    • Shelton CH, Bowen C, Guenther WC, Jordan B, Boehmer LM, Weldon CB, Trosman JR, Ruiz A.
    • N C Med J. 2022 May-Jun;83(3):221-228. doi: 10.18043/ncm.83.3.221.
    • Jewish cultural and religious factors and uptake of population-based BRCA testing across denominations: a cohort study.
    • Reisel D, Burnell M, Side L, Loggenberg K, Gessler S, Desai R, Sanderson S, Brady AF, Dorkins H, Wallis Y, Jacobs C, Legood R, Beller U, Tomlinson I, Wardle J, Menon U, Jacobs I, Manchanda R.
    • BJOG. 2022 May;129(6):959-968. doi: 10.1111/1471-0528.16994. Epub 2021 Nov 25.
    • Germline Variant Spectrum Among African American Men Undergoing Prostate Cancer Germline Testing: Need for Equity in Genetic Testing.
    • Giri VN, Hartman R, Pritzlaff M, Horton C, Keith SW.
    • JCO Precis Oncol. 2022 May;6(1):e2200234. doi: 10.1200/PO.22.00234.
    • A pragmatic implementation research study for In Our DNA SC: a protocol to identify multi-level factors that support the implementation of a population-wide genomic screening initiative in diverse populations.
    • Allen CG, Judge DP, Levin E, Sterba K, Hunt K, Ramos PS, Melvin C, Wager K, Catchpole K, Clinton C, Ford M, McMahon LL, Lenert L.
    • Implement Sci Commun. 2022 Apr 28;3(1):48. doi: 10.1186/s43058-022-00286-2.
    • Incomplete Penetrance of Population-Based Genetic Screening Results in Electronic Health Record.
    • Elhanan G, Kiser D, Neveux I, Dabe S, Bolze A, Metcalf WJ, Lu JT, Grzymski JJ.
    • Front Genet. 2022 Apr 27;13:866169. doi: 10.3389/fgene.2022.866169.
    • Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model.
    • Azzollini J, Vingiani A, Agnelli L, Tamborini E, Perrone F, Conca E, Capone I, Busico A, Peissel B, Rosina E, Ducceschi M, Mantiero M, Lopez S, Raspagliesi F, Niger M, Duca M, Damian S, Proto C, de Braud F, Pruneri G, Manoukian S.
    • Front Oncol. 2022 Apr 8;12:857515. doi: 10.3389/fonc.2022.857515.
    • A randomized controlled trial comparing self-referred message to family-referred message promoting men's adherence to evidence-based guidelines on BRCA1/2 germline genetic testing: A registered study protocol.
    • Petrocchi S, Ongaro G, Calvello M, Feroce I, Bonanni B, Pravettoni G.
    • PLoS One. 2022 Apr 8;17(4):e0266327. doi: 10.1371/journal.pone.0266327.

    Related:

    Identifier: NCT04683068: Promoting Men's Adherence to BRCA1/2 Germline Genetic Testing (BRCA-MEN). (ClinicalTrials.gov)

    • Psychological Determinants of Men's Adherence to Cascade Screening for BRCA1/2.
    • Ongaro G, Petrocchi S, Calvello M, Bonanni B, Feroce I, Pravettoni G.
    • Curr Oncol. 2022 Apr 2;29(4):2490-2503. doi: 10.3390/curroncol29040203.
    • Demographic Differences Among US Department of Veterans Affairs Patients Referred for Genetic Consultation to a Centralized VA Telehealth Program, VA Medical Centers, or the Community.
    • Scheuner MT, Huynh AK, Chanfreau-Coffinier C, Lerner B, Gable AR, Lee M, Simon A, Coeshott R, Hamilton AB, Patterson OV, DuVall S, Russell MM.
    • JAMA Netw Open. 2022 Apr 1;5(4):e226687. doi: 10.1001/jamanetworkopen.2022.6687.
    • Genetic Testing for All: Overcoming Disparities in Ovarian Cancer Genetic Testing.
    • Frey MK, Finch A, Kulkarni A, Akbari MR, Chapman-Davis E.
    • Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-12. doi: 10.1200/EDBK_350292.
    • Recommendation and Acceptance of Counselling for Familial Cancer Risk in Newly Diagnosed Breast Cancer Cases.
    • Kast K, Häfner J, Schröck E, Jahn A, Werner C, Meisel C, Wimberger P.
    • Breast Care (Basel). 2022 Apr;17(2):153-158. doi: 10.1159/000517021. Epub 2021 Jun 17.
    • Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer.
    • Slootbeek PHJ, Kloots ISH, Smits M, van Oort IM, Gerritsen WR, Schalken JA, Ligtenberg MJL, Grünberg K, Kroeze LI, Bloemendal HJ, Mehra N.
    • Br J Cancer. 2022 Apr;126(6):907-916. doi: 10.1038/s41416-021-01663-9. Epub 2021 Dec 15.
    • Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context.
    • Kolinsky MP, Niederhoffer KY, Kwan EM, Hotte SJ, Hamilou Z, Yip SM, Chi KN, Wyatt AW, Saad F.
    • Can Urol Assoc J. 2022 Apr;16(4):132-143. doi: 10.5489/cuaj.7621.
    • Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice.
    • Giri VN, Walker A, Gross L, Trabulsi EJ, Lallas CD, Kelly WK, Gomella LG, Fischer C, Loeb S.
    • Clin Genitourin Cancer. 2022 Apr;20(2):e104-e113. doi: 10.1016/j.clgc.2021.11.009. Epub 2021 Nov 27.
    • 30 year experience of index case identification and outcomes of cascade testing in high-risk breast and colorectal cancer predisposition genes.
    • Woodward ER, Green K, Burghel GJ, Bulman M, Clancy T, Lalloo F, Schlecht H, Wallace AJ, Evans DG.
    • Eur J Hum Genet. 2022 Apr;30(4):413-419. doi: 10.1038/s41431-021-01011-8. Epub 2021 Dec 6.
    • Following NCCN guidelines within one hospital system in the United States: Comparison between cancer centers and genetic counselor utilization.
    • Powell K, Rakestraw J, Gupta S, Shou W, Lee K, Leitner O.
    • J Genet Couns. 2022 Apr;31(2):356-363. doi: 10.1002/jgc4.1495. Epub 2021 Aug 9.
    • Uptake of genetic counseling and multi-gene panel testing among women in the Intermountain West with previous negative BRCA1 and BRCA2 results contacted for updated testing.
    • Mooney R, Espinel W, Elrick A, Kehoe K, Kohlmann W, Kaphingst KA.
    • J Genet Couns. 2022 Apr;31(2):470-478. doi: 10.1002/jgc4.1513. Epub 2021 Sep 27.
    • In AMIA Keynote, U of Chicago's Olopade Calls for More Diverse Data to Inform Precision Medicine.
    • Versel N.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Mar 28.
    • Conference report
    • Intention to Inform Relatives, Rates of Cascade Testing, and Preference for Patient-Mediated Communication in Families Concerned with Hereditary Breast and Ovarian Cancer and Lynch Syndrome: The Swiss CASCADE Cohort.
    • Sarki M, Ming C, Aissaoui S, Bürki N, Caiata-Zufferey M, Erlanger TE, Graffeo-Galbiati R, Heinimann K, Heinzelmann-Schwarz V, Monnerat C, Probst-Hensch N, Rabaglio M, Zürrer-Härdi U, Chappuis PO, Katapodi MC, On Behalf Of The Cascade Consortium.
    • Cancers (Basel). 2022 Mar 23;14(7):1636. doi: 10.3390/cancers14071636.
    • Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Future-Five-Years' Single-Institution Experience of 762 Consecutive Patients.
    • Fumagalli C, Betella I, Rappa A, di Giminiani M, Gaiano M, De Vitis LA, Zambetti B, Vacirca D, Multinu F, Venetis K, Colombo N, Barberis M, Guerini Rocco E.
    • Cancers (Basel). 2022 Mar 23;14(7):1638. doi: 10.3390/cancers14071638.
    • Do current family history-based genetic testing guidelines contribute to breast cancer health inequities?
    • Jakuboski SH, McDonald JA, Terry MB.
    • NPJ Breast Cancer. 2022 Mar 22;8(1):36. doi: 10.1038/s41523-022-00391-4.
    • Investigating men's motivations to engage in genetic screening for BRCA1 and BRCA2 mutations.
    • Annoni AM, Longhini C.
    • PLoS One. 2022 Mar 18;17(3):e0265387. doi: 10.1371/journal.pone.0265387.
    • Psychosocial factors associated with genetic testing status among African American women with ovarian cancer: Results from the African American Cancer Epidemiology Study.
    • McBride CM, Pathak S, Johnson CE, Alberg AJ, Bandera EV, Barnholtz-Sloan JS, Bondy ML, Cote ML, Moorman PG, Peres LC, Peters ES, Schwartz AG, Terry PD, Schildkraut JM.
    • Cancer. 2022 Mar 15;128(6):1252-1259. doi: 10.1002/cncr.34053. Epub 2021 Dec 9.
    • Impact of BRCA Status on Reproductive Decision-Making and Self-Concept: A Mixed-Methods Study Informing the Development of Tailored Interventions.
    • Hesse-Biber S, Seven M, Jiang J, Schaik SV, Dwyer AA.
    • Cancers (Basel). 2022 Mar 15;14(6):1494. doi: 10.3390/cancers14061494.
    • The Medical Side Effect We Must Stop Ignoring: Financial Toxicity.
    • Matloff E.
    • Forbes. 2022 Mar 11.

    Related:

    Commentary: Genetic Risks for Cancer Should Not Mean Financial Hardship. (The New York Times)

    • Demographic Barriers for Genetic Testing in High-Risk Breast Cancer Patients in the Northern Michigan Area.
    • Hebert D, Pacheco F, WintonLi L, Taj A.
    • Cureus. 2022 Mar 8;14(3):e22966. doi: 10.7759/cureus.22966.
    • Factors influencing genetic counseling and testing for hereditary breast and ovarian cancer syndrome in a large US health care system.
    • Powell CB, Laurent C, Garcia C, Hoodfar E, Karlea A, Kobelka C, Lee J, Roh J, Kushi LH.
    • Clin Genet. 2022 Mar;101(3):324-334. doi: 10.1111/cge.14100. Epub 2021 Dec 27.
    • Real-world multi-country study of BRCA1/2 mutation testing among adult women with HER2-negative advanced breast cancer.
    • Lux MP, Lewis K, Rider A, Niyazov A.
    • Future Oncol. 2022 Mar;18(9):1089-1101. doi: 10.2217/fon-2021-1387. Epub 2022 Jan 31.
    • Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan.
    • Leith A, Ribbands A, Kim J, Last M, Barlow S, Yang L, Ghate SR.
    • Future Oncol. 2022 Mar;18(8):937-951. doi: 10.2217/fon-2021-1113. Epub 2022 Jan 19.
    • Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.
    • Morgan KM, Hamilton JG, Symecko H, Kamara D, Jenkins C, Lester J, Spielman K, Pace LE, Gabriel C, Levin JD, Tejada PR, Braswell A, Marcell V, Wildman T, Devolder B, Baum RC, Block JN, Fesko Y, Boehler K, Howell V, Heitler J, Robson ME, Nathanson KL, Tung N, Karlan BY, Domchek SM, Garber JE, Offit K.
    • Genet Med. 2022 Mar;24(3):564-575. doi: 10.1016/j.gim.2021.10.016. Epub 2021 Dec 3.
    • Motivations and concerns of patients considering participation in an implementation study of a hereditary cancer risk assessment program in diverse primary care settings.
    • Duenas DM, Shipman KJ, Porter KM, Shuster E, Guerra C, Reyes A, Kauffman TL, Hunter JE, Goddard KAB, Wilfond BS, Kraft SA.
    • Genet Med. 2022 Mar;24(3):610-621. doi: 10.1016/j.gim.2021.11.017. Epub 2021 Nov 23.
    • Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake.
    • Weinmann S, Phillips S, Sweet K, Cosgrove CM, Senter L.
    • Gynecol Oncol. 2022 Mar;164(3):615-621. doi: 10.1016/j.ygyno.2021.12.027. Epub 2022 Jan 5.
    • US Bill Seeks to Expand Access to Genetic Cancer Testing for Medicare Members.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Feb 23.
    • Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria.
    • Andoni T, Wiggins J, Robinson R, Charlton R, Sandberg M, Eeles R.
    • Sci Rep. 2022 Feb 21. doi: 10.1038/s41598-022-06376-4. [Epub ahead of print]

    Related:

    Research news: NHS gene testing misses half of people at risk of cancer, study warns. (Sky News)

    • BRCA testing and testing results among women 18-65 years old.
    • Guo F, Scholl M, Fuchs EL, Berenson AB, Kuo YF.
    • Prev Med Rep. 2022 Feb 19;26:101738. doi: 10.1016/j.pmedr.2022.101738.
    • Senate Bill Proposes to Expand Medicare Coverage for Hereditary Cancer Testing.
    • [No author given]
    • GenomeWeb. Disease Areas. Cancer. 2022 Feb 17.
    • Residential Locale Is Associated with Disparities in Genetic Testing-Related Outcomes Among BRCA1/2-Positive Women.
    • Dibble KE, Connor AE.
    • J Racial Ethn Health Disparities. 2022 Feb 17. doi: 10.1007/s40615-022-01259-w. Epub ahead of print.
    • The impact of race and ethnicity in breast cancer-disparities and implications for precision oncology.
    • Hirko KA, Rocque G, Reasor E, Taye A, Daly A, Cutress RI, Copson ER, Lee DW, Lee KH, Im SA, Park YH.
    • BMC Med. 2022 Feb 11;20(1):72. doi: 10.1186/s12916-022-02260-0.
    • Retrospective assessment of barriers and access to genetic services for hereditary cancer syndromes in an integrated health care delivery system.
    • Muessig KR, Zepp JM, Keast E, Shuster EE, Reyes AA, Arnold B, Ingphakorn C, Gilmore MJ, Kauffman TL, Hunter JE, Knerr S, Feigelson HS, Goddard KAB.
    • Hered Cancer Clin Pract. 2022 Feb 10;20(1):7. doi: 10.1186/s13053-022-00213-5.
    • "It was an important part of my treatment": a qualitative study of Norwegian breast Cancer patients' experiences with mainstreamed genetic testing.
    • Strømsvik N, Olsson P, Gravdehaug B, Lurås H, Schlichting E, Jørgensen K, Wangensteen T, Vamre T, Heramb C, Mæhle L, Grindedal EM.
    • Hered Cancer Clin Pract. 2022 Feb 5;20(1):6. doi: 10.1186/s13053-022-00212-6.
    • Should all patients undergoing genetic testing for hereditary breast cancer syndromes be offered a multigene panel?
    • Silver EL, Niell-Swiller M.
    • Curr Opin Obstet Gynecol. 2022 Feb 1;34(1):36-40. doi: 10.1097/GCO.0000000000000764.
    • Review
    • ASO Author Reflections: Germline Testing for All Patients With Breast Cancer: Has the Time Finally Come?
    • Mittal A, Pramanik R.
    • Ann Surg Oncol. 2022 Feb;29(2):1433-1434. doi: 10.1245/s10434-021-10880-8. Epub 2021 Oct 15.
    • An overview of genetic services delivery for hereditary breast cancer.
    • Reid S, Spalluto LB, Lang K, Weidner A, Pal T.
    • Breast Cancer Res Treat. 2022 Feb;191(3):491-500. doi: 10.1007/s10549-021-06478-z. Epub 2022 Jan 26.
    • Awareness and Availability of Routine Germline BRCA1/2 Mutation Testing in Patients with Advanced Breast Cancer in Germany.
    • Lux MP, Decker T, Runkel ED, Niyazov A, Quek RGW, Marschner N, Harbeck N.
    • Breast Care (Basel). 2022 Feb;17(1):40-46. doi: 10.1159/000513596. Epub 2021 Feb 18.
    • Hereditary cancer panel testing challenges and solutions for the latinx community: costs, access, and variants.
    • Douglas MP, Lin GA, Trosman JR, Phillips KA.
    • J Community Genet. 2022 Feb;13(1):75-80. doi: 10.1007/s12687-021-00563-y. Epub 2021 Nov 6.
    • Remote AI Supported E-Multidisciplinary Oncology Conference in Breast Cancer as a Technology and Method to Optimize Outcomes in the Peripheries.
    • Mammas CS, Mamma AS, Papaxoinis G, Georgiou I.
    • Stud Health Technol Inform. 2022 Jan 14;289:309-312. doi: 10.3233/SHTI210921.
    • Characteristics and experiences of patients from a community-based and consumer-directed hereditary cancer population screening initiative.
    • Greve V, Odom K, Pudner S, Lamb NE, Cooper SJ, East K.
    • HGG Adv. 2021 Aug 24 [eCollection 2022 Jan 13];3(1):100055. doi: 10.1016/j.xhgg.2021.100055.
    • Barriers Exist to Cancer Genetic Testing for Black Women, Survey Shows.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Jan 5.

    Related:

    Original research:

    Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists.

    • Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance.
    • Cham S, Landrum MB, Keating NL, Armstrong J, Wright AA.
    • JAMA Netw Open. 2022 Jan 4;5(1):e2142703. doi: 10.1001/jamanetworkopen.2021.42703.

    Related:

    News: BRCA Testing Underused in Women With Ovarian Cancer (Medscape)

    • Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    • Arun BK, Peterson SK, Sweeney LE, Bluebond RD, Tidwell RSS, Makhnoon S, Kushwaha AC.
    • Cancer. 2022 Jan 1;128(1):94-102. doi: 10.1002/cncr.33866. Epub 2021 Aug 23.

    Related:

    Editorial:

    Population screening to identify women at risk for hereditary breast cancer syndromes: The path forward or the road not taken?

    • Metastatic ovarian carcinoma in breast cancer patients during risk-reducing salpingo-oophorectomy: Report of two cases.
    • Shakya P, Bajracharya A, Shrestha S, Kharel S, Maharjan R, Shrestha AK.
    • Ann Med Surg (Lond). 2021 Dec 6;73:103158. doi: 10.1016/j.amsu.2021.103158. eCollection 2022 Jan.
    • Heterogeneity in how women value risk-stratified breast screening.
    • Wheeler JCW, Keogh L, Sierra MA, Devereux L, Jones K, IJzerman MJ, Trainer AH.
    • Genet Med. 2022 Jan;24(1):146-156. doi: 10.1016/j.gim.2021.09.002. Epub 2021 Nov 30.
    • Genetic testing in Non-Hispanic Black women with breast cancer treated within an equal-access healthcare system.
    • Vargason AB, Turner CE, Shriver CD, Ellsworth RE.
    • Genet Med. 2022 Jan;24(1):232-237. doi: 10.1016/j.gim.2021.08.002. Epub 2021 Nov 30.

    Related:

    Podcast: January 2022: Providing access to quality healthcare for Non-Hispanic Black women reduces mortality. (Genetics in Medicine. GenePod)

    • Mainstreaming Genetic Testing for Epithelial Ovarian Cancer by Oncology Providers: A Survey of Current Practice.
    • Czekalski MA, Huziak RC, Durst AL, Taylor S, Mai PL.
    • JCO Precis Oncol. 2022 Jan;6:e2100409. doi: 10.1200/PO.21.00409.
    • Stay at home: implementation and impact of virtualising cancer genetic services during COVID-19.
    • Norman ML, Malcolmson J, Randall Armel S, Gillies B, Ou B, Thain E, McCuaig JM, Kim RH.
    • J Med Genet. 2022 Jan;59(1):23-27. doi: 10.1136/jmedgenet-2020-107418. Epub 2020 Oct 16.
    • Disparities in Genetic Testing for Heritable Solid-Tumor Malignancies.
    • Dillon J, Ademuyiwa FO, Barrett M, Moss HA, Wignall E, Menendez C, Hughes KS, Plichta JK.
    • Surg Oncol Clin N Am. 2022 Jan;31(1):109-126. doi: 10.1016/j.soc.2021.08.004. Epub 2021 Oct 19.
    • Review
    • Genetic testing for hereditary predisposition to breast cancer in the real world: Initial experience.
    • da Silva Fontinele DR, Assunção Ribeiro da Costa RE, da Silva Magalhães MK, Vieira SC.
    • Breast Dis. 2022;41(1):249-254. doi: 10.3233/BD-210082.
    • Genetic Counseling, Screening and Risk-Reducing Surgery in Patients with Primary Breast Cancer and Germline BRCA Mutations: Unmet Needs in Low- and Middle-Income Countries.
    • Moukadem HA, Al Masry A, Atwani RW, Kreidieh F, Khalil LE, Saroufim R, Daouk S, Dalle IA, El Saghir NS.
    • Eur J Breast Health. 2021 Dec 30;18(1):16-20. doi: 10.4274/ejbh.galenos.2021.2021-5-1.
    • A dangerous breast cancer gene mutation changed my life. As a health reporter, I want you to know about it. The PALB2 mutation is lesser-known than BRCA. It’s time to change that.
    • Berger S.
    • The Lily. (Washington Post). 2021 Dec 27.
    • Genetic Testing Challenges in Oncology: Prior Retinoblastoma Not Considered in Test Ordering.
    • Ray T.
    • Precision Oncology News. Disease Areas. 2021 Dec 22.
    • Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists.
    • Ademuyiwa FO, Salyer P, Tao Y, Luo J, Hensing WL, Afolalu A, Peterson LL, Weilbaecher K, Housten AJ, Baumann AA, Desai M, Jones S, Linnenbringer E, Plichta J, Bierut L.
    • J Clin Oncol. 2021 Dec 20;39(36):4020-4028. doi: 10.1200/JCO.21.01426. Epub 2021 Oct 18.

    Related:

    Commentary:

    Acknowledging Disparities in Hereditary Cancer Testing.

    Press: Physician Bias May Contribute to Lower Genetic Testing Rates Among Black Women, Study Suggests. (Precision Oncology News)

    Press: Barriers Exist to Cancer Genetic Testing for Black Women, Survey Shows. (Inside Precision Medicine)

    • Genetic Literacy and Communication of Genetic Information in Families Concerned with Hereditary Breast and Ovarian Cancer: A Cross-Study Comparison in Two Countries and within a Timeframe of More Than 10 Years.
    • Pedrazzani C, Ming C, Bürki N, Caiata-Zufferey M, Chappuis PO, Duquette D, Heinimann K, Heinzelmann-Schwarz V, Graffeo-Galbiati R, Merajver SD, Milliron KJ, Monnerat C, Pagani O, Rabaglio M, Katapodi MC.
    • Cancers (Basel). 2021 Dec 13;13(24):6254. doi: 10.3390/cancers13246254.
    • Real-World Data Points to Racial Disparity in BRCA1/2 Testing Among TNBC Patients.
    • Ray T.
    • GenomeWeb. 2021 Dec 10.
    • Young Women with Breast Cancer in Resource-Limited Settings: What We Know and What We Need to Do Better.
    • Martinez-Cannon BA, Barragan-Carrillo R, Villarreal-Garza C.
    • Breast Cancer (Dove Med Press). 2021 Dec 2;13:641-650. doi: 10.2147/BCTT.S303047.
    • Hereditary Cancer Risk Using a Genetic Chatbot Before Routine Care Visits.
    • Nazareth S, Hayward L, Simmons E, Snir M, Hatchell KE, Rojahn S, Slotnick RN, Nussbaum RL.
    • Obstet Gynecol. 2021 Dec 1;138(6):860-870. doi: 10.1097/AOG.0000000000004596.
    • Creating Breast and Gynecologic Cancer Guidelines for Transgender Patients With BRCA Mutations.
    • Bedrick BS, Fruhauf TF, Martin SJ, Ferriss JS.
    • Obstet Gynecol. 2021 Dec 1;138(6):911-917. doi: 10.1097/AOG.0000000000004597.
    • Commentary
    • Understanding patients' views and willingness toward the use of telehealth in a cancer genetics service in Asia.
    • Sim J, Shaw T, Li ST, Courtney E, Yuen J, Chiang J, Nazir M, Tan R, Ngeow J.
    • J Genet Couns. 2021 Dec;30(6):1658-1670. doi: 10.1002/jgc4.1432. Epub 2021 May 1.
    • The role of psychosocial factors in Black women's self-efficacy in receiving genetic counseling and testing.
    • Ding H, Sutton AL, Hurtado-de-Mendoza A, Sheppard VB.
    • J Genet Couns. 2021 Dec;30(6):1719-1726. doi: 10.1002/jgc4.1439. Epub 2021 Jun 4.
    • Genetic Testing Challenges in Oncology: No Follow-up on Insurer Denial Delays Cancer Risk Management.
    • Ray T.
    • Precision Oncology News. Cancer Specialties. Breast Cancer. 2021 Nov 29.
    • Genetic Risks for Cancer Should Not Mean Financial Hardship.
    • Pierson L, Pierson E.
    • New York Times. Opinion. 2021 Nov 26.
    • Commentary

    Related:

    Commentary: The Medical Side Effect We Must Stop Ignoring: Financial Toxicity. (Forbes)

    • Survey Reveals Groups, Strategies to Focus Awareness Efforts for Cancer Germline Testing.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2021 Nov 23.
    • News
    • Conference Session Highlight: I'm Not White, Can I Still Have a Mutation?
    • Stallings E, Goldberg D.
    • FORCE. Blog. 2021 Nov 19.
    • Feasibility of a Traceback Approach for Using Pathology Specimens to Facilitate Genetic Testing in the Genetic Risk Analysis in Ovarian Cancer (GRACE) Study Protocol.
    • Kauffman TL, Prado YK, Reyes AA, Zepp JM, Sawyer J, White LL, Martucci J, Salas SB, Vertrees S, Rope AF, Weinmann S, Henrikson NB, Lee SS, Feigelson HS, Hunter JE.
    • J Pers Med. 2021 Nov 13;11(11):1194. doi: 10.3390/jpm11111194.
    • Access to Information and Support is the Key to Education for the Deaf Community.
    • Lesser D.
    • FORCE. Blog. 2021 Nov 10.
    • Predictors of Population Awareness of Cancer Genetic Tests: Implications for Enhancing Equity in Engaging in Cancer Prevention and Precision Medicine.
    • Giri VN, Shimada A, Leader AE.
    • JCO Precis Oncol. 2021 Nov 3;5:PO.21.00231. doi: 10.1200/PO.21.00231.
    • Challenges and Errors in Genetic Testing: The Fifth Case Series.
    • Farmer MB, Bonadies DC, Pederson HJ, Mraz KA, Whatley JW, Darnes DR, Denton JJ, De Rosa D, Heatherly A, Kenney J, Lane K, Paul D, Pelletier RC, Shannon K, Williams D, Matloff ET.
    • Cancer J. 2021 Nov-Dec 01;27(6):417-422. doi: 10.1097/PPO.0000000000000553.
    • Case series
    • Mutations in BRCA-related breast and ovarian cancer in the South African Indian population: A descriptive study.
    • Combrink HM, Oosthuizen J, Visser B, Chabilal N, Buccimazza I, Foulkes WD, van der Merwe NC.
    • Cancer Genet. 2021 Nov;258-259:1-6. doi: 10.1016/j.cancergen.2021.06.002. Epub 2021 Jun 15.

    Related:

    Dataset description:

    A South African Indian population group dataset for breast cancer and BRCA1/2 variants.

    • Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study.
    • Furniss CS, Yurgelun MB, Ukaegbu C, Constantinou PE, Lafferty CC, Talcove-Berko ER, Schwartz AN, Stopfer JE, Underhill-Blazey M, Kenner B, Nelson SH, Okumura S, Law S, Zhou AY, Coffin TB, Rodriguez NJ, Uno H, Ocean AJ, McAllister F, Lowy AM, Lippman SM, Klein AP, Madlensky L, Petersen GM, Garber JE, Goggins MG, Maitra A, Syngal S.
    • Cancer Prev Res (Phila). 2021 Nov;14(11):1021-1032. doi: 10.1158/1940-6207.CAPR-20-0642. Epub 2021 Oct 8.
    • Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer.
    • Hamilton JG, Symecko H, Spielman K, Breen K, Mueller R, Catchings A, Trottier M, Salo-Mullen EE, Shah I, Arutyunova A, Batson M, Gebert R, Pundock S, Schofield E, Offit K, Stadler ZK, Cadoo K, Carlo MI, Narayan V, Reiss KA, Robson ME, Domchek SM.
    • Genet Med. 2021 Nov;23(11):2105-2113. doi: 10.1038/s41436-021-01262-2. Epub 2021 Jul 13.
    • Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer Prevention.
    • Whitaker KD, Obeid E, Daly MB, Hall MJ.
    • JCO Precis Oncol. 2021 Nov;5:1387-1396. doi: 10.1200/PO.21.00163.
    • Results of a 2021 French National Survey on Management of Patients with Advanced Stage Epithelial Ovarian Cancer.
    • Drouin L, Guani B, Balaya V, Azaïs H, Betrian S, Bolze PA, Dabi Y, Kerbage Y, Sanson C, Zaccarini F, Mathevet P, Lécuru F, Guyon F, Akladios C, Bendifallah S, Deluche E, On Behalf Of The Sfog Campus Young Of French Society Of Gynecological Oncology.
    • J Clin Med. 2021 Oct 21;10(21):4829. doi: 10.3390/jcm10214829.
    • MSK Fellows Develop Online Resource to Increase Awareness of Genetic Cascade Testing.
    • Kanski A.
    • Precision Oncology News. Technology. 2021 Oct 21.
    • News
    • Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design.
    • Blomen CL, Pott A, Volk AE, Budäus L, Witzel I.
    • Sci Rep. 2021 Oct 11;11(1):20178. doi: 10.1038/s41598-021-98737-8.
    • Invitae, Outcomes4Me Collaborate to Improve Breast Cancer Genetic Testing Access.
    • [No author given]
    • GenomeWeb. Diagnostics. 2021 Oct 8.
    • A culturally targeted video to promote genetic counseling in a community sample of at-risk US Latina women: The role of the concrete mindset.
    • Carrera P, Sheppard VB, Caballero A, Gómez-Trillos S, Hurtado-de-Mendoza A.
    • J Community Psychol. 2021 Oct 4. doi: 10.1002/jcop.22718. Epub ahead of print.
    • Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients.
    • Hur YM, Mun J, Kim MK, Lee M, Kim YH, Kim SC.
    • J Korean Med Sci. 2021 Oct 4;36(38):e241. doi: 10.3346/jkms.2021.36.e241.
    • Clinical genetic counselor experience in the adoption of telehealth in the United States and Canada during the COVID-19 pandemic.
    • Ma D, Ahimaz PR, Mirocha JM, Cook L, Giordano JL, Mohan P, Cohen SA.
    • J Genet Couns. 2021 Oct;30(5):1214-1223. doi: 10.1002/jgc4.1516. Epub 2021 Nov 10.
    • Research to reduce inequities in cancer risk services: Insights for remote genetic counseling in a pandemic and beyond.
    • Lee R, Frick M, Joseph G, Guerra C, Stewart S, Kaplan C, Dixit N, Tsoh JY, Flores S, Pasick RJ.>
    • J Genet Couns. 2021 Oct;30(5):1292-1297. doi: 10.1002/jgc4.1525. Epub 2021 Oct 23.
    • Telehealth for genetic counseling: A systematic evidence review.
    • Danylchuk NR, Cook L, Shane-Carson KP, Cacioppo CN, Hardy MW, Nusbaum R, Steelman SC, Malinowski J.
    • J Genet Couns. 2021 Oct;30(5):1361-1378. doi: 10.1002/jgc4.1481. Epub 2021 Aug 6.
    • Review
    • Study: Genetic testing for inherited mutations may be helpful for all people with advanced or metastatic cancer.
    • [No author given]
    • FORCE. XRAY. 2021 Sep 30.

    Related:

    Original research:

    Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.

    • Pioneering BRCA1/2 Point-Of-Care Testing for Integration of Germline and Tumor Genetics in Breast Cancer Risk Management: A Vision for the Future of Translational Pharmacogenomics.
    • Mampunye L, van der Merwe NC, Grant KA, Peeters AV, Torrorey-Sawe R, French DJ, Moremi KE, Kidd M, van Eeden PC, Pienaar FM, Kotze MJ.
    • Front Oncol. 2021 Sep 29;11:619817. doi: 10.3389/fonc.2021.619817.
    • Improving our model of cascade testing for hereditary cancer risk by leveraging patient peer support: a concept report.
    • O'Neill SC, Hamilton JG, Conley CC, Peshkin BN, Sacca R, McDonnell GA, Isaacs C, Robson ME, Tercyak KP.
    • Hered Cancer Clin Pract. 2021 Sep 26;19(1):40. doi: 10.1186/s13053-021-00198-7.
    • Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing.
    • Wang Y, Golesworthy B, Cuggia A, Domecq C, Chaudhury P, Barkun J, Metrakos P, Asselah J, Bouganim N, Gao ZH, Chong G, Foulkes WD, Zogopoulos G.
    • J Med Genet. 2021 Sep 23:jmedgenet-2021-108054. doi: 10.1136/jmedgenet-2021-108054. Epub ahead of print.
    • Management of breast cancer patients with BRCA gene mutations in Lebanon of the Middle East: perspectives and challenges.
    • El Saghir NS, Ghanem H, El Karak F, Farhat F, Ghosn M, Makdessi J, Chouaib K, Debs J, Tabchy AB.
    • Hosp Pract (1995). 2021 Sep 22:1-5. doi: 10.1080/21548331.2021.1974678. Epub ahead of print.
    • Commentary
    • Building the What Comes Next Cohort for BRCA1 and BRCA2 testing: a descriptive analysis.
    • Dossa F, Metcalfe K, Sutradhar R, Little T, Eisen A, Chun K, Meschino WS, Velsher L, Ellis JL, Baxter NN.
    • CMAJ Open. 2021 Sep 21;9(3):E874-E885. doi: 10.9778/cmajo.20200228.
    • Researchers Call for More Uniformity in Cancer Genetic Testing, Risk Guidelines in Europe.
    • Kanski A.
    • Precision Oncology News. 2021 Sep 19.
    • News
    • Genetic testing in women with early-onset breast cancer: a Traceback pilot study.
    • Augustinsson A, Nilsson MP, Ellberg C, Kristoffersson U, Olsson H, Ehrencrona H.
    • Breast Cancer Res Treat. 2021 Sep 16:1–9. doi: 10.1007/s10549-021-06351-z. Epub ahead of print.
    • Feasibility of genetic testing for cancer risk assessment programme in Nigeria.
    • Adejumo PO, Aniagwu TIG, Awolude OA, Oni AO, Ajayi OO, Fagbenle O, Ogungbade D, Kochheiser M, Ogundiran T, Olopade OI.
    • Ecancermedicalscience. 2021 Sep 7;15:1283. doi: 10.3332/ecancer.2021.1283.
    • Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.
    • Kim SR, Tone A, Kim RH, Cesari M, Clarke BA, Eiriksson L, Hart TL, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, Ferguson SE.
    • Cancer. 2021 Sep 1;127(17):3082-3091. doi: 10.1002/cncr.33625. Epub 2021 May 13.
    • Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs.
    • Russo J, McDougall C, Bowler N, Shimada A, Gross L, Hyatt C, Kelly WK, Calvaresi A, Handley NR, Hirsch IH, Izes JK, Lallas CD, Mann M, Mark JR, Mille PJ, Preate D Jr, Trabulsi EJ, Tsang M, Chandrasekar T, Weiner PR, Gomella LG, Giri VN.
    • JCO Precis Oncol. 2021 Sep 1;5:PO.21.00238. doi: 10.1200/PO.21.00238.

    Related:

    Research news: Men Give Thumbs Up to Video on Genetic Testing in Prostate Cancer. (Medscape Oncology)

    • Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study.
    • Chandrasekaran D, Sobocan M, Blyuss O, Miller RE, Evans O, Crusz SM, Mills-Baldock T, Sun L, Hammond RFL, Gaba F, Jenkins LA, Ahmed M, Kumar A, Jeyarajah A, Lawrence AC, Brockbank E, Phadnis S, Quigley M, El Khouly F, Wuntakal R, Faruqi A, Trevisan G, Casey L, Burghel GJ, Schlecht H, Bulman M, Smith P, Bowers NL, Legood R, Lockley M, Wallace A, Singh N, Evans DG, Manchanda R.
    • Cancers (Basel). 2021 Aug 27;13(17):4344. doi: 10.3390/cancers13174344.
    • Patient-Reported Outcomes following Genetic Testing for Familial Hypercholesterolemia, Breast and Ovarian Cancer Syndrome, and Lynch Syndrome: A Systematic Review.
    • Hendricks-Sturrup RM, Joseph L, Lu CY.
    • J Pers Med. 2021 Aug 27;11(9):850. doi: 10.3390/jpm11090850.
    • Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
    • Somasegar S, Weiss AS, Norquist BM, Khasnavis N, Radke M, Manhardt E, Pennil C, Pennington KP, Eckert MA, Chryplewicz A, Lengyel E, Swisher EM.
    • Gynecol Oncol. 2021 Aug 24:S0090-8258(21)01315-9. doi: 10.1016/j.ygyno.2021.08.017. Epub ahead of print.
    • "Being proactive, not reactive": exploring perceptions of genetic testing among White, Latinx, and Pacific Islander Populations.
    • Chavez-Yenter D, Vagher J, Clayton MF, Rindler M, Shukovich M, Kaphingst KA.
    • J Community Genet. 2021 Aug 20. doi: 10.1007/s12687-021-00542-3. Epub ahead of print.
    • Next-Generation Sequencing of Patients With Breast Cancer in Community Oncology Clinics.
    • Sturgill EG, Misch A, Lachs R, Jones CC, Schlauch D, Jones SF, Shastry M, Yardley DA, Burris HA 3rd, Spigel DR, Hamilton EP, McKenzie AJ.
    • JCO Precis Oncol. 2021 Nov [Epub 2021 Aug 19];5:1297-1311. doi: 10.1200/PO.20.00469.

    Related:

    Press: NGS Use for Breast Cancer Increases Sixfold in Community Oncology Clinics, Study Finds. (Precision Oncology News)

    • Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America.
    • Herzog JS, Chavarri-Guerra Y, Castillo D, Abugattas J, Villarreal-Garza C, Sand S, Clague-Dehart J, Alvarez-Gómez RM, Wegman-Ostrosky T, Mohar A, Mora P, Del Toro-Valero A, Daneri-Navarro A, Rodriguez Y, Cruz-Correa M, Ashton-Prolla P, Alemar B, Mejia R, Gallardo L, Shaw R, Yang K, Cervantes A, Tsang K, Nehoray B, Barrera Saldana H, Neuhausen S, Weitzel JN.
    • NPJ Breast Cancer. 2021 Aug 19;7(1):107. doi: 10.1038/s41523-021-00317-6.
    • Study: Frequency of inherited mutations linked to breast cancer are similar in Black and white women.
    • [No author given]
    • FORCE. XRAY. 2021 Aug 13.

    Related:

    Original research:

    Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States.

    • Attitudes toward Risk-Reducing Mastectomy and Risk-Reducing Salpingo-oophorectomy among Young, Unmarried, Healthy Women in Korea.
    • Park B, Kim D, Kim J, Lee BY, Yoon J, Kim SW.
    • Cancer Res Treat. 2021 Aug 9. doi: 10.4143/crt.2021.449. Epub ahead of print.
    • Update: Breast cancer disparities in Black Americans.
    • [No author given]
    • FORCE. XRAY. 2021 Aug 5.

    Related:

    Progress Report: Cancer Disparities Progress Report 2020: Achieving the Bold Vision of Health Equity for Racial and Ethnic Minorities and Other Underserved Populations. (AACR, American Association for Cancer Research)

    • A report on the 73th Annual Congress of the Japan Society of Obstetrics and Gynecology International Workshop for Junior Fellows: Risk-reducing surgery for hereditary breast and ovarian cancer.
    • Hirayama T, Inayama Y, Odajima S, Yamanaka A, Sekine M, Terao Y, Koide K, Kuwabara Y, Yahata H, Yanaihara N, Nagase S, Kobayashi Y, Sekizawa A.
    • J Obstet Gynaecol Res. 2021 Aug 1. doi: 10.1111/jog.14952. Epub ahead of print.
    • Conference news
    • Effect of a health literacy training program for surgical oncologists and specialized nurses on disparities in referral to breast cancer genetic testing.
    • van der Giessen JAM, van Dulmen S, Velthuizen ME, van den Muijsenbergh METC, van Engelen K, Collée M, van Dalen T, Aalfs CM, Hooning MJ, Spreeuwenberg PMM, Fransen MP, Ausems MGEM.
    • Breast. 2021 Aug;58:80-87. doi: 10.1016/j.breast.2021.04.008. Epub 2021 Apr 22.
    • Towards population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives.
    • Ficarazzi F, Vecchi M, Ferrari M, Pierotti MA.
    • Breast. 2021 Aug;58:121-129. doi: 10.1016/j.breast.2021.04.011. Epub 2021 May 12.
    • Germline BRCA1 Mutation and Prostate Cancer: Be Careful on Causality.
    • Boilève A, Lavaud P, Caron O.
    • Eur Urol Oncol. 2021 Aug;4(4):674-675. doi: 10.1016/j.euo.2021.06.004. Epub 2021 Jun 19.
    • Letter, Comment

    Related:

    Review:

    Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.

    • Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis.
    • Lin J, Sharaf RN, Saganty R, Ahsan D, Feit J, Khoury A, Bergeron H, Chapman-Davis E, Cantillo E, Holcomb K, Blank SV, Liu Y, Thomas C, Christos PJ, Wright DN, Lipkin S, Offit K, Frey MK.
    • Gynecol Oncol. 2021 Aug;162(2):506-516. doi: 10.1016/j.ygyno.2021.05.011. Epub 2021 May 19.
    • Benefits and limitations of telegenetics: A literature review.
    • Gorrie A, Gold J, Cameron C, Krause M, Kincaid H.
    • J Genet Couns. 2021 Aug;30(4):924-937. doi: 10.1002/jgc4.1418. Epub 2021 Apr 4.
    • Review
    • Adapting genetic counseling operations amidst the COVID-19 pandemic.
    • Mauer C, Zimmerman J, Lahiri S, Watson E, Parsi L, Berg J, Pirzadeh-Miller S.
    • J Genet Couns. 2021 Aug;30(4):949-955. doi: 10.1002/jgc4.1474. Epub 2021 Jul 19.
    • 'Steep learning curves' to 'Smooth Sailing': A reappraisal of telegenetics amidst the COVID-19 pandemic.
    • Mueller R, Schindewolf E, Williams S, Jay Kessler L.
    • J Genet Couns. 2021 Aug;30(4):1010-1023. doi: 10.1002/jgc4.1487. Epub 2021 Aug 6.
    • Genetic counseling, virtual visits, and equity in the era of COVID-19 and beyond.
    • Uhlmann WR, McKeon AJ, Wang C.
    • J Genet Couns. 2021 Aug;30(4):1038-1045. doi: 10.1002/jgc4.1469. Epub 2021 Jul 21.
    • Update: variable implementation of the 2018 UKCGG/UKGTN guidelines for breast cancer gene panel tests offered by UK genetics services.
    • Wedderburn S, Archer S, Tischkowitz M, Hanson H; UKCGG.
    • J Med Genet. 2021 Aug;58(8):579-580. doi: 10.1136/jmedgenet-2020-107529. Epub 2021 Feb 10.
    • Overview of Prostate Cancer Genetic Testing.
    • Chandrasekar T, Kelly WK, Gomella LG.
    • Urol Clin North Am. 2021 Aug;48(3):279-282. doi: 10.1016/j.ucl.2021.04.002. Epub 2021 Jun 10.
    • Review
    • Risk-Stratified Approach to Breast Cancer Screening in Canada: Women's Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data.
    • Alarie S, Hagan J, Dalpé G, Faraji S, Mbuya-Bienge C, Nabi H, Pashayan N, Brooks JD, Dorval M, Chiquette J, Eloy L, Turgeon A, Lambert-Côté L, Paquette JS, Walker MJ, Lapointe J, Granados Moreno P, Blackmore K, Wolfson M, Broeders M, The Perspective I I Study Group, Knoppers BM, Chiarelli AM, Simard J, Joly Y.
    • J Pers Med. 2021 Jul 27;11(8):726. doi: 10.3390/jpm11080726.
    • Barriers to family history knowledge and family communication among LGBTQ+ individuals in the context of hereditary cancer risk assessment.
    • Rolf BA, Schneider JL, Amendola LM, Davis JV, Mittendorf KF, Schmidt MA, Jarvik GP, Wilfond BS, Goddard KAB, Ezzell Hunter J.
    • J Genet Couns. 2021 Jul 23. doi: 10.1002/jgc4.1476. Epub ahead of print.
    • Genetic Landscape of Male Breast Cancer.
    • Campos FAB, Rouleau E, Torrezan GT, Carraro DM, Casali da Rocha JC, Mantovani HK, da Silva LR, Osório CABT, Moraes Sanches S, Caputo SM, Santana Dos Santos E.
    • Cancers (Basel). 2021 Jul 15;13(14):3535. doi: 10.3390/cancers13143535.
    • Search Behavior Regarding Cancer Susceptibility Genes Using a Clinical Decision Support Tool for Gene-Specific Penetrance: Content Analysis.
    • Yin K, Zhou J, Singh P, Wang J, Braun D, Hughes KS.
    • JMIR Cancer. 2021 Jul 13;7(3):e28527. doi: 10.2196/28527.
    • Success Factors and Barriers in Combining Personalized Medicine and Patient Centered Care in Breast Cancer. Results from a Systematic Review and Proposal of Conceptual Framework.
    • de Belvis AG, Pellegrino R, Castagna C, Morsella A, Pastorino R, Boccia S.
    • J Pers Med. 2021 Jul 13;11(7):654. doi: 10.3390/jpm11070654.
    • Development and pilot testing of a training for bilingual community education professionals about hereditary breast and ovarian cancer among Latinas: ÁRBOLES Familiares.
    • Vadaparampil ST, Moreno Botero L, Fuzzell L, Garcia J, Jandorf L, Hurtado-de-Mendoza A, Campos-Galvan C, Peshkin BN, Schwartz MD, Lopez K, Ricker C, Fiallos K, Quinn GP, Graves KD.
    • Transl Behav Med. 2021 Jul 13:ibab093. doi: 10.1093/tbm/ibab093. Epub ahead of print.
    • Patient ethnicity and cascade genetic testing: a descriptive study of a publicly funded hereditary cancer program.
    • Braley EF, Bedard AC, Nuk J, Hong Q, Bedard JEJ, Sun S, Schrader KA.
    • Fam Cancer. 2021 Jul 7. doi: 10.1007/s10689-021-00270-0. Epub ahead of print.
    • Influence of payer coverage and out-of-pocket costs on ordering of NGS panel tests for hereditary cancer in diverse settings.
    • Lin GA, Trosman JR, Douglas MP, Weldon CB, Scheuner MT, Kurian A, Phillips KA.
    • J Genet Couns. 2021 Jul 7. doi: 10.1002/jgc4.1459. Epub ahead of print.
    • Hereditary breast cancer and ancestry in the Madeira archipelago: an exploratory study.
    • Miguel I, Rodrigues F, Fragoso S, Freixo J, Clara A, Luís A, Bento S, Fernandes M, Bacelar F, Câmara S, Parreira J, Duarte T, Rodrigues P, Santos S, Vaz F.
    • Ecancermedicalscience. 2021 Jul 5;15:1261. doi: 10.3332/ecancer.2021.1261.
    • Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States.
    • Domchek SM, Yao S, Chen F, Hu C, Hart SN, Goldgar DE, Nathanson KL, Ambrosone CB, Haiman CA, Couch FJ, Polley EC, Palmer JR; CARRIERS Consortium.
    • JAMA Oncol. 2021 Jul 1;7(7):1045-1050. doi: 10.1001/jamaoncol.2021.1492.

    Related:

    Research news: Study: Frequency of inherited mutations linked to breast cancer are similar in Black and white women. (FORCE. XRAY)

    Research news: UPenn Study Finds Similar Rates of Risk Mutations Among Black, White Breast Cancer Patients. (Precision Oncology News)

    • Disclosure of familial implications of pathogenic variants in breast-cancer genes to patients: Opportunity for prompting family communication.
    • Makhnoon S, Smith HS, Bednar EM, Bhatt A, Turner L, Arun B, Volk RJ, Peterson SK.
    • J Community Genet. 2021 Jul;12(3):439-447. doi: 10.1007/s12687-021-00504-9. Epub 2021 Jan 22.
    • Expanding the search for germline pathogenic variants for breast cancer. How far should we go and how high should we jump? The missed opportunity!
    • Abdel-Razeq H.
    • Oncol Rev. 2021 Jun 24;15(1):544. doi: 10.4081/oncol.2021.544.
    • The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat.
    • Clark R, Kenk M, McAlpine K, Thain E, Farncombe KM, Pritchard CC, Nussbaum R, Wyatt AW, de Bono J, Vesprini D, Bombard Y, Lorentz J, Narod S, Kim R, Fleshner N.
    • Can Urol Assoc J. 2021 Jun 22. doi: 10.5489/cuaj.7383. Epub ahead of print.
    • Framing Effects on Decision-Making for Diagnostic Genetic Testing: Results from a Randomized Trial.
    • Dwyer AA, Shen H, Zeng Z, Gregas M, Zhao M.
    • Genes (Basel). 2021 Jun 20;12(6):941. doi: 10.3390/genes12060941.
    • A Retrospective 5-Year Single Center Study Highlighting the Risk of Cancer Predisposition in Adolescents and Young Adults.
    • Jordan F, Huber S, Sommer S, Schenkirsch G, Frühwald MC, Trepel M, Claus R, Kuhlen M.
    • Cancers (Basel). 2021 Jun 17;13(12):3033. doi: 10.3390/cancers13123033.
    • Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?
    • Dunn C, Gately L, Gibbs P.
    • JAMA Oncol. 2021 Jun 17. doi: 10.1001/jamaoncol.2021.1904. Epub ahead of print.
    • Letter, Comment

    Related:

    Letter, Reply:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply.

    Original research:

    Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.

    • Disparity in Access to Oncology Precision Care: A Geospatial Analysis of Driving Distances to Genetic Counselors in the U.S.
    • Bellaiche MMJ, Fan W, Walbert HJ, McClave EH, Goodnight BL, Sieling FH, Moore RA, Meng W, Black CM.
    • Front Oncol. 2021 Jun 16;10:689927. doi: 10.3389/fonc.2021.689927.
    • Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.
    • Stadler ZK, Maio A, Chakravarty D, Kemel Y, Sheehan M, Salo-Mullen E, Tkachuk K, Fong CJ, Nguyen B, Erakky A, Cadoo K, Liu Y, Carlo MI, Latham A, Zhang H, Kundra R, Smith S, Galle J, Aghajanian C, Abu-Rustum N, Varghese A, O'Reilly EM, Morris M, Abida W, Walsh M, Drilon A, Jayakumaran G, Zehir A, Ladanyi M, Ceyhan-Birsoy O, Solit DB, Schultz N, Berger MF, Mandelker D, Diaz LA Jr, Offit K, Robson ME.
    • J Clin Oncol. 2021 Jun 16:JCO2003661. doi: 10.1200/JCO.20.03661. Epub ahead of print.
    • Germline Genetic Testing for All Patients With Cancer?
    • Nelson R.
    • Medscape Oncology. 2021 Jun 15.
    • Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer.
    • Wang A, Everett JN, Chun J, Cen C, Simeone DM, Schnabel F.
    • Sci Rep. 2021 Jun 14;11(1):12491. doi: 10.1038/s41598-021-91971-0.
    • Community research collaboration to develop a promotores-based hereditary breast cancer education program for Spanish-speaking Latinas.
    • Almeida R, Lopez-Macha A, Dugatkin T, Joseph G, Duron Y, Hurtado de Mendoza A, D Graves K, Fejerman L.
    • Health Educ Res. 2021 Jun 11:cyab011. doi: 10.1093/her/cyab011. Epub ahead of print.
    • Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion.
    • Hopkins C.
    • GenomeWeb. Disease Areas. Cancer. 2021 Jun 7.
    • News
    • Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I).
    • Brooks JD, Nabi HH, Andrulis IL, Antoniou AC, Chiquette J, Després P, Devilee P, Dorval M, Droit A, Easton DF, Eisen A, Eloy L, Fienberg S, Goldgar D, Hahnen E, Joly Y, Knoppers BM, Lofters A, Masson JY, Mittmann N, Paquette JS, Pashayan N, Schmutzler R, Stockley T, Tavtigian SV, Walker MJ, Wolfson M, Chiarelli AM, Simard J.
    • J Pers Med. 2021 Jun 4;11(6):511. doi: 10.3390/jpm11060511.
    • Out-of-pocket and private pay in clinical genetic testing: a scoping review.
    • Grant P, Langlois S, Lynd LD; GenCOUNSEL Study, Austin JC, Elliott AM.
    • Clin Genet. 2021 Jun 3. doi: 10.1111/cge.14006. Epub ahead of print.
    • Review
    • Health Care Disparities and Demand for Expanding Hereditary Breast Cancer Screening Guidelines in African Americans.
    • Ciuro J, Beyer A, Fritzler J, Jackson N, Ahsan S.
    • Clin Breast Cancer. 2021 Jun;21(3):e220-e227. doi: 10.1016/j.clbc.2020.08.010. Epub 2020 Sep 3.
    • Cancer genetic testing in marginalized groups during an era of evolving healthcare reform.
    • Modell SM, Allen CG, Ponte A, Marcus G.
    • J Cancer Policy. 2021 Jun;28:100275. doi: 10.1016/j.jcpo.2021.100275. Epub 2021 Feb 16. [Also as PMID: 35559905]
    • Development and Pilot Implementation of the Genomic Risk Assessment for Cancer Implementation and Sustainment (GRACIAS) Intervention in Mexico.
    • Blazer KR, Chavarri-Guerra Y, Villarreal Garza C, Nehoray B, Mohar A, Daneri-Navarro A, Del Toro A, Aguilar D, Arteaga J, Álvarez RM, Mejia R, Herzog J, Castillo D, Fernandez M, Weitzel JN.
    • JCO Glob Oncol. 2021 Jun;7:992-1002. doi: 10.1200/GO.20.00587.
    • State of recent literature on communication about cancer genetic testing among Latinx populations.
    • Chavez-Yenter D, Chou WS, Kaphingst KA.
    • J Genet Couns. 2021 Jun;30(3):911-918. doi: 10.1002/jgc4.1351. Epub 2020 Nov 3.
    • Genetic testing and surgical treatment after breast cancer diagnosis: Results from a national online cohort.
    • Verdial FC, Bartek MA, Anderson BO, Javid SH.
    • J Surg Oncol. 2021 Jun;123(7):1504-1512. doi: 10.1002/jso.26372. Epub 2021 Mar 18.
    • Motivations and barriers to pursue cancer genomic testing: A systematic review.
    • Smith-Uffen M, Bartley N, Davies G, Best M.
    • Patient Educ Couns. 2021 Jun;104(6):1325-1334. doi: 10.1016/j.pec.2020.12.024. Epub 2020 Dec 25.
    • Review
    • Training courses on hereditary breast and ovarian cancer to strengthen cross-sectoral care in underserved areas.
    • Kühn F, Karsten MM, Kendel F, Feufel MA, Speiser D.
    • Patient Educ Couns. 2021 Jun;104(6):1431-1437. doi: 10.1016/j.pec.2020.10.035. Epub 2020 Nov 1.
    • A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study.
    • Lapointe J, Dorval M, Chiquette J, Joly Y, Guertin JR, Laberge M, Gekas J, Hébert J, Pomey MP, Cruz-Marino T, Touhami O, Blanchet Saint-Pierre A, Gagnon S, Bouchard K, Rhéaume J, Boisvert K, Brousseau C, Castonguay L, Fortier S, Gosselin I, Lachapelle P, Lavoie S, Poirier B, Renaud MC, Ruizmangas MG, Sebastianelli A, Roy S, Côté M, Racine MM, Roy MC, Côté N, Brisson C, Charette N, Faucher V, Leblanc J, Dubeau MÈ, Plante M, Desbiens C, Beaumont M, Simard J, Nabi H.
    • Cancers (Basel). 2021 May 31;13(11):2729. doi: 10.3390/cancers13112729.
    • Risk-Adjusted Prevention. Perspectives on the Governance of Entitlements to Benefits in the Case of Genetic (Breast Cancer) Risks.
    • Meier F, Harney A, Rhiem K, Neusser S, Neumann A, Braun M, Wasem J, Huster S, Dabrock P, Schmutzler RK.
    • Recent Results Cancer Res. 2021 [First Online: 22 May 2021];218:47-66. doi: 10.1007/978-3-030-63749-1_5.
    • eBook chapter
    • Perthera, Side-Out Foundation Partner to Advance Precision Oncology in Breast Cancer.
    • [No author given]
    • Precision Oncology News. Cancer Specialties. Breast Cancer. 2021 May 21.
    • Health system interventions to integrate genetic testing in routine oncology services: A systematic review.
    • O'Shea R, Taylor N, Crook A, Jacobs C, Jung Kang Y, Lewis S, Rankin NM.
    • PLoS One. 2021 May 19;16(5):e0250379. doi: 10.1371/journal.pone.0250379.
    • Oncologists, Patients Still Face Unpredictable Payor Coverage for Broad Tissue NGS Panels.
    • Hopkins C.
    • Precision Oncology News. Business & Policy. 2021 May 17.
    • News
    • Oncologists' perspectives of telephone genetic counseling to facilitate germline BRCA1/2 testing for their patients with high-grade serous ovarian cancer.
    • Hemming P, Kaur R, Meiser B, McKinley J, Young MA, James PA, Forrest LE.
    • J Community Genet. 2021 May 6. doi: 10.1007/s12687-021-00530-7. Epub ahead of print.
    • Novel Approach Using Administrative Claims to Evaluate Trends in Oncology Multigene Panel Testing for Patients Enrolled in Medicare Advantage Health Plans.
    • Caplan EO, Wong WB, Ferries E, Hulinsky R, Brown VT, Bordenave K, Suehs BT.
    • JCO Precis Oncol. 2021 May 5;5:PO.20.00422. doi: 10.1200/PO.20.00422.
    • Mainstream genetic testing for breast cancer patients: early experiences from the Parkville Familial Cancer Centre.
    • Beard C, Monohan K, Cicciarelli L, James PA.
    • Eur J Hum Genet. 2021 May;29(5):872-880. doi: 10.1038/s41431-021-00848-3. Epub 2021 Mar 15.
    • Screening High-Risk Women Veterans for Breast Cancer.
    • Park YA, Keller A, Hsu TM, Bidassie B, Venne V, Hawley D, Hoffman-Högg L, Heron B, Colonna S, Aggarwal A.
    • Fed Pract. 2021 May;38(Suppl 2):S35-S41. doi: 10.12788/fp.0122.
    • Hérédité et cancer [Heredity and cancer].
    • Docampo E, Martin M, Gangolf M, Harvengt J, Bulk S, Segers K, Leroi N, Lete C, Palmariciotti V, Freire Chadrina V, Lambert F, Bours V.
    • Rev Med Liege. 2021 May;76(5-6):327-336. French.
    • An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
    • Cortesi L, Rugo HS, Jackisch C.
    • Target Oncol. 2021 May;16(3):255-282. doi: 10.1007/s11523-021-00796-4. Epub 2021 Mar 12.
    • Baseline knowledge and receptiveness to genetic testing for hereditary breast and ovarian cancer syndromes in Chinese high-risk females.
    • Chu AT, Tse DM, Suen DTK, Kwong A.
    • J Community Genet. 2021 Apr 30. doi: 10.1007/s12687-021-00518-3. Epub ahead of print.
    • Use of a Standardized Tool to Identify Women at Risk for Hereditary Breast and Ovarian Cancer.
    • Nurs Womens Health. 2021 Apr 29:S1751-4851(21)00080-5. doi: 10.1016/j.nwh.2021.03.008. Epub ahead of print.
    • Real-world genetic testing patterns in metastatic castration-resistant prostate cancer.
    • Shore N, Ionescu-Ittu R, Yang L, Laliberté F, Mahendran M, Lejeune D, Yu L, Burgents J, Duh MS, Ghate SR.
    • Future Oncol. 2021 Apr 28. doi: 10.2217/fon-2021-0153. Epub ahead of print.
    • High-risk women are facing barriers to preventive breast cancer care.
    • Branigin A.
    • Washington Post. The Lily. 2021 Apr 27.

    Related:

    Original research:

    Financial constraints on genetic counseling and further risk-management decisions among U.S. women at elevated breast cancer risk.

    • Factors Influencing Discussion of Cancer Genetic Testing with Health-Care Providers in a Population-Based Survey.
    • Makhnoon S, Yu R, Cunningham SA, Peterson SK, Shete S.
    • Public Health Genomics. 2021 Apr 22:1-11. doi: 10.1159/000515465. Epub ahead of print.
    • Value of a genetics clinic evaluation in identifying women at risk for hereditary breast-ovarian cancer syndrome.
    • Hinshaw JC, Zhao LP, Brimm JE, Payne TH, Hisama FM.
    • J Genet Couns. 2021 Apr 21. doi: 10.1002/jgc4.1425. Epub ahead of print.
    • Universal access to genetic counseling for women with epithelial ovarian cancer in Nova Scotia: Evaluating a new collaborative care model.
    • Warias A, Ferguson M, Chamberlain E, Currie L, Snow N, Matheson K, Penney LS, Kieser K.
    • J Genet Couns. 2021 Apr 19. doi: 10.1002/jgc4.1416. Epub ahead of print.
    • The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada.
    • Narod SA, Gojska N, Sun P, Tryon A, Kotsopoulos J, Metcalfe K, Akbari MR.
    • Cancers (Basel). 2021 Apr 15;13(8):1894. doi: 10.3390/cancers13081894.
    • The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches.
    • Tone AA, McCuaig JM, Ricker N, Boghosian T, Romagnuolo T, Stickle N, Virtanen C, Zhang T, Kim RH, Ferguson SE, May T, Laframboise S, Armel S, Demsky R, Volenik A, Stuart-McEwan T, Shaw P, Oza A, Kamel-Reid S, Stockley T, Bernardini MQ.
    • Gynecol Oncol. 2021 Apr 13:S0090-8258(21)00321-8. doi: 10.1016/j.ygyno.2021.04.011. Epub ahead of print.
    • Management and outcomes of men diagnosed with primary breast cancer.
    • Johnson AE, Coopey SB, Spring LM, Horick NK, Leone JP, Lin NU, Dominici LS, Hughes KS, Jimenez RB.
    • Breast Cancer Res Treat. 2021 Apr 8. doi: 10.1007/s10549-021-06174-y. Epub ahead of print.
    • A Comparison of Patient-Reported Outcomes Following Consent for Genetic Testing Using an Oncologist- or Genetic Counselor-Mediated Model of Care.
    • McCuaig JM, Thain E, Malcolmson J, Keshavarzi S, Armel SR, Kim RH.
    • Curr Oncol. 2021 Apr 8;28(2):1459-1471. doi: 10.3390/curroncol28020138.
    • Development of a culturally sensitive narrative intervention to promote genetic counseling among African American women at risk for hereditary breast cancer.
    • Henderson V, Chukwudozie IB, Comer-Hagans D, Coffey V, Grumbach G, Spencer S, Rodgers C, Kaur R, Newsome J, Balay L, Maga T, Kendall L, Balthazar C, Watson K, Winn R, Odoms-Young A, Hoskins KF.
    • Cancer. 2021 Apr 1. doi: 10.1002/cncr.33525. Epub ahead of print.
    • Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
    • Cobain EF, Wu YM, Vats P, Chugh R, Worden F, Smith DC, Schuetze SM, Zalupski MM, Sahai V, Alva A, Schott AF, Caram MEV, Hayes DF, Stoffel EM, Jacobs MF, Kumar-Sinha C, Cao X, Wang R, Lucas D, Ning Y, Rabban E, Bell J, Camelo-Piragua S, Udager AM, Cieslik M, Lonigro RJ, Kunju LP, Robinson DR, Talpaz M, Chinnaiyan AM.
    • JAMA Oncol. 2021 Apr 1;7(4):525-533. doi: 10.1001/jamaoncol.2020.7987.

    Related:

    Editorial:

    Precision Medicine in Oncology-Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations.

    Letter, Comment:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?

    Letter, Reply:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply.

    Press: Germline Testing: Variant in 1 in 6 Cases of Advanced Cancer. (Medscape Oncology)

    • Tumor phenotype and concordance in synchronous bilateral breast cancer in young women.
    • Pak LM, Gaither R, Rosenberg SM, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Snow C, Collins LC, King TA, Partridge AH.
    • Breast Cancer Res Treat. 2021 Apr;186(3):815-821. doi: 10.1007/s10549-020-06027-0. Epub 2020 Nov 26.
    • Genetic Counseling Clinic at AIIMS (New Delhi).
    • Maitra D, Manek P, Gupta N, Srivastava A.
    • Indian J Surg Oncol. 2021 Apr;12(Suppl 1):30-33. doi: 10.1007/s13193-020-01054-1. Epub 2020 Apr 4.
    • Breast cancer polygenic risk scores in the clinical cancer genetic counseling setting: Current practices and impact on patient management.
    • McGuinness M, Fassi E, Wang C, Hacking C, Ellis V.
    • J Genet Couns. 2021 Apr;30(2):588-597. doi: 10.1002/jgc4.1347. Epub 2020 Oct 30.
    • What improves the likelihood of people receiving genetic test results communicating to their families about genetic risk?
    • Bowen DJ, Makhnoon S, Shirts BH, Fullerton SM, Larson E, Ralston JD, Leppig K, Crosslin DR, Veenstra D, Jarvik GP.
    • Patient Educ Couns. 2021 Apr;104(4):726-731. doi: 10.1016/j.pec.2021.01.001. Epub 2021 Jan 7.
    • O'Neal Comprehensive Cancer Center, My Gene Counsel Partner for Digital Genetic Testing Support.
    • [No author given]
    • Precision Oncology News. Technology. 2021 Mar 26.
    • Germline evaluation of patients undergoing tumor genomic profiling: An academic cancer center's experience with implementing a germline review protocol.
    • Stachowiak S, Jacquart A, Zimmermann MT, George B, Dong H, Geurts JL.
    • J Genet Couns. 2021 Mar 22. doi: 10.1002/jgc4.1392. Epub ahead of print.
    • Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer.
    • Kalra M, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM, Miller KD.
    • NPJ Breast Cancer. 2021 Mar 22;7(1):29. doi: 10.1038/s41523-021-00240-w.
    • Financial constraints on genetic counseling and further risk-management decisions among U.S. women at elevated breast cancer risk.
    • Meadows RJ, Padamsee TJ.
    • J Genet Couns. 2021 Mar 21. doi: 10.1002/jgc4.1413. Epub ahead of print.

    Related:

    Press: High-risk women are facing barriers to preventive breast cancer care. (Washington Post / The Lily)

    • Clinical implementation of an oncology-specific family health history risk assessment tool.
    • Fung SM, Wu RR, Myers RA, Goh J, Ginsburg GS, Matchar D, Orlando LA, Ngeow J.
    • Hered Cancer Clin Pract. 2021 Mar 20;19(1):20. doi: 10.1186/s13053-021-00177-y.
    • Correspondence on "Assessing relatives' readiness for hereditary cancer cascade genetic testing" by Bednar et al.
    • Carlson J.
    • Genet Med. 2021 Mar 19. doi: 10.1038/s41436-020-01094-6. Epub ahead of print.
    • Letter

    Related:

    Original research:

    Assessing relatives' readiness for hereditary cancer cascade genetic testing.

    • Clinical and community genetics services in the Dutch Caribbean.
    • Verberne EA, Ecury-Goossen GM, Manshande ME, Ponson-Wever M, de Vroomen M, Tilanus M, Mannens MMAM, Henneman L, van Haelst MM.
    • J Community Genet. 2021 Mar 10:1-5. doi: 10.1007/s12687-021-00515-6. Epub ahead of print.

    Related:

    Duplicate:

    Clinical and community genetics services in the Dutch Caribbean.

    • Foundation Medicine, InformedDNA Partner to Expand Genetic Counseling for Cancer Patients.
    • [No author given]
    • GenomeWeb. Business & Policy. Business News. 2021 Mar 9.
    • Genetic Testing for Breast and Ovarian Cancer: What Has Changed and What Still Needs To Change?
    • Lyss AP.
    • Medscape. News & Perspective. 2021 Mar 8.

    Related:

    Original research:

    Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.

    • Clinical Utility of Next-Generation Sequencing-Based Panel Testing under the Universal Health-Care System in Japan: A Retrospective Analysis at a Single University Hospital.
    • Inagaki C, Maeda D, Hatake K, Sato Y, Hashimoto K, Sakai D, Yachida S, Nonomura N, Satoh T.
    • Cancers (Basel). 2021 Mar 5;13(5):1121. doi: 10.3390/cancers13051121.
    • Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service.
    • [No author given]
    • GenomeWeb. Business & Policy. Business News. 2021 Mar 2.
    • Assessment of genetic referrals and outcomes for women with triple negative breast cancer in regional cancer centres in Australia.
    • Hallenstein LG, Sorensen C, Hodgson L, Wen S, Westhuyzen J, Hansen C, Last ATJ, Amalaseelan JV, Salindera S, Ross W, Spigelman AD, Shakespeare TP, Aherne NJ.
    • Hered Cancer Clin Pract. 2021 Feb 26;19(1):19. doi: 10.1186/s13053-021-00176-z.
    • The Knowledge and Attitude of Patients Diagnosed with Epithelial Ovarian Cancer towards Genetic Testing.
    • Shin W, Jeong G, Son Y, Seo SS, Kang S, Park SY, Lim MC.
    • Int J Environ Res Public Health. 2021 Feb 26;18(5):2312. doi: 10.3390/ijerph18052312.
    • Barriers and Facilitators to Genetic Service Delivery Models: Scoping Review.
    • Raspa M, Moultrie R, Toth D, Haque SN.
    • Interact J Med Res. 2021 Feb 25;10(1):e23523. doi: 10.2196/23523.
    • Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study.
    • Oosthuizen J, Kotze MJ, Van Der Merwe N, Myburgh EJ, Bester P, van der Merwe NC.
    • Front Oncol. 2021 Feb 12;10:619469. doi: 10.3389/fonc.2020.619469.
    • Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
    • Kurian AW, Ward KC, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Morrow M, Berek JS, Hofer TP, Katz SJ.
    • J Clin Oncol. 2021 Feb 9:JCO2002785. doi: 10.1200/JCO.20.02785. Epub ahead of print.

    Related:

    Research news: Genetic Testing for Breast and Ovarian Cancer: What Has Changed and What Still Needs To Change? (Medscape)

    • Downstream Revenue Generated by a Cancer Genetic Counselor.
    • Mauer CB, Reys BD, Hall RE, Campbell CL, Pirzadeh-Miller SM.
    • JCO Oncol Pract. 2021 Feb 8:OP2000464. doi: 10.1200/OP.20.00464. Epub ahead of print.
    • Implementing genomic screening in diverse populations.
    • Abul-Husn NS, Soper ER, Braganza GT, Rodriguez JE, Zeid N, Cullina S, Bobo D, Moscati A, Merkelson A, Loos RJF, Cho JH, Belbin GM, Suckiel SA, Kenny EE.
    • Genome Med. 2021 Feb 5;13(1):17. doi: 10.1186/s13073-021-00832-y.
    • Preliminary Screening for Hereditary Breast and Ovarian Cancer Using a Chatbot Augmented Intelligence Genetic Counselor: Development and Feasibility Study.
    • Sato A, Haneda E, Suganuma N, Narimatsu H.
    • JMIR Form Res. 2021 Feb 5;5(2):e25184. doi: 10.2196/25184.
    • Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
    • Kikuchi J, Ohhara Y, Takada K, Tanabe H, Hatanaka K, Amano T, C Hatanaka K, Hatanaka Y, Mitamura T, Kato M, Shibata Y, Yabe I, Endoh A, Komatsu Y, Matsuno Y, Sugiyama M, Manabe A, Sakurai A, Takahashi M, Naruse H, Torimoto Y, Dosaka-Akita H, Kinoshita I.
    • Jpn J Clin Oncol. 2021 Feb 3:hyaa277. doi: 10.1093/jjco/hyaa277. Epub ahead of print.
    • Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine.
    • Horgan D, Ciliberto G, Conte P, Curigliano G, Seijo L, Montuenga LM, Garassino M, Penault-Llorca F, Galli F, Ray-Coquard I, Querleu D, Riegman P, Kerr K, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Koeva-Balabanova J, Paradiso A, Maravic Z, Fotaki V, Malats N, Bernini C, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeeck J, Duffy M, Jagielska B, Capoluongo E.
    • Cancers (Basel). 2021 Feb 2;13(3):583. doi: 10.3390/cancers13030583.
    • Barriers and strategies to integrate medical genetics and primary care in underserved populations: a scoping review.
    • Chou AF, Duncan AR, Hallford G, Kelley DM, Dean LW.
    • J Community Genet. 2021 Feb 1. doi: 10.1007/s12687-021-00508-5. Epub ahead of print.
    • Oncologist-led BRCA counselling improves access to cancer genetic testing in middle-income Asian country, with no significant impact on psychosocial outcomes.
    • Yoon SY, Wong SW, Lim J, Ahmad S, Mariapun S, Padmanabhan H, Hassan NT, Lau SY, Ch'ng GS, Haniffa M, Ong WP, Rethanavelu K, Moey LH, Keng WT, Omar J, Mohd Abas MN, Yong CM, Ramasamy V, Md Noor MR, Aliyas I, Lim MCK, Suberamaniam A, Mat Adenan NA, Ahmad ZA, Ho GF, Abdul Malik R, Subramaniam S, Khoo BP, Raja A, Chin YS, Sim WW, Teh BH, Kho SK, Ong ESE, Voon PJ, Ismail G, Lee CL, Abdullah BZ, Loo KS, Lim CS, Lee SJ, Lim KJL, Shafiee MN, Ismail F, Latiff ZA, Ismail MP, Mohamed Jamli MF, Kumarasamy S, Leong KW, Low J, Md Yusof M, Ahmad Mustafa AM, Mat Ali NH, Makanjang M, Tayib S, Cheah N, Lim BK, Fong CK, Foo YC, Mellor Abdullah M, Tan TS, Chow DSY, Ho KF, Raman R, Radzi A, Deniel A, Teoh DCY, Ang SF, Joseph JK, Ng PHO, Tho LM, Ahmad AR, Muin I, Bleiker E, George A, Thong MK, Woo YL, Teo SH.
    • J Med Genet. 2021 Feb 1:jmedgenet-2020-107416. doi: 10.1136/jmedgenet-2020-107416. Epub ahead of print.
    • Initiatives to Scale Up and Expand Reach of Cancer Genomic Services Outside of Specialty Clinical Settings: A Systematic Review.
    • Guan Y, McBride CM, Rogers H, Zhao J, Allen CG, Escoffery C.
    • Am J Prev Med. 2021 Feb;60(2):e85-e94. doi: 10.1016/j.amepre.2020.08.029. Epub 2020 Nov 7.
    • Review
    • SARS-CoV-2 Testing Survey Results - Cancer Diagnostic Testing Amidst COVID-19 Pandemic.
    • [No author given]
    • Association for Medical Pathology. Advocacy. 2021 Feb?.

    Related:

    Press: AMP Survey Finds Significant Decline in Molecular Cancer Testing Due to COVID-19 Pandemic. (GenomeWeb)

    • Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients.
    • Lattimore V, Parsons MT, Spurdle AB, Pearson J, Lehnert K, Sullivan J, Lintott C, Bawden S, Morrin H, Robinson B, Walker L.
    • Breast Cancer Res Treat. 2021 Feb;185(3):583-590. doi: 10.1007/s10549-020-05986-8. Epub 2020 Oct 28.
    • Effects of Germline Pathogenic Variants, Cancer Subtypes, Tumor-related Characteristics, and Pregnancy-associated Diagnosis on Outcomes.
    • Tsai ML, Knaack M, Martone P, Krueger J, Baldinger SR, Lillemoe TJ, Susnik B, Grimm E, Olet S, Rueth N, Swenson KK.
    • Clin Breast Cancer. 2021 Feb;21(1):47-56. doi: 10.1016/j.clbc.2020.07.003. Epub 2020 Jul 9.
    • Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.
    • Loeb S, Giri VN.
    • Eur Urol Oncol. 2021 Feb;4(1):1-9. doi: 10.1016/j.euo.2020.11.011. Epub 2020 Dec 31.

    Related:

    Commentary:

    Streamlining Germline Genetic Testing in Prostate Cancer.

    Commentary:

    Germline BRCA1 Mutation and Prostate Cancer: Be Careful on Causality.

    • Implementation of a High-Risk Breast Clinic for Comprehensive Care of Women With Elevated Breast Cancer Risk Identified by Risk Assessment Models in the Community.
    • Laws A, Mulvey TM.
    • JCO Oncol Pract. 2021 Feb;17(2):e217-e225. doi: 10.1200/OP.20.00256. Epub 2020 Aug 21.
    • Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer.
    • Chittenden A, Haraldsdottir S, Ukaegbu C, Underhill-Blazey M, Gaonkar S, Uno H, Brais LK, Perez K, Wolpin BM, Syngal S, Yurgelun MB.
    • JCO Oncol Pract. 2021 Feb;17(2):e236-e247. doi: 10.1200/OP.20.00678. Epub 2021 Jan 13.
    • The impact of the number of tests presented and a provider recommendation on decisions about genetic testing for cancer risk.
    • Schwartz MLB, Klein WMP, Erby LAH, Smith CH, Roter DL.
    • Patient Educ Couns. 2021 Feb;104(2):265-275. doi: 10.1016/j.pec.2020.09.020. Epub 2020 Sep 18.
    • Recontacting non-BRCA1/2 breast cancer patients for germline CHEK2 c.1100del pathogenic variant testing: uptake and patient experiences.
    • Velthuizen ME, van der Luijt RB, de Vries BJ, Koudijs MJ, Bleiker EMA, Ausems MGEM.
    • Hered Cancer Clin Pract. 2021 Jan 19;19(1):9. doi: 10.1186/s13053-021-00166-1.
    • Challenges of Genomic Testing for Hereditary Breast and Ovarian Cancers.
    • McAlarnen L, Stearns K, Uyar D.
    • Appl Clin Genet. 2021 Jan 14;14:1-9. doi: 10.2147/TACG.S245021.
    • FLABRA, frontline approach for BRCA testing in an ovarian cancer population: a Latin America epidemiologic study.
    • Giornelli G, Gallardo D, Hegg R, Abuin GG, La Vega M, Lim-Law M, Caceres V, Trujillo L, Pilar Estevez-Diz MD, Pacheco C, Sganga L, Goncalves S.
    • Future Oncol. 2021 Jan 8. doi: 10.2217/fon-2020-1152. Epub ahead of print.
    • BRCA testing and outcomes in women with breast cancer.
    • Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer MB, Ye X, Tak CR, Ma J, Dalvi TB, Gutierrez L, Kaye JA, Tyczynski JE, Brixner DI, Biskupiak JE.
    • Breast Cancer Res Treat. 2021 Jan 3. doi: 10.1007/s10549-020-06038-x. Epub ahead of print.
    • Increased ease of access to genetic counseling for low-income women with breast cancer using a point of care screening tool.
    • Rao SK, Thomas KA, Singh R, Biltibo E, Lammers PE, Wiesner GL.
    • J Community Genet. 2021 Jan 3. doi: 10.1007/s12687-020-00499-9. Epub ahead of print.
    • Facilitated cascade testing (FaCT): a randomized controlled trial.
    • Nitecki R, Moss HA, Watson CH, Urbauer DL, Melamed A, Lu KH, Lipkin SM, Offit K, Rauh-Hain JA, Frey MK.
    • Int J Gynecol Cancer. 2020 Dec 18:ijgc-2020-002118. doi: 10.1136/ijgc-2020-002118. Epub ahead of print.
    • Examining the uptake of predictive BRCA testing in the UK; findings and implications.
    • Martin AP, Downing J, Collins B, Godman B, Alfirevic A, Greenhalgh KL, Pirmohamed M.
    • Eur J Hum Genet. 2020 Dec 16. doi: 10.1038/s41431-020-00783-9. Epub ahead of print.
    • BRCA testing delay during the COVID-19 pandemic: How to act?
    • Minucci A, Scambia G, De Bonis M, De Paolis E, Santonocito C, Fagotti A, Capoluongo E, Concolino P, Urbani A.
    • Mol Biol Rep. 2020 Dec 12. doi: 10.1007/s11033-020-06060-8. Epub ahead of print.
    • Exploring the real-world effect of the SARS-CoV-2 pandemic on the molecular diagnostics for cancer patients and high-risk individuals.
    • Cavic M, Krivokuca A, Boljevic I, Spasic J, Mihajlovic M, Pavlovic M, Damjanovic A, Radosavljevic D, Jankovic R.
    • Expert Rev Mol Diagn. 2020 Dec 5. doi: 10.1080/14737159.2021.1860760. Epub ahead of print.
    • Transition to telephone genetic counseling services during the COVID-19 pandemic.
    • Shannon KM, Emmet MM, Rodgers LH, Wooters M, Seidel ML.
    • J Genet Couns. 2020 Dec 4. doi: 10.1002/jgc4.1365. Epub ahead of print.
    • DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review.
    • Armstrong N, Quek RG, Ryder S, Ross J, Titas Buksnys, Forbes C, Fox KM, Castro E.
    • Future Oncol. 2020 Dec 2. doi: 10.2217/fon-2020-0569. Epub ahead of print.
    • Review
    • Screening entire populations for breast and ovarian cancer could prevent millions of cases worldwide, study says.
    • Printz C.
    • Cancer. 2020 Dec 1;126(23):5007. doi: 10.1002/cncr.33302.

    Related:

    Original research:

    Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems.

    • Genetics and the Gynecologic Patient.
    • Wade KS, Estes JM, Kline RC.
    • Ochsner J. 2020 Winter;20(4):446-451. doi: 10.31486/toj.20.0051.
    • Women's Intentions to Engage in Risk-Reducing Behaviours after Receiving Personal Ovarian Cancer Risk Information: An Experimental Survey Study.
    • Gallagher A, Waller J, Manchanda R, Jacobs I, Sanderson S.
    • Cancers (Basel). 2020 Nov 27;12(12):3543. doi: 10.3390/cancers12123543.
    • Communication about positive BRCA1 and BRCA2 genetic test results and uptake of testing in relatives in a diverse Asian setting.
    • Lee DS, Meiser B, Mariapun S, Hassan T, Yip CH, Mohd Taib NA, Teo SH, Thong MK, Yoon SY.
    • J Genet Couns. 2020 Nov 27. doi: 10.1002/jgc4.1360. Epub ahead of print.
    • Genotype-first approach to the detection of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank participants.
    • Leitsalu L, Palover M, Sikka TT, Reigo A, Kals M, Pärn K, Nikopensius T, Esko T, Metspalu A, Padrik P, Tõnisson N.
    • Eur J Hum Genet. 2020 Nov 23. doi: 10.1038/s41431-020-00760-2. Epub ahead of print.
    • BRCA gene testing in women with high-grade serous ovarian carcinoma.
    • Kansu B, Gardner J, Price-Tate R, Murch O, Murray A.
    • J Obstet Gynaecol. 2020 Nov 23:1-4. doi: 10.1080/01443615.2020.1820466. Epub ahead of print.
    • Process evaluation of a culturally targeted video for Latinas at risk of hereditary breast and ovarian cancer.
    • Hurtado-de-Mendoza A, Gómez-Trillos S, Graves KD, Carrera P, Campos C, Anderson L, Gronda A, Orellana H, Peshkin BN, Schwartz MD, Cupertino P, Ostrove N, Luta G, Gonzalez N, Sheppard VB.
    • J Genet Couns. 2020 Nov 22. doi: 10.1002/jgc4.1361. Epub ahead of print.
    • Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer.
    • Rana HQ, Kipnis L, Hehir K, Cronin A, Jaung T, Stokes SM, Fekrmandi F, Vatnick D, Matulonis UA, Garber JE, Wright AA.
    • Gynecol Oncol. 2020 Nov 21:S0090-8258(20)34111-1. doi: 10.1016/j.ygyno.2020.11.003. Epub ahead of print.
    • Cancer Previvors in an Active Duty Service Women Population: An Opportunity for Prevention and Increased Force Readiness.
    • Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE.
    • Mil Med. 2020 Nov 18:usaa485. doi: 10.1093/milmed/usaa485. Epub ahead of print.
    • Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
    • Benusiglio PR, Korenbaum C, Vibert R, Ezenfis J, Geoffron S, Paul C, Richard S, Byrde V, Lejeune M, Guillerm E, Basset N, Lotz JP, Chabbert-Buffet N, Gligorov J, Coulet F.
    • Eur J Med Genet. 2020 Nov 10;63(12):104098. doi: 10.1016/j.ejmg.2020.104098. Epub ahead of print.
    • Trends in Positive BRCA Test Results Among Older Women in the United States, 2008-2018.
    • Guo F, Scholl M, Fuchs EL, Wong R, Kuo YF, Berenson AB.
    • JAMA Netw Open. 2020 Nov 2;3(11):e2024358. doi: 10.1001/jamanetworkopen.2020.24358.

    Related:

    Commentary:

    Time for BRCA Testing Among Women 65 Years or Older in the United States.

    • BRCA-Related Cancer Genetic Counseling is Indicated in Many Women Seeking Primary Care.
    • Parente DJ.
    • J Am Board Fam Med. 2020 Nov-Dec;33(6):885-893. doi: 10.3122/jabfm.2020.06.190461.
    • BRCA testing in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral.
    • Piedimonte S, Power J, Foulkes WD, Weber E, Palma L, Schiavi A, Ambrosio E, Konci R, Gilbert L, Jardon K, Baret L, Zeng X.
    • Int J Gynecol Cancer. 2020 Nov;30(11):1757-1761. doi: 10.1136/ijgc-2020-001261. Epub 2020 Aug 5.
    • Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer.
    • [No author given]
    • FORCE. XRAY. 2020 Oct 26.

    Related:

    Original research:

    Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.

    • Doing a Better Job at Reaching LatinX People and Families about Hereditary Cancer.
    • Gómez Trillos S, Hurtado de Mendoza A.
    • FORCE. Blog. 2020 Oct 21.
    • Clinically Actionable Findings Derived From Predictive Genomic Testing Offered in a Medical Practice Setting.
    • Anderson JL, Kruisselbrink TM, Lisi EC, Hughes TM, Steyermark JM, Winkler EM, Berg CM, Vierkant RA, Gupta R, Ali AH, Faubion SS, Aoudia SL, McAllister TM, Farrugia G, Stewart AK, Lazaridis KN.
    • Mayo Clin Proc. 2020 Oct 21:S0025-6196(20)31119-8. doi: 10.1016/j.mayocp.2020.08.051. Epub ahead of print.
    • The mediating effects of public genomic knowledge in precision medicine implementation: A structural equation model approach.
    • Mogaka JJO, Chimbari MJ.
    • PLoS One. 2020 Oct 14;15(10):e0240585. doi: 10.1371/journal.pone.0240585.
    • Pfizer, Invitae Focus on Expanding Global BRCA1/2 Test Access Amid Treatment, Screening Barriers.
    • Hopkins C.
    • Precision Oncology News. 2020 Oct 14.
    • News
    • Experiences and attitudes of hereditary cancer screening patients in a consumer directed testing model.
    • Greve V, Garner M, Odom K, Cooper SJ, East KM.
    • Patient Educ Couns. 2020 Oct 11:S0738-3991(20)305498. doi: 10.1016/j.pec.2020.10.014. Epub ahead of print.
    • Knowledge and Attitudes About Genetic Testing Among Black and White Women with Breast Cancer.
    • McCall MK, Ibikunle S, Murphy Y, Hunter K, Rosenzweig MQ.
    • J Racial Ethn Health Disparities. 2020 Oct 6. doi: 10.1007/s40615-020-00878-5. Epub ahead of print.
    • Male Breast Cancer: 13-Year Single Institution Experience.
    • Srour MK, Amersi F, Mirocha J, Giuliano AE, Chung A.
    • Am Surg. 2020 Oct;86(10):1345-1350. doi: 10.1177/0003134820964444. Epub 2020 Oct 25.
    • Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.
    • Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.
    • Cancer Treat Res Commun. 2020 Sep 28;25:100212. doi: 10.1016/j.ctarc.2020.100212. Epub ahead of print.
    • "I think that a brief conversation from their provider can go a very long way": Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer.
    • Mallen AR, Conley CC, Fuzzell L, Ketcher D, Augusto BM, McIntyre M, Barton LV, Townsend MK, Fridley BL, Tworoger SS, Wenham RM, Vadaparampil ST.
    • Support Care Cancer. 2020 Sep 25. doi: 10.1007/s00520-020-05779-1. Epub ahead of print.
    • Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer.
    • Scheinberg T, Goodwin A, Ip E, Linton A, Mak B, Smith DP, Stockler MR, Strach MC, Tran B, Young AL, Zhang AY, Mahon KL, Horvath LG.
    • JCO Oncol Pract. 2020 Sep 24:OP2000399. doi: 10.1200/OP.20.00399. Epub ahead of print.
    • Electronic health records contain dispersed risk factor information that could be used to prevent breast and ovarian cancer.
    • Payne TH, Zhao LP, Le C, Wilcox P, Yi T, Hinshaw J, Hussey D, Kostrinsky-Thomas A, Hale M, Brimm J, Hisama FM.
    • J Am Med Inform Assoc. 2020 Sep 17:ocaa152. doi: 10.1093/jamia/ocaa152. Epub ahead of print.
    • Implementing Cancer Genomics in State Health Agencies: Mapping Activities to an Implementation Science Outcome Framework.
    • Green RF, Kumerow MT, Rodriguez JL, Addie S, Beachy SH, Senier L.
    • Public Health Genomics. 2020 Sep 17:1-12. doi: 10.1159/000510336. Epub ahead of print.

    Related:

    Original research:

    Proposed outcomes measures for state public health genomic programs.

    • A pilot randomized trial of an educational intervention to increase genetic counseling and genetic testing among Latina breast cancer survivors.
    • Conley CC, Castro-Figueroa EM, Moreno L, Dutil J, García JD, Burgos C, Ricker C, Kim J, Graves KD, Ashing KT, Quinn GP, Soliman H, Vadaparampil ST.
    • J Genet Couns. 2020 Sep 16. doi: 10.1002/jgc4.1324. Epub ahead of print.
    • Adherence to NCCN Guidelines for Genetic Testing in Breast Cancer Patients: Who Are We Missing?
    • Alberty-Oller JJ, Weltz S, Santos A, Pisapati K, Ru M, Weltz C, Schmidt H, Port E.
    • Ann Surg Oncol. 2020 Sep 11. doi: 10.1245/s10434-020-09123-z. Epub ahead of print.
    • BRCA1/2 Testing in Massachusetts Among Women With Private Insurance or Medicaid, 2011-2015.
    • Pace LE, Baum CF, Horvath K, Raja SC, Cohen J, Hawkins SS.
    • Med Care. 2020 Sep 10. doi: 10.1097/MLR.0000000000001405. Epub ahead of print.
    • Relaunched Canadian BRCA1/2 Screening Project Aims to ID High-Risk Carriers, Intervene Early.
    • Anderson A.
    • Precision Oncology News. 2020 Sep 8.
    • News
    • Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial.
    • Katapodi MC, Ming C, Northouse LL, Duffy SA, Duquette D, Mendelsohn-Victor KE, Milliron KJ, Merajver SD, Dinov ID, Janz NK.
    • Cancers (Basel). 2020 Sep 5;12(9):2526. doi: 10.3390/cancers12092526.
    • Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.
    • Hadar T, Mor P, Amit G, Lieberman S, Gekhtman D, Rabinovitch R, Levy-Lahad E.
    • JAMA Oncol. 2020 Sep 1;6(9):1460-1463. doi: 10.1001/jamaoncol.2020.2059.

    Related:

    Research news: Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis. (GenomeWeb)

    Research news: 'Knowledge Is Power': Knowing BRCA1/2 Status Tied to Survival. (Medscape)

    Research news: Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer. (FORCE. XRAY.)

    • Disparities in Genetic Testing and Care among Black women with Hereditary Breast Cancer.
    • Reid S, Cadiz S, Pal T.
    • Curr Breast Cancer Rep. 2020 Sep;12(3):125-131. doi: 10.1007/s12609-020-00364-1. Epub 2020 May 19.
    • Strategies to enhance identification of hereditary breast cancer gene carriers.
    • Reid S, Spalluto LB, Pal T.
    • Expert Rev Mol Diagn. 2020 Aug 28. doi: 10.1080/14737159.2020.1816829. Epub ahead of print.
    • Germline mutations and prostate cancer: is it time to change treatment algorithms?
    • Telvizian T, Mukherji D.
    • Chin Clin Oncol. 2020 Aug 27:cco-19-207. doi: 10.21037/cco-19-207. Epub ahead of print.
    • The management of BRCA1 and BRCA2 carriers in Singapore.
    • Chiang J, Ngeow J.
    • Chin Clin Oncol. 2020 Aug 17:cco-20-104. doi: 10.21037/cco-20-104. Epub ahead of print.
    • Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
    • Dawood S, Konstantinova M, Perazzo F, Kim SB, Villarreal-Garza C, Franco SX, Simon SD, El-Nahas T.
    • Chin Clin Oncol. 2020 Aug 17:cco-20-138. doi: 10.21037/cco-20-138. Epub ahead of print.
    • From Probands to Relatives: Communication of Genetic Risk for Hereditary Breast-Ovarian Cancer and Its Influence on Subsequent Testing.
    • Seven M, Shah LL, Yazici H, Daack-Hirsch S.
    • Cancer Nurs. 2020 Aug 13. doi: 10.1097/NCC.0000000000000876. Epub ahead of print.
    • Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation.
    • Jeong GW, Shin W, Lee DO, Seo SS, Kang S, Park SY, Lim MC.
    • Cancer Res Treat. 2020 Aug 11. doi: 10.4143/crt.2020.364. Epub ahead of print.
    • Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.
    • Powell CB, Laurent C, Ciaravino G, Garcia C, Han L, Hoodfar E, Karlea A, Kobelka C, Lee J, Littell RD, Roh J, Vay A, Kushi LH.
    • Gynecol Oncol. 2020 Aug 7:S0090-8258(20)33662-3. doi: 10.1016/j.ygyno.2020.07.027. Epub ahead of print.
    • Breast imaging, breast surgery, and cancer genetics in the age of COVID-19.
    • Yin K, Singh P, Drohan B, Hughes KS.
    • Cancer. 2020 Aug 4. doi: 10.1002/cncr.33113. Epub ahead of print.
    • Patterns of cancer family history and genetic counseling eligibility among African Americans with breast, prostate, lung, and colorectal cancers: A Detroit Research on Cancer Survivors cohort study.
    • Purrington KS, Schwartz AG, Ruterbusch JJ, Manning MA, Nair M, Wenzlaff AS, Pandolfi SS, Simon MS, Beebe-Dimmer J.
    • Cancer. 2020 Aug 4. doi: 10.1002/cncr.33126. Epub ahead of print.
    • Ancestry-specific hereditary cancer panel yields: Moving toward more personalized risk assessment.
    • Roberts ME, Susswein LR, Janice Cheng W, Carter NJ, Carter AC, Klein RT, Hruska KS, Marshall ML.
    • J Genet Couns. 2020 Aug;29(4):598-606. doi: 10.1002/jgc4.1257. Epub 2020 Mar 30.
    • Clinicopathological characteristics of gene-positive breast cancer in the United Arab Emirates.
    • Altinoz A, Al Ameri M, Qureshi W, Boush N, Nair SC, Abdel-Aziz A.
    • Breast. 2020 Jul 27;53:119-124. doi: 10.1016/j.breast.2020.07.005. Epub ahead of print.
    • Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center.
    • Chapman-Davis E, Zhou ZN, Fields JC, Frey MK, Jordan B, Sapra KJ, Chatterjee-Paer S, Carlson AD, Holcomb KM.
    • J Gen Intern Med. 2020 Jul 27. doi: 10.1007/s11606-020-06064-x. Epub ahead of print.
    • Population genetic screening efficiently identifies carriers of autosomal dominant diseases.
    • Grzymski JJ, Elhanan G, Morales Rosado JA, Smith E, Schlauch KA, Read R, Rowan C, Slotnick N, Dabe S, Metcalf WJ, Lipp B, Reed H, Sharma L, Levin E, Kao J, Rashkin M, Bowes J, Dunaway K, Slonim A, Washington N, Ferber M, Bolze A, Lu JT.
    • Nat Med. 2020 Jul 27. doi: 10.1038/s41591-020-0982-5. Epub ahead of print.
    • Disclosure of secondary findings in exome sequencing of 2480 Japanese cancer patients.
    • Horiuchi Y, Matsubayashi H, Kiyozumi Y, Nishimura S, Higashigawa S, Kado N, Nagashima T, Mizuguchi M, Ohnami S, Arai M, Urakami K, Kusuhara M, Yamaguchi K.
    • Hum Genet. 2020 Jul 24. doi: 10.1007/s00439-020-02207-6. Epub ahead of print.
    • Germlines 'Rich Source' of Prostate Cancer Info.
    • O'Rourke K, Giri V.
    • Medscape Oncology. 2020 Jul 21.
    • Economic Evaluation of Population-Based BRCA1/BRCA2 Mutation Testing across Multiple Countries and Health Systems.
    • Manchanda R, Sun L, Patel S, Evans O, Wilschut J, De Freitas Lopes AC, Gaba F, Brentnall A, Duffy S, Cui B, Coelho De Soarez P, Husain Z, Hopper J, Sadique Z, Mukhopadhyay A, Yang L, Berkhof J, Legood R.
    • Cancers (Basel). 2020 Jul 17;12(7):1929. doi: 10.3390/cancers12071929.

    Related:

    Press: BRCA1/2 Population Screening Predicted to be Cost-Effective in Countries With Different Income Levels (GenomeWeb)

    Commentary:

    Screening entire populations for breast and ovarian cancer could prevent millions of cases worldwide, study says.

    • Utilization of clinical genetic counseling among childhood and young adult cancer survivors in a registry trial.
    • Anderson N, Delavar A, Friedman DN, Joseph V, Mubdi N, Oeffinger KC, Sklar CA, Offit K, Matasar M, Raghunathan N, Antal Z, Straus D, Walsh M, Latham A, Tonorezos ES.
    • J Community Genet. 2020 Jul 16. doi: 10.1007/s12687-020-00478-0. Epub ahead of print.
    • Year 1: Experiences of a tertiary cancer centre following implementation of reflex BRCA1 and BRCA2 tumor testing for all high-grade serous ovarian cancers in a universal healthcare system.
    • McCuaig JM, Care M, Ferguson SE, Kim RH, Stockley TL, Metcalfe KA.
    • Gynecol Oncol. 2020 Jul 13:S0090-8258(20)32333-7. doi: 10.1016/j.ygyno.2020.06.507. Epub ahead of print.
    • Mechanisms to increase cascade testing in hereditary breast and ovarian cancer: Impact of introducing standardized communication aids into genetic counseling.
    • Garcia C, Sullivan MW, Lothamer H, Harrison KM, Chatfield L, Thomas MH, Modesitt SC.
    • J Obstet Gynaecol Res. 2020 Jul 12. doi: 10.1111/jog.14366. Epub ahead of print.
    • Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
    • Flaum N, Morgan RD, Burghel GJ, Bulman M, Clamp AR, Hasan J, Mitchell CL, Badea D, Moon S, Hogg M, Hadjiyiannakis D, Clancy T, Schlecht H, Woodward ER, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Lalloo FI, Harkness EF, Evans DGR.
    • Eur J Hum Genet. 2020 Jul 10. doi: 10.1038/s41431-020-0692-y. Epub ahead of print.
    • Variations in the Referral Pattern for Genetic Counseling of Patients with Early-Onset Breast Cancer: A Population-Based Study in Southern Sweden.
    • Augustinsson A, Ellberg C, Kristoffersson U, Olsson H, Ehrencrona H.
    • Public Health Genomics. 2020 Jul 8:1-10. doi: 10.1159/000508684. Epub ahead of print.
    • Genetic Counseling, Testing, and Management of HBOC in India: An Expert Consensus Document from Indian Society of Medical and Pediatric Oncology.
    • Malhotra H, Kowtal P, Mehra N, Pramank R, Sarin R, Rajkumar T, Gupta S, Bapna A, Bhattacharyya GS, Gupta S, Maheshwari A, Mannan AU, Reddy Kundur R, Sekhon R, Singhal M, Smruti BK, Sp S, Suryavanshi M, Verma A.
    • JCO Glob Oncol. 2020 Jul;6:991-1008. doi: 10.1200/JGO.19.00381.
    • Genetic testing and results disclosure in diverse populations: what does it take?
    • Horowitz CR.
    • Genet Med. 2020 Jun 22. doi: 10.1038/s41436-020-0874-6. Epub ahead of print.
    • Commentary
    • Genetic counselors' perspectives on population-based screening for BRCA-related hereditary breast and ovarian cancer and Lynch syndrome.
    • De Simone LM, Arjunan A, Vogel Postula KJ, Maga T, Bucheit LA.
    • J Genet Couns. 2020 Jun 20. doi: 10.1002/jgc4.1305. Epub ahead of print.
    • Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach.
    • Marchetti C, Minucci A, D'Indinosante M, Ergasti R, Arcieri M, Capoluongo ED, Pietragalla A, Caricato C, Scambia G, Fagotti A.
    • Gynecol Oncol. 2020 Jun 15:S0090-8258(20)32294-0. doi: 10.1016/j.ygyno.2020.06.479. Epub ahead of print.
    • Improving primary care identification of familial breast cancer risk using proactive invitation and decision support.
    • Qureshi N, Dutton B, Weng S, Sheehan C, Chorley W, Robertson JFR, Kendrick D, Kai J.
    • Fam Cancer. 2020 Jun 11. doi: 10.1007/s10689-020-00188-z. Epub ahead of print.
    • Web-based return of BRCA2 research results: one-year genetic counselling experience in Iceland.
    • Stefansdottir V, Thorolfsdottir E, Hognason HB, Patch C, van El C, Hentze S, Cordier C, Mendes Á, Jonsson JJ.
    • Eur J Hum Genet. 2020 Jun 10. doi: 10.1038/s41431-020-0665-1. Epub ahead of print.
    • Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
    • Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG.
    • J Clin Oncol. 2020 Jun 9:JCO2000046. doi: 10.1200/JCO.20.00046. Epub ahead of print.

    Related:

    Press: Cancer Experts Develop Precision Medicine-Based Genetic Testing Framework for Prostate Cancer. (GenomeWeb)

    Press: Consider Genetic Testing in All Metastatic Prostate Cancers. (MedPage Today)

    • How to improve the identification of patients with cancer eligible for genetic counselling?
    • Bracci R, Gasperini B, Capalbo M, Campanelli T, Caimmi E, Mattioli R, Espinosa E, Prospero E.
    • Eur J Cancer Care (Engl). 2020 Jun 8:e13276. doi: 10.1111/ecc.13276. Epub ahead of print.
    • Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study.
    • Bobbili P, Olufade T, DerSarkissian M, Shenolikar R, Yu H, Duh MS, Tung N.
    • Hered Cancer Clin Pract. 2020 Jun 6;18:13. doi: 10.1186/s13053-020-00144-z.
    • Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing.
    • Rosenberger LH, Thomas SM, Nimbkar SN, Hieken TJ, Ludwig KK, Jacobs LK, Miller ME, Gallagher KK, Wong J, Neuman HB, Tseng J, Hassinger TE, Jakub JW.
    • Ann Surg Oncol. 2020 Jun 5. doi: 10.1245/s10434-020-08480-z. Epub ahead of print.
    • Studies Show Potential of Video, Online Education to Expand Cancer Risk Genetic Test Access.
    • Ray T.
    • Precision Oncology News. 2020 Jun 4.
    • Press
    • "It wasn't just for me": Motivations and implications of genetic testing for women at a low risk of hereditary breast and ovarian cancer syndrome.
    • Gill G, Beard C, Storey K, Taylor S, Sexton A.
    • Psychooncology. 2020 Jun 4. doi: 10.1002/pon.5436. Epub ahead of print.
    • Setting a baseline: A 7-year review of referral rates and outcomes for serous ovarian cancer prior to implementation of oncologist mediated genetic testing.
    • Armel SR, Volenik A, Demsky R, Malcolmson J, Maganti M, McCuaig J.
    • Gynecol Oncol. 2020 Jun 3:S0090-8258(20)31082-9. doi: 10.1016/j.ygyno.2020.05.014. Epub ahead of print.
    • BFOR Study Uses Digital Tools to Facilitate Population BRCA Screening in Ashkenazi Jewish Community.
    • Anderson A.
    • Precision Oncology News. 2020 Jun 3.
    • Sequencing technology status of BRCA1/2 testing in Latin American Countries.
    • Solano AR, Palmero EI, Delgado L, Carraro DM, Ortíz-López R, Carranza CL, Santamaria C, Cifuentes L, Jara Sosa LE, Toland AE.
    • NPJ Genom Med. 2020 Jun 2;5(1):22. doi: 10.1038/s41525-020-0126-3.

    Duplicate of:

    • Sequencing technology status of BRCA1/2 testing in Latin American Countries.
    • Solano AR, Palmero EI, Delgado L, Carraro DM, Ortíz-López R, Carranza CL, Santamaria C, Cifuentes L, Jara Sosa LE, Toland AE.
    • NPJ Genom Med. 2020 Jun 2;5:22. doi: 10.1038/s41525-020-0126-3.
    • BRCA testing in a genomic diagnostics referral center during the COVID-19 pandemic.
    • Minucci A, Scambia G, Santonocito C, Concolino P, Urbani A.
    • Mol Biol Rep. 2020 Jun;47(6):4857-4860. doi: 10.1007/s11033-020-05479-3. Epub 2020 May 9.
    • Changing practice: moving to a specialist nurse-led service for BRCA gene testing.
    • Scott N, O'Sullivan J, Asgeirsson K, Macmillan D, Wilson E.
    • Br J Nurs. 2020 May 28;29(10):S6-S13. doi: 10.12968/bjon.2020.29.10.S6.
    • How can Australia integrate routine genetic sequencing in oncology: a qualitative study through an implementation science lens.
    • O'Shea R, Rankin NM, Kentwell M, Gleeson M, Salmon L, Tucker KM, Lewis S, Taylor N.
    • Genet Med. 2020 May 28. doi: 10.1038/s41436-020-0838-x. Epub ahead of print.
    • Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention.
    • Gaba F, Blyuss O, Liu X, Goyal S, Lahoti N, Chandrasekaran D, Kurzer M, Kalsi J, Sanderson S, Lanceley A, Ahmed M, Side L, Gentry-Maharaj A, Wallis Y, Wallace A, Waller J, Luccarini C, Yang X, Dennis J, Dunning A, Lee A, Antoniou AC, Legood R, Menon U, Jacobs I, Manchanda R.
    • Cancers (Basel). 2020 May 15;12(5):E1241. doi: 10.3390/cancers12051241.
    • Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.
    • Tennen RI, Laskey SB, Koelsch BL, McIntyre MH, Tung JY.
    • Sci Rep. 2020 May 6;10(1):7669. doi: 10.1038/s41598-020-63466-x.
    • Utilization of genetic testing in breast cancer treatment after implementation of comprehensive multi-disciplinary care.
    • Doe S, Petersen S, Swain M.
    • Breast J. 2020 May;26(5):911-916. doi: 10.1111/tbj.13747. Epub 2020 Jan 9.
    • Positive impact of genetic counseling assistants on genetic counseling efficiency, patient volume, and cost in a cancer genetics clinic.
    • Hallquist MLG, Tricou EP, Hallquist MN, Savatt JM, Rocha H, Evans AE, Deckard N, Hu Y, Kirchner HL, Pervola J, Rahm AK, Rashkin M, Schmidlen TJ, Schwartz MLB, Williams JL, Williams MS, Buchanan AH.
    • Genet Med. 2020 Apr 30. doi: 10.1038/s41436-020-0797-2. Epub ahead of print.
    • Uptake of pre-symptomatic testing for BRCA1 and BRCA2 is age, gender, offspring and time-dependent.
    • Forde C, Brunstrom K, Woodward E, Bowers N, Pereira M, Wallace AJ, Lalloo F, Harkness EF, Evans DG.
    • J Med Genet. 2020 Apr 30. pii: jmedgenet-2019-106544. doi: 10.1136/jmedgenet-2019-106544. [Epub ahead of print]
    • Predictors of genetic testing uptake in newly diagnosed breast cancer patients.
    • Ladd MK, Peshkin BN, Isaacs C, Hooker G, Willey S, Valdimarsdottir H, DeMarco T, O'Neill S, Binion S, Schwartz MD; other members of the Surgery After Genetic Evaluation Study Group.
    • J Surg Oncol. 2020 Apr 28. doi: 10.1002/jso.25956. [Epub ahead of print]
    • Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer.
    • Krepline AN, Geurts JL, Akinola I, Christians KK, Clarke CN, George B, Ritch PS, Khan AH, Hall WA, Erickson BA, Griffin MO, Evans DB, Tsai S.
    • HPB (Oxford). 2020 Apr 27. pii: S1365-182X(20)30109-X. doi: 10.1016/j.hpb.2020.03.022. [Epub ahead of print]
    • Acceptability and outcomes of multigene panel testing among young Black breast cancer survivors.
    • Conley CC, Garcia JD, Radford C, Reich RR, Monteiro AN, Pal T, Vadaparampil ST.
    • Breast J. 2020 Apr 22. doi: 10.1111/tbj.13848. Epub ahead of print.
    • Commentary
    • Systematic development of a training program for healthcare professionals to improve communication about breast cancer genetic counseling with low health literate patients.
    • van der Giessen JAM, Ausems MGEM, van den Muijsenbergh METC, van Dulmen S, Fransen MP.
    • Fam Cancer. 2020 Apr 22. doi: 10.1007/s10689-020-00176-3. [Epub ahead of print]
    • Population Screening for Inherited Predisposition to Breast and Ovarian Cancer.
    • Manchanda R, Lieberman S, Gaba F, Lahad A, Levy-Lahad E.
    • Annu Rev Genomics Hum Genet. 2020 Apr 21. doi: 10.1146/annurev-genom-083118-015253. [Epub ahead of print]
    • Unanswered Questions: Hereditary breast and gynecological cancer risk assessment in transgender adolescents and young adults.
    • Sutherland N, Espinel W, Grotzke M, Colonna S.
    • J Genet Couns. 2020 Apr 18. doi: 10.1002/jgc4.1278. [Epub ahead of print]
    • The uptake of predictive DNA testing in 40 families with a pathogenic BRCA1/BRCA2 variant. An evaluation of the proband-mediated procedure.
    • Menko FH, Jeanson KN, Bleiker EMA, van Tiggelen CWM, Hogervorst FBL, Ter Stege JA, Ait Moha D, van der Kolk LE.
    • Eur J Hum Genet. 2020 Apr 16. doi: 10.1038/s41431-020-0618-8. [Epub ahead of print]
    • A road map for the future: An exploration of attitudes, perceptions, and beliefs among African Americans to tailor health promotion of cancer-related genetic counseling and testing.
    • Lumpkins CY, Philp A, Nelson KL, Miller LM, Greiner KA.
    • J Genet Couns. 2020 Apr 15. doi: 10.1002/jgc4.1277. [Epub ahead of print]
    • Adventist Health, CancerIQ Collaboration Identifying More Patients for Guidelines-Supported Genetic Testing.
    • Versel N.
    • GenomeWeb. 2020 Apr 3.
    • News
    • A regional population-based hereditary breast cancer screening tool in Italy: First 5-year results.
    • Cortesi L, Baldassarri B, Ferretti S, Razzaboni E, Bella M, Bucchi L, Canuti D, De Iaco P, De Santis G, Falcini F, Galli V, Godino L, Leoni M, Perrone AM, Pignatti M, Saguatti G, Santini D, Sassoli de'Bianchi P, Sebastiani F, Taffurelli M, Tazzioli G, Turchetti D, Zamagni C, Naldoni C.
    • Cancer Med. 2020 Apr;9(7):2579-2589. doi: 10.1002/cam4.2824. Epub 2020 Feb 11.
    • Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients.
    • Bradbury AR, Egleston BL, Patrick-Miller LJ, Rustgi N, Brandt A, Brower J, DiGiovanni L, Fetzer D, Berkelbach C, Long JM, Powers J, Stopfer JE, Domchek SM.
    • Clin Genet. 2020 Apr;97(4):601-609. doi: 10.1111/cge.13716.
    • Assessing relatives' readiness for hereditary cancer cascade genetic testing.
    • Bednar EM, Sun CC, McCurdy S, Vernon SW.
    • Genet Med. 2020 Apr;22(4):719-726. doi: 10.1038/s41436-019-0735-3. Epub 2019 Dec 20.

    Related:

    Letter:

    Correspondence on "Assessing relatives' readiness for hereditary cancer cascade genetic testing" by Bednar et al.

    • Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.
    • Frey MK, Lee SS, Gerber D, Schwartz ZP, Martineau J, Lutz K, Reese E, Dalton E, Olsen A, Girdler J, Pothuri B, Boyd L, Curtin JP, Levine DA, Blank SV.
    • Gynecol Oncol. 2020 Apr;157(1):280-286. doi: 10.1016/j.ygyno.2020.01.007. Epub 2020 Feb 11.
    • Uptake of Risk Appropriate Behaviors After Breast Cancer Risk Stratification in the Mammography Screening Population.
    • Conley CC, Niell BL, Augusto BM, McIntyre M, Roetzheim R, Funaro K, Vadaparampil ST.
    • J Am Coll Radiol. 2020 Mar 27. pii: S1546-1440(20)30240-4. doi: 10.1016/j.jacr.2020.02.019. [Epub ahead of print]

    Related:

    Press: Mailed Notices of High Breast Cancer Risk Do Not Often Translate Into Behavior Changes. (Medscape/Reuters)

    • Public perception of predictive cancer genetic testing and research in Oregon.
    • Alvord TW, Marriott LK, Nguyen PT, Shafer A, Brown K, Stoller W, Volpi JL, Vandehey-Guerrero J, Ferrara LK, Blakesley S, Solomon E, Kuehl H, Palma AJ, Farris PE, Hamman KJ, Cotter M, Shannon J.
    • J Genet Couns. 2020 Mar 27. doi: 10.1002/jgc4.1262. [Epub ahead of print]
    • Genetic Testing for Cancer Predisposition Syndromes in Adolescents and Young Adults (AYAs)
    • Cullinan N, Capra M, McVeigh TP.
    • Curr Genet Med Rep. 2020 Mar 24. doi: 10.1007/s40142-020-00187-7. [Epub ahead of print]
    • Review
    • Germline Genetic Testing, Counseling Move Remote as Pandemic Limits In-Person Care Capacity.
    • Hu C.
    • GenomeWeb. 2020 Mar 24.
    • Germline BRCA Mutation Rates in Latina Women Presenting for Gynecologic Oncology Care.
    • Hong L, Gonzalez R, Unternaehrer J, Ioffe Y.
    • Gynecol Obstet Invest. 2020 Mar 23:1-8. doi: 10.1159/000506108. [Epub ahead of print]
    • Education on cancer risk assessment and genetic counseling to address cancer health disparities among racial/ethnic groups and rural populations: Implementing culturally tailored outreach through community health educators.
    • San Miguel-Majors SL, Whitaker DE, Davis BC, Bailey LO, Springfield SA.
    • J Genet Couns. 2020 Mar 21. doi: 10.1002/jgc4.1272. [Epub ahead of print]
    • Factors shaping at-risk individuals' decisions to undergo genetic testing for cancer in Asia.
    • Sun S, Li ST, Ngeow J.
    • Health Soc Care Community. 2020 Mar 20. doi: 10.1111/hsc.12981. [Epub ahead of print]
    • Racial disparities in breast cancer hereditary risk assessment referrals.
    • Peterson JM, Pepin A, Thomas R, Biagi T, Stark E, Sparks AD, Johnson K, Kaltman R.
    • J Genet Couns. 2020 Mar 20. doi: 10.1002/jgc4.1250. [Epub ahead of print]
    • Knowledge and attitude of hereditary breast cancer among Japanese university female students.
    • Terui-Kohbata H, Egawa M, Yura K, Yoshida M.
    • J Hum Genet. 2020 Mar 18. doi: 10.1038/s10038-020-0743-9. [Epub ahead of print]
    • Exploring the barriers preventing Indigenous Australians from accessing cancer genetic counseling.
    • Gonzalez T, Harris R, Williams R, Wadwell R, Barlow-Stewart K, Fleming J, Buckman M.
    • J Genet Couns. 2020 Mar 16. doi: 10.1002/jgc4.1251. [Epub ahead of print]
    • Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer.
    • Kurian AW, Bernhisel R, Larson K, Caswell-Jin JL, Shadyab AH, Ochs-Balcom H, Stefanick ML.
    • JAMA. 2020 Mar 10;323(10):995-997. doi: 10.1001/jama.2020.0229.

    Related:

    Press: Inherited Mutations in Postmenopausal Breast Cancer Patients Suggest Genetic Testing Is Warranted. (GenomeWeb)

    Press Release: Older women with breast cancer may benefit from genetic testing. (Stanford Medicine)

    Press: Genetic testing may benefit some postmenopausal women with breast cancer. (Healio)

    • Use of an Online Breast Cancer Risk Assessment and Patient Decision Aid in Primary Care Practices.
    • Eden KB, Ivlev I, Bensching KL, Franta G, Hersh AR, Case J, Fu R, Nelson HD.
    • J Womens Health (Larchmt). 2020 Mar 10. doi: 10.1089/jwh.2019.8143. [Epub ahead of print]
    • Pioneering Informed Consent for Return of Research Results to Breast Cancer Patients Facing Barriers to Implementation of Genomic Medicine: The Kenyan BRCA1/2 Testing Experience Using Whole Exome Sequencing.
    • Torrorey-Sawe R, van der Merwe N, Mining SK, Kotze MJ.
    • Front Genet. 2020 Mar 6;11:170. doi: 10.3389/fgene.2020.00170. eCollection 2020.
    • Genetic Counseling and Germline Testing in the Era of Tumor Sequencing: A Cohort Study.
    • Klek S, Heald B, Milinovich A, Ni Y, Abraham J, Mahdi H, Estfan B, Khorana AA, Bolwell BJ, Grivas P, Sohal DPS, Funchain P.
    • JNCI Cancer Spectr. 2020 Mar 5;4(3):pkaa018. doi: 10.1093/jncics/pkaa018.

    Related:

    Editorial:

    A Clinical Approach to Detecting Germline Pathogenic Variants From Tumor-Only Sequencing.

    • The Provision of Genetic Testing and Related Services in Quebec, Canada.
    • Unim B, De Vito C, Hagan J, Villari P, Knoppers BM, Zawati M.
    • Front Genet. 2020 Mar 4;11:127. doi: 10.3389/fgene.2020.00127. eCollection 2020.
    • Involving patients and their families in deciding to use next generation sequencing: Results from a nationally representative survey of U.S. oncologists.
    • Spees LP, Roberts MC, Freedman AN, Butler EN, Klein WMP, Prabhu Das I, de Moor JS.
    • Patient Educ Couns. 2020 Mar 3. pii: S0738-3991(20)30116-6. doi: 10.1016/j.pec.2020.03.001. [Epub ahead of print]
    • Breast Cancer in Men: A Single Center Experience Over a Period of 22 years.
    • Hoffman A, Ben Ishay O, Horesh N, Shabtai M, Forschmidt E, Rosin D, Gutman M, Ram E.
    • Isr Med Assoc J. 2020 Mar;22(3):160-163.
    • Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil.
    • Achatz MI, Caleffi M, Guindalini R, Marques RM, Nogueira-Rodrigues A, Ashton-Prolla P.
    • JCO Glob Oncol. 2020 Mar;6:439-452. doi: 10.1200/JGO.19.00170.
    • Precision Prevention: The Current State and Future of Genomically Guided Cancer Prevention.
    • Kassem N, Stout LA, Hunter C, Schneider B, Radovich M.
    • JCO Precis Oncol. 2020;4:96. doi: 10.1200/PO.19.00278. Epub 2020 Feb 26.
    • Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC.
    • Iavazzo C, Fotiou A, Tsiatas M, Christopoulou A, Spiliotis J, Sugarbaker P.
    • Pleura Peritoneum. 2020 Feb 26;5(1):20190029. doi: 10.1515/pp-2019-0029.
    • Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management.
    • Rumford M, Lythgoe M, McNeish I, Gabra H, Tookman L, Rahman N, George A, Krell J.
    • Sci Rep. 2020 Feb 25;10(1):3390. doi: 10.1038/s41598-020-60149-5.
    • Group plus "mini" individual pre-test genetic counselling sessions for hereditary cancer shorten provider time and improve patient satisfaction.
    • Hynes J, MacMillan A, Fernandez S, Jacob K, Carter S, Predham S, Etchegary H, Dawson L.
    • Hered Cancer Clin Pract. 2020 Feb 19;18:3. doi: 10.1186/s13053-020-0136-2. eCollection 2020.
    • Evaluation of Triple-Negative Breast Cancer Early Detection via Mammography Screening and Outcomes in African American and White American Patients.
    • Chen Y, Susick L, Davis M, Bensenhaver J, Nathanson SD, Burns J, Newman LA.
    • JAMA Surg. 2020 Feb 19. doi: 10.1001/jamasurg.2019.6032. [Epub ahead of print]
    • Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial.
    • Golan T, Kindler HL, Park JO, Reni M, Macarulla T, Hammel P, Van Cutsem E, Arnold D, Hochhauser D, McGuinness D, Locker GY, Goranova T, Schatz P, Liu YZ, Hall MJ.
    • J Clin Oncol. 2020 Feb 19:JCO1901890. doi: 10.1200/JCO.19.01890. [Epub ahead of print]
    • Disparities in BRCA counseling across providers in a diverse population of young breast cancer survivors.
    • Reid S, Cragun D, Tezak A, Weidner A, Moore J, Mayer IA, Shu XO, Ye F, Fan R, Vadaparampil S, Pal T.
    • Genet Med. 2020 Feb 18. doi: 10.1038/s41436-020-0762-0. [Epub ahead of print]
    • Despite Barriers, Labs Starting to Report Suspected Cancer Risk Mutations Seen in Tumor Testing.
    • Ray T.
    • GenomeWeb. 2020 Feb 6.
    • Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program.
    • Hao J, Hassen D, Manickam K, Murray MF, Hartzel DN, Hu Y, Liu K, Rahm AK, Williams MS, Lazzeri A, Buchanan A, Sturm A, Snyder SR.
    • J Pers Med. 2020 Feb 3;10(1). pii: E7. doi: 10.3390/jpm10010007.
    • Health Care Provider Perceptions of Caring for Individuals with Inherited Pancreatic Cancer Risk.
    • Underhill ML, Pozzar R, Chung D, Sawhney M, Yurgelun M.
    • J Cancer Educ. 2020 Feb;35(1):194-203. doi: 10.1007/s13187-019-01623-1.
    • Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.
    • Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N; OPA Working Group.
    • J Natl Cancer Inst. 2020 Feb 1;112(2):161-169. doi: 10.1093/jnci/djz080.

    Related:

    Letter:

    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

    • Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway.
    • Grindedal EM, Jørgensen K, Olsson P, Gravdehaug B, Lurås H, Schlichting E, Vamre T, Wangensteen T, Heramb C, Mæhle L.
    • Fam Cancer. 2020 Jan 30. doi: 10.1007/s10689-020-00160-x. [Epub ahead of print]
    • Medicare to Cover Gene Tests in Inherited Breast and Ovarian Cancer.
    • Young KD.
    • Medscape Oncology. 2020 Jan 29.

    Related:

    Decision Memo: Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R) (Centers for Medicare & Medicaid Services)

    • Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R)
    • Syrek Jensen T, Chin J, Evans MA, Ashby L, Ward A, Rollins J, Li C, Long K.
    • Centers for Medicare & Medicaid Services. 2020 Jan 27.
    • CMS to Cover FDA-Approved, -Cleared NGS Germline Tests for Breast, Ovarian Cancer Patients.
    • [No author given]
    • GenomeWeb. 2020 Jan 27.

    Related:

    Decision Memo: Decision Memo for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer (CAG-00450R) (Centers for Medicare & Medicaid Services)

    • Characteristics predicting recommendation for familial breast cancer referral in a cohort of women from primary care.
    • Lee SI, Qureshi N, Dutton B, Kai J, Weng S.
    • J Community Genet. 2020 Jan 22. doi: 10.1007/s12687-020-00452-w. [Epub ahead of print]
    • As Home Genetic Tests Flood Market, Are Physicians Being Left Behind?
    • Miller KD, Domchek S.
    • Medscape Oncology. 2020 Jan 22.
    • Should Genetic Testing for Cancer Predisposition Be Standard-of-Care for Women with Invasive Breast Cancer? The Murtha Cancer Center Experience.
    • Rummel SK, Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE.
    • Cancers (Basel). 2020 Jan 17;12(1). pii: E234. doi: 10.3390/cancers12010234.
    • Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling.
    • Frey MK, Kahn RM, Chapman-Davis E, Tubito F, Pires , Christos P, Anderson S, Mukherjee S, Jordan B, Blank , Caputo TA, Sharaf , Offit K, Holcomb K, Lipkin S.
    • J Clin Oncol. 2020 Jan 10:JCO1902005. doi: 10.1200/JCO.19.02005. [Epub ahead of print]
    • Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening.
    • Offit K, Tkachuk KA, Stadler ZK, Walsh MF, Diaz-Zabala H, Levin JD, Steinsnyder Z, Ravichandran V, Sharaf RN, Frey MK, Lipkin SM, Robson ME, Hamilton JG, Vijai J, Mukherjee S.
    • J Clin Oncol. 2020 Jan 10:JCO1902010. doi: 10.1200/JCO.19.02010. [Epub ahead of print]
    • Implications of celebrity endorsement of prostate cancer awareness in a tertiary referral unit- The "Fry-Turnbull" Effect.
    • Lovegrove CE, Musbahi O, Ranasinha N, Omer A, Lopez F, Campbell A, Bryant RJ, Leslie T, Bell R, Brewster S, Hamdy FC, Wright B, Lamb AD.
    • BJU Int. 2020 Jan 7. doi: 10.1111/bju.14992. [Epub ahead of print]
    • Commentary
    • Mental Illness and BRCA1/2 Genetic Testing Intention Among Multiethnic Women Undergoing Screening Mammography.
    • Jones T, Freeman K, Ackerman M, Trivedi MS, Silverman T, Shapiro P, Kukafka R, Crew KD.
    • Oncol Nurs Forum. 2020 Jan 1;47(1):E13-E24. doi: 10.1188/20.ONF.E13-E24.
    • Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank.
    • Abul-Husn NS, Soper ER, Odgis JA, Cullina S, Bobo D, Moscati A, Rodriguez JE; CBIPM Genomics Team; Regeneron Genetics Center, Loos RJF, Cho JH, Belbin GM, Suckiel SA, Kenny EE.
    • Genome Med. 2019 Dec 31;12(1):2. doi: 10.1186/s13073-019-0691-1.
    • Latinas' knowledge of and experiences with genetic cancer risk assessment: Barriers and facilitators.
    • Gómez-Trillos S, Sheppard VB, Graves KD, Song M, Anderson L, Ostrove N, Lopez K, Campos C, Gonzalez N, Hurtado-de-Mendoza A.
    • J Genet Couns. 2019 Dec 27. doi: 10.1002/jgc4.1201. [Epub ahead of print]
    • Online BRCA1/2 screening in the Australian Jewish community: a qualitative study.
    • Yuen J, Cousens N, Barlow-Stewart K, O'Shea R, Andrews L.
    • J Community Genet. 2019 Dec 26. doi: 10.1007/s12687-019-00450-7. [Epub ahead of print]
    • The changing surgical treatment of breast cancer in the United States: The tipping point.
    • Carlson GW.
    • Breast J. 2019 Dec 22. doi: 10.1111/tbj.13725. [Epub ahead of print]
    • Review
    • Black Women's Confidence in the Genetic Information Nondiscrimination Act.
    • Sutton AL, Henderson A, Hurtado-de-Mendoza A, Tanner E, Khan M, Quillin J, Sheppard VB.
    • Int J Environ Res Public Health. 2019 Dec 14;16(24). pii: E5112. doi: 10.3390/ijerph16245112.
    • Uptake of Polygenic Risk Information among Women at Increased Risk of Breast Cancer.
    • Yanes T, Meiser B, Kaur R, Scheepers-Joynt M, McInerny S, Taylor S, Barlow-Stewart K, Antill Y, Salmon L, Smyth C, Young MA, James PA.
    • Clin Genet. 2019 Dec 12. doi: 10.1111/cge.13687. [Epub ahead of print]
    • Racial and Ethnic Differences in BRCA1/2 and Multigene Panel Testing Among Young Breast Cancer Patients.
    • Jones T, Trivedi MS, Jiang X, Silverman T, Underhill M, Chung WK, Kukafka R, Crew KD.
    • J Cancer Educ. 2019 Dec 4. doi: 10.1007/s13187-019-01646-8. [Epub ahead of print]

    Related:

    Research news: Study: Racial and ethnic differences in genetic testing among young breast cancer survivors. (FORCE. XRAYS.)

    • Study on the differences of opinions and choices of high-risk breast cancer populations in China before and after genetic testing.
    • Cheng X, Gu Z, Sun X, Zhuang Z.
    • Transl Cancer Res. 2019 Dec;8(8):2893-2905. doi: 10.21037/tcr.2019.11.43.
    • Culturally Targeted Video Improves Psychosocial Outcomes in Latina Women at Risk of Hereditary Breast and Ovarian Cancer.
    • Hurtado-de-Mendoza A, Graves KD, Gómez-Trillos S, Carrera P, Campos C, Anderson L, Luta G, Peshkin BN, Schwartz MD, Cupertino AP, Gonzalez N, Sheppard VB.
    • Int J Environ Res Public Health. 2019 Nov 29;16(23). pii: E4793. doi: 10.3390/ijerph16234793.
    • Reducing Disparities in Receipt of Genetic Counseling for Underserved Women at Risk of Hereditary Breast and Ovarian Cancer.
    • Sutton AL, Hurtado-de-Mendoza A, Quillin J, Rubinsak L, Temkin SM, Gal T, Sheppard VB.
    • J Womens Health (Larchmt). 2019 Nov 27. doi: 10.1089/jwh.2019.7984. [Epub ahead of print]
    • Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention.
    • Griffin NE, Buchanan TR, Smith SH, Leon AA, Meyer MF, Liu J, Tabak RG, Fuh KC, Thaker PH, Powell MA, Mutch DG, Massad LS, Colditz GA, Hagemann AR.
    • Gynecol Oncol. 2019 Nov 25. pii: S0090-8258(19)31626-9. doi: 10.1016/j.ygyno.2019.11.005. [Epub ahead of print]
    • As Genetic Testing Access Grows, Travel Time Remains Barrier to In-Person Counseling.
    • Ray T.
    • GenomeWeb. 2019 Nov 20.
    • Employee Benefits Programs Share Early Experiences Implementing Genetic Testing.
    • Ray T.
    • GenomeWeb. 2019 Nov 15.
    • Knowledge and opinions regarding BRCA1 and BRCA2 genetic testing among primary care physicians.
    • Dekanek EW, Thull DL, Massart M, Grubs RE, Rajkovic A, Mai PL.
    • J Genet Couns. 2019 Nov 14. doi: 10.1002/jgc4.1189. [Epub ahead of print]
    • Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing.
    • Vlessis K, Purington N, Chun N, Haraldsdottir S, Ford JM.
    • JNCI Cancer Spectr. 2019 Nov 11;4(1):pkz095. doi: 10.1093/jncics/pkz095. eCollection 2020 Feb.
    • Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study.
    • Conley CC, Kasting ML, Augusto BM, Garcia JD, Cragun D, Gonzalez BD, Kim J, Ashing KT, Knott CL, Hughes-Halbert C, Pal T, Vadaparampil ST.
    • Ann Surg Oncol. 2019 Nov 1. doi: 10.1245/s10434-019-07982-9. [Epub ahead of print]
    • Mainstreaming genetic counseling for BRCA testing into oncology clinics - Indian perspective.
    • Verma A, Nag S, Hasan Q, Selvakumar VPP.
    • Indian J Cancer. 2019 Nov;56(Supplement):S38-S47. doi: 10.4103/ijc.IJC_458_19.
    • Calling on Primary Care to Prevent BRCA-Related Cancers.
    • Armstrong K.
    • J Gen Intern Med. 2019 Oct 21. doi: 10.1007/s11606-019-05469-7. [Epub ahead of print]
    • Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer.
    • Scott D, Friedman S, Telli ML, Kurian AW.
    • J Oncol Pract. 2019 Oct 15:JOP1900221. doi: 10.1200/JOP.19.00221. [Epub ahead of print]
    • Patterns and Predictors of Genetic Referral among Ovarian Cancer Patients at a National Cancer Institute Comprehensive Cancer Center.
    • Mallen AR, Conley CC, Townsend MK, Wells A, Boac BM, Todd S, Gandhi A, Kuznicki M, Augusto BM, McIntyre M, Fridley BL, Tworoger SS, Wenham RM, Vadaparampil ST.
    • Clin Genet. 2019 Oct 10. doi: 10.1111/cge.13654. [Epub ahead of print]
    • BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.
    • Capoluongo E, Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.
    • Diagnostics (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146.
    • All For BRCA, BRCA For All?
    • Resta R.
    • The DNA Exchange. 2019 Oct 7.
    • Genetic testing in ovarian cancer - clinical impact and current practices.
    • Knabben L, Imboden S, Mueller MD.
    • Horm Mol Biol Clin Investig. 2019 Oct 2. pii: /j/hmbci.ahead-of-print/hmbci-2019-0025/hmbci-2019-0025.xml. doi: 10.1515/hmbci-2019-0025. [Epub ahead of print]
    • Review
    • Genetic counseling and oncology: proposed approaches for collaborative care delivery.
    • Powers J, Spielman K, Mueller R, Batson M, Pundock S, Arutyunova A, Symecko H, Domchek S.
    • Can J Urol. 2019 Oct;26(5S2):57-59.
    • Integrating a Next Generation Sequencing Panel into Clinical Practice in Ovarian Cancer.
    • Lee YJ, Kim D, Kim HS, Na K, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT.
    • Yonsei Med J. 2019 Oct;60(10):914-923. doi: 10.3349/ymj.2019.60.10.914.
    • BRCA testing in unaffected young women in the United States, 2006-2017.
    • Guo F, Scholl M, Fuchs EL, Berenson AB, Kuo YF.
    • Cancer. 2019 Sep 30. doi: 10.1002/cncr.32536. [Epub ahead of print]
    • Recontacting patients for multigene panel testing in hereditary cancer: Efficacy and insights.
    • Sawyer L, Creswick H, Lewandowski R, Quillin J.
    • J Genet Couns. 2019 Sep 25. doi: 10.1002/jgc4.1173. [Epub ahead of print]
    • Patients' willingness to reconsider cancer genetic testing after initially declining: Mention it again.
    • Halverson CME, Wessinger BC, Clayton EW, Wiesner GL.
    • J Genet Couns. 2019 Sep 25. doi: 10.1002/jgc4.1174. [Epub ahead of print]
    • Inequities in multi-gene hereditary cancer testing: lower diagnostic yield and higher VUS rate in individuals who identify as Hispanic, African or Asian and Pacific Islander as compared to European.
    • Ndugga-Kabuye MK, Issaka RB.
    • Fam Cancer. 2019 Sep 17. doi: 10.1007/s10689-019-00144-6. [Epub ahead of print]
    • Germline BRCA1 and BRCA2 testing for breast cancer survivors.
    • Wiggins J, McLoughlin A, George A, Ring A, Kemp Z.
    • J Med Genet. 2019 Sep 11. pii: jmedgenet-2019-106420. doi: 10.1136/jmedgenet-2019-106420. [Epub ahead of print]
    • A family pedigree of malignancies associated with BRCA1 pathogenic variants: a reflection of the state of art in China.
    • Li W, Li L, Wu M.
    • Hered Cancer Clin Pract. 2019 Sep 10;17:26. doi: 10.1186/s13053-019-0126-4. eCollection 2019.
    • Understanding Medical Mistrust in Black Women at Risk of BRCA 1/2 Mutations.
    • Sutton AL, He J, Tanner E, Edmonds MC, Henderson A, Hurtado de Mendoza A, Sheppard VB.
    • J Health Dispar Res Pract. 2019 Fall;12(3):35-47.
    • Cancer: more genetic BRCA testing for men.
    • Marabelli M, Calvello M, Bonanni B.
    • Nature. 2019 Sep;573(7774):346. doi: 10.1038/d41586-019-02775-2.

    Related:

    Commentary:

    New name for breast-cancer syndrome could help to save lives.

    • Universal Genetic Testing for All Breast Cancer Patients.
    • Copur MS.
    • Oncology (Williston Park). 2019 Aug 23;33(8). pii: 683731.
    • USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.
    • Rajagopal PS, Nielsen S, Olopade OI.
    • JAMA Netw Open. 2019 Aug 20;2(8.10):e1910142. doi: 10.1001/jamanetworkopen.2019.10142.

    Related:

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • BRCA mutation in high grade epithelial ovarian cancers.
    • Manchana T, Phoolcharoen N, Tantbirojn P.
    • Gynecol Oncol Rep. 2019 Aug 13;29:102-105. doi: 10.1016/j.gore.2019.07.007. eCollection 2019 Aug.
    • The Genetic Education for Men (GEM) Trial: Development of Web-Based Education for Untested Men in BRCA1/2-Positive Families.
    • Peshkin BN, Ladd MK, Isaacs C, Segal H, Jacobs A, Taylor KL, Graves KD, O'Neill SC, Schwartz MD.
    • J Cancer Educ. 2019 Aug 11. doi: 10.1007/s13187-019-01599-y. [Epub ahead of print]
    • The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance.
    • Neusser S, Lux B, Barth C, Pahmeier K, Rhiem K, Schmutzler R, Engel C, Wasem J, Neumann A.
    • Curr Med Res Opin. 2019 Aug 8:1. doi: 10.1080/03007995.2019.1654689. [Epub ahead of print]
    • Strategies for Improving Access to Hereditary Cancer Testing: Recommendations from Stakeholders.
    • Ready K, Johansen Taber KA, Bonhomme N, Lichtenfeld JL.
    • Genet Med. 2019 Aug;21(8):1702-1704. doi: 10.1038/s41436-018-0430-9. Epub 2019 Jan 28.
    • Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations.
    • Ademuyiwa FO, Salyer P, Ma Y, Fisher S, Colditz G, Weilbaecher K, Bierut LJ.
    • Breast Cancer Res Treat. 2019 Jul 19. doi: 10.1007/s10549-019-05359-w. [Epub ahead of print]
    • Insurance coverage does not predict outcomes of genetic testing: The search for meaning in payer decisions for germline cancer tests.
    • Amendola LM, Hart MR, Bennett RL, Horike-Pyne M, Dorschner M, Shirts B, Jarvik GP.
    • J Genet Couns. 2019 Jul 17. doi: 10.1002/jgc4.1155. [Epub ahead of print]
    • Uptake of genetic counseling among adult children of BRCA1/2 mutation carriers in France.
    • Gauna Cristaldo FB, Touzani R, Apostolidis T, Mouret-Fourme E, Stoppa-Lyonnet D, Lasset C, Fricker JP, Berthet P, Julian-Reynier C, Mancini J, Noguès C, Bouhnik AD.
    • Psychooncology. 2019 Jul 5. doi: 10.1002/pon.5169. [Epub ahead of print]
    • Adverse Events in Genetic Testing: The Fourth Case Series.
    • Farmer MB, Bonadies DC, Mahon SM, Baker MJ, Ghate SM, Munro C, Nagaraj CB, Besser AG, Bui K, Csuy CM, Kirkpatrick B, McCarty AJ, McQuaid SW, Sebastian J, Sternen DL, Walsh LK, Matloff ET.
    • Cancer J. 2019 Jul/Aug;25(4):231-236. doi: 10.1097/PPO.0000000000000391.
    • Case series
    • Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care.
    • Hallowell N, Wright S, Stirling D, Gourley C, Young O, Porteous M.
    • Fam Cancer. 2019 Jul;18(3):293-301. doi: 10.1007/s10689-019-00122-y.
    • Knowledge, attitudes, and perceived barriers towards genetic testing across three rural Illinois communities.
    • Fogleman AJ, Zahnd WE, Lipka AE, Malhi RS, Ganai S, Delfino KR, Jenkins WD.
    • J Community Genet. 2019 Jul;10(3):417-423. doi: 10.1007/s12687-019-00407-w. Epub 2019 Jan 23.
    • New name for breast-cancer syndrome could help to save lives.
    • Pritchard CC.
    • Nature. 2019 Jul;571(7763):27-29. doi: 10.1038/d41586-019-02015-7.

    Related:

    Letter:

    Cancer: more genetic BRCA testing for men.

    Press: New Name of 'King Syndrome' for Hereditary BRCA Mutations. (Medscape Oncology)

    • Genetic Testing for Breast Cancer Susceptibility Should Be Offered before Unilateral Abdominally Based Free Flap Breast Reconstruction.
    • Dayan E, Chittenden A, Garber JE, Wo L, Caterson SA, Carty MJ, Erdmann-Sager J.
    • Plast Reconstr Surg. 2019 Jul;144(1):12-20. doi: 10.1097/PRS.0000000000005693.
    • Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers.
    • Swink A, Nair A, Hoof P, Matthews A, Burden C, Johnson K, Blum JL.
    • Proc (Bayl Univ Med Cent). 2019 Jun 11;32(3):340-344. doi: 10.1080/08998280.2019.1612702. eCollection 2019 Jul.
    • CancerIQ, GeneMatters Integrate Technology to Widen Access to Genetic Counselors.
    • [No author given]
    • GenomeWeb. 2019 Jun 27.
    • Current Genetic Service Delivery Models for the Provision of Genetic Testing in Europe: A Systematic Review of the Literature.
    • Unim B, Pitini E, Lagerberg T, Adamo G, De Vito C, Marzuillo C, Villari P.
    • Front Genet. 2019 Jun 19;10:552. doi: 10.3389/fgene.2019.00552. eCollection 2019.
    • Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    • Boitano TKL, Barrington DA, Batra S, McGwin G Jr, Turner TB, Farmer MB, Brown AM, Straughn MJ Jr, Leath CA 3rd.
    • Gynecol Oncol. 2019 Jun 10. pii: S0090-8258(19)31275-2. doi: 10.1016/j.ygyno.2019.05.031. [Epub ahead of print]
    • Genetic testing and eHealth usage among Deaf women.
    • Kushalnagar P, Holcomb J, Sadler GR.
    • J Genet Couns. 2019 Jun 10. doi: 10.1002/jgc4.1134. [Epub ahead of print]
    • Online Platform Helping Adventist Health Improve Breast Cancer Risk Assessment.
    • Versel N.
    • Precision Oncology News. Disease Areas. Cancer. 2019 Jun 7.
    • Press
    • Genetic counseling of patients with ovarian carcinoma: acceptance, timing, and psychological wellbeing.
    • Van de Beek I, Smets EMA, Legdeur MA, de Hullu JA, Lok CAR, Buist MR, Mourits MJE, Kets CM, van der Kolk LE, Oosterwijk JC, Aalfs CM.
    • J Community Genet. 2019 Jun 5. doi: 10.1007/s12687-019-00427-6. [Epub ahead of print]
    • Understanding Factors Associated with Uptake of BRCA1/2 Genetic Testing among Orthodox Jewish Women in the USA Using a Mixed-Methods Approach.
    • Trivedi MS, Colbeth H, Yi H, Vanegas A, Starck R, Chung WK, Appelbaum PS, Kukafka R, Schechter I, Crew KD.
    • Public Health Genomics. 2019 Jun 4:1-11. doi: 10.1159/000499852. [Epub ahead of print]
    • Psychosocial and clinical factors of probands impacting intrafamilial disclosure and uptake of genetic testing among 103 French families with BRCA1/2 or MMR gene mutations.
    • Alegre N, Vande Perre P, Bignon YJ, Michel A, Galibert V, Mophawe O, Corsini C, Coupier I, Chiesa J, Robert L, Bernhard L, Picot MC, Bertet H, Macioce V, Bastide N, Solassol J, Rey JM, Thomas F, Carton S, Pujol P.
    • Psychooncology. 2019 Jun 1. doi: 10.1002/pon.5142. [Epub ahead of print]
    • Referral patterns for genetic counselling of women diagnosed with tubo-ovarian or peritoneal high-grade serous carcinoma (HGSC) within the Auckland Gynaecological Oncology Centre.
    • Burling MJ, Gamet K, Eva L, Tan AL.
    • Aust N Z J Obstet Gynaecol. 2019 Jun;59(3):444-449. doi: 10.1111/ajo.12964. Epub 2019 Mar 18.
    • Disparities in genetic services utilization in a random sample of young breast cancer survivors.
    • Nikolaidis C, Duquette D, Mendelsohn-Victor KE, Anderson B, Copeland G, Milliron KJ, Merajver SD, Janz NK, Northouse LL, Duffy SA, Katapodi MC.
    • Genet Med. 2019 Jun;21(6):1363-1370. doi: 10.1038/s41436-018-0349-1. Epub 2018 Nov 2.
    • Genetic counseling, genetic testing, and risk perceptions for breast and colorectal cancer: Results from the 2015 National Health Interview Survey.
    • Turbitt E, Roberts MC, Taber JM, Waters EA, McNeel TS, Biesecker BB, Klein WMP.
    • Prev Med. 2019 Jun;123:12-19. doi: 10.1016/j.ypmed.2019.02.027. Epub 2019 Feb 25.
    • Challenges in Managing Patients with Hereditary Cancer at Gynecological Services.
    • Ueda M, Tsubamoto H, Kashima-Morii M, Torii Y, Kamihigashi M, Wakimoto Y, Nakagomi N, Hashimoto-Tamaoki T, Sawai H, Shibahara H.
    • Obstet Gynecol Int. 2019 May 27;2019:4365754. doi: 10.1155/2019/4365754. eCollection 2019.
    • Developing a culturally targeted video to enhance the use of genetic counseling in Latina women at increased risk for hereditary breast and ovarian cancer.
    • Hurtado-de-Mendoza A, Graves KD, Gómez-Trillos S, Song M, Anderson L, Campos C, Carrera P, Ostrove N, Peshkin BN, Schwartz MD, Ficca N, Cupertino AP, Gonzalez N, Otero A, Huerta E, Sheppard VB.
    • J Community Genet. 2019 May 18. doi: 10.1007/s12687-019-00423-w. [Epub ahead of print]
    • Uptake of testing for germline BRCA mutations in patients with non-mucinous epithelial ovarian cancers in Western Australia: a comparison of different genetic counseling methods.
    • Stearnes G, Nichols CB, Schofield L, O'Sullivan S, Pachter N, Cohen PA.
    • Int J Gynecol Cancer. 2019 May 17. pii: ijgc-2019-000389. doi: 10.1136/ijgc-2019-000389. [Epub ahead of print]
    • Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
    • Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N.
    • J Natl Cancer Inst. 2019 May 11. pii: djz080. doi: 10.1093/jnci/djz080. [Epub ahead of print]

    Related:

    Letter, Comment:

    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

    • Exploring Predictors of Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer: Findings from the 2015 U.S. National Health Interview Survey.
    • Allen CG, Roberts M, Guan Y.
    • J Pers Med. 2019 May 10;9(2). pii: E26. doi: 10.3390/jpm9020026.
    • Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services.
    • Moss CA, Cojocaru E, Hanwell J, Ward S, Xu W, van Zyl M, O'Leary L, de Bono JS, Banerji U, Kaye SB, Minchom A, George AJ, Lopez J, McVeigh TP.
    • Eur J Cancer. 2019 May 9;114:97-106. doi: 10.1016/j.ejca.2019.04.009. [Epub ahead of print]
    • Effectiveness of interventions to identify and manage patients with familial cancer risk in primary care: a systematic review.
    • Lee SI, Patel M, Dutton B, Weng S, Luveta J, Qureshi N.
    • J Community Genet. 2019 May 6. doi: 10.1007/s12687-019-00419-6. [Epub ahead of print]
    • Review
    • Trends in BRCA testing and socioeconomic deprivation.
    • Martin AP, Pedra G, Downing J, Collins B, Godman B, Alfirevic A, Pirmohamed M, Lynn Greenhalgh K.
    • Eur J Hum Genet. 2019 May 3. doi: 10.1038/s41431-019-0424-3. [Epub ahead of print]
    • Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
    • Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E, Warren-Perry M, Eccleston A, Tan MM, Teo SH, Turner N, Strydom A, George A, Rahman N.
    • JAMA Netw Open. 2019 May 3;2(5):e194428. doi: 10.1001/jamanetworkopen.2019.4428.
    • Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study.
    • Manchanda R, Burnell M, Gaba F, Sanderson S, Loggenberg K, Gessler S, Wardle J, Side L, Desai R, Brady AF, Dorkins H, Wallis Y, Chapman C, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.
    • BJOG. 2019 May;126(6):784-794. doi: 10.1111/1471-0528.15654. Epub 2019 Mar 18.
    • Identifying disparities in germline and somatic testing for ovarian cancer.
    • Huang M, Kamath P, Schlumbrecht M, Miao F, Driscoll D, Oldak S, Slomovitz B, Koru-Sengul T, George S.
    • Gynecol Oncol. 2019 May;153(2):297-303. doi: 10.1016/j.ygyno.2019.03.007. Epub 2019 Mar 16.
    • A randomized controlled intervention to promote readiness to genetic counseling for breast cancer survivors.
    • Kasting ML, Conley CC, Hoogland AI, Scherr CL, Kim J, Thapa R, Reblin M, Meade CD, Lee MC, Pal T, Quinn GP, Vadaparampil ST.
    • Psychooncology. 2019 May;28(5):980-988. doi: 10.1002/pon.5059. Epub 2019 Apr 11.
    • Global Disparities in Breast Cancer Genetics Testing, Counselling and Management.
    • Yip CH, Evans DG, Agarwal G, Buccimazza I, Kwong A, Morant R, Prakash I, Song CY, Taib NA, Tausch C, Ung O, Meterissian S.
    • World J Surg. 2019 May;43(5):1264-1270. doi: 10.1007/s00268-018-04897-6.
    • Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer.
    • Rotter J, Wilson L, Greiner MA, Pollack CE, Dinan M.
    • Breast Cancer Res Treat. 2019 Apr 26. doi: 10.1007/s10549-019-05248-2. [Epub ahead of print]
    • Scientific supremacy as an obstacle to establishing and sustaining interdisciplinary dialogue across knowledge paradigms in health medicine.
    • Gripsrud BH, Solbrække KN.
    • Med Health Care Philos. 2019 Apr 25. doi: 10.1007/s11019-019-09901-x. [Epub ahead of print]

    Related:

    Commentary:

    Our genes, our selves: hereditary breast cancer and biological citizenship in Norway.

    Our genes, our selves: hereditary breast cancer and biological citizenship in Norway.

    • Uptake of genetic testing for germline BRCA1/2 pathogenic variants in a predominantly Hispanic population.
    • McGuinness JE, Trivedi MS, Silverman T, Marte A, Mata J, Kukafka R, Crew KD.
    • Cancer Genet. 2019 Apr 24. pii: S2210-7762(19)30059-6. doi: 10.1016/j.cancergen.2019.04.063. [Epub ahead of print]
    • Improving access to cancer genetic services: perspectives of high-risk clients in a community-based setting.
    • Miller I, Greenberg S, Yashar BM, Marvin ML.
    • J Community Genet. 2019 Apr 24. doi: 10.1007/s12687-019-00420-z. [Epub ahead of print]
    • The Burden of Breast Cancer Predisposition Variants Across The Age Spectrum Among 10 000 Patients.
    • Chavarri-Guerra Y, Hendricks CB, Brown S, Marcum C, Hander M, Segota ZE, Hake C, Sand S, Slavin TP, Hurria A, Soto-Perez-de-Celis E, Nehoray B, Blankstein KB, Blazer KR, Weitzel JN; Clinical Cancer Genomics Community Research Network.
    • J Am Geriatr Soc. 2019 Apr 23. doi: 10.1111/jgs.15937. [Epub ahead of print]
    • Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.
    • Paller CJ, Antonarakis ES, Beer TM, Borno HT, Carlo MI, George DJ, Graff JN, Gupta S, Heath EI, Higano CS, McKay RR, Morgans AK, Patnaik A, Petrylak DP, Rettig MB, Ryan C, Taplin ME, Whang YE, Vinson J, Cheng HH, Giri VN; PCCTC Germline Genetics Working Group.
    • Clin Genitourin Cancer. 2019 Apr 18. pii: S1558-7673(19)30139-9. doi: 10.1016/j.clgc.2019.04.013. [Epub ahead of print]
    • Genetic counseling referral for ovarian cancer patients: a call to action.
    • Garcia C, Harrison K, Ring KL, Sullivan MW, Rauh LA, Modesitt SC.
    • Fam Cancer. 2019 Apr 16. doi: 10.1007/s10689-019-00129-5. [Epub ahead of print]
    • Hereditary Breast Cancer Risk Analysis in Uninsured Mexican-Origin Women Living in the U.S.-Mexico Border Region.
    • Salinas JJ, Roy R, Dwivedi AK, Shokar NK.
    • Hisp Health Care Int. 2019 Apr 12:1540415319837850. doi: 10.1177/1540415319837850. [Epub ahead of print]
    • Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.
    • Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, Miller D, Penberthy LS, Katz SJ.
    • J Clin Oncol. 2019 Apr 9:JCO1801854. doi: 10.1200/JCO.18.01854. [Epub ahead of print]

    Related:

    Press: Genetic Testing Under-Utilized in Ovarian Cancer. (Medscape Oncology)

    • Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer.
    • Tutty E, Petelin L, McKinley J, Young MA, Meiser B, Rasmussen VM, Forbes Shepherd R, James PA, Forrest LE.
    • Eur J Hum Genet. 2019 Apr 8. doi: 10.1038/s41431-019-0390-9. [Epub ahead of print]
    • Racial/Ethnic Disparities in BRCA Counseling and Testing: a Narrative Review.
    • Williams CD, Bullard AJ, O'Leary M, Thomas R, Redding TS 4th, Goldstein K.
    • J Racial Ethn Health Disparities. 2019 Apr 8. doi: 10.1007/s40615-018-00556-7. [Epub ahead of print]
    • Review
    • 23andMe DTC Breast and Ovarian Cancer Risk Test Misses Almost 90 Percent of BRCA Mutation Carriers.
    • Karow J.
    • Precision Oncology News. 2019 Apr 5.
    • Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort.
    • Rhiem K, Bücker-Nott HJ, Hellmich M, Fischer H, Ataseven B, Dittmer-Grabowski C, Latos K, Pelzer V, Seifert M, Schmidt A, Rezek D, Groh U, Meinerz W, Crommelinck D, Hahnen E, Wesselmann S, Schmutzler RK.
    • Breast J. 2019 Apr 5. doi: 10.1111/tbj.13257. [Epub ahead of print]
    • Direct Genetics Referral Pathway for High-Grade Serous Ovarian Cancer Patients: The "Opt-Out" Process.
    • McGee J, Peart TM, Foley N, Bertrand M, Prefontaine M, Sugimoto A, Ettler H, Welch S, Panabaker K.
    • J Oncol. 2019 Apr 2;2019:6029097. doi: 10.1155/2019/6029097. eCollection 2019.
    • A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    • Donenberg T, George S, Ali J, Bravo G, Hernandez K, Sookar N, Ashing KT, Narod SA, Akbari MR, Hurley J.
    • Breast Cancer Res Treat. 2019 Apr;174(2):469-477. doi: 10.1007/s10549-018-5045-y. Epub 2018 Dec 4.
    • Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.
    • Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH.
    • Fam Cancer. 2019 Apr;18(2):241-251. doi: 10.1007/s10689-018-0106-2.
    • Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility.
    • Rowley SM, Mascarenhas L, Devereux L, Li N, Amarasinghe KC, Zethoven M, Lee JEA, Lewis A, Morgan JA, Limb S, Young MA, James PA, Trainer AH, Campbell IG.
    • Genet Med. 2019 Apr;21(4):913-922. doi: 10.1038/s41436-018-0277-0. Epub 2018 Sep 26.
    • A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial.
    • Vogel RI, Niendorf K, Petzel S, Lee H, Teoh D, Blaes AH, Argenta P, Rivard C, Winterhoff B, Lee HY, Geller MA.
    • Gynecol Oncol. 2019 Apr;153(1):100-107. doi: 10.1016/j.ygyno.2019.01.019. Epub 2019 Feb 1.
    • Disparities in gynecologic cancer genetics evaluation.
    • Hinchcliff EM, Bednar EM, Lu KH, Rauh-Hain JA.
    • Gynecol Oncol. 2019 Apr;153(1):184-191. doi: 10.1016/j.ygyno.2019.01.024. Epub 2019 Jan 31.
    • Review
    • Current Approaches to Cancer Genetic Counseling Services for Spanish-Speaking Patients.
    • Augusto B, Kasting ML, Couch FJ, Lindor NM, Vadaparampil ST.
    • J Immigr Minor Health. 2019 Apr;21(2):434-437. doi: 10.1007/s10903-018-0772-z.
    • Breast surgeons recommend genetic testing for all breast cancer patients.
    • [No author given]
    • FORCE. XRAYS. 2019 Mar 25.

    Related:

    Guideline: Consensus Guideline on Genetic Testing for Hereditary Breast Cancer. (PDF) (American Society of Breast Surgeons.)

    • Discoveries beyond BRCA1/2: Multigene testing in an Asian multi-ethnic cohort suspected of hereditary breast cancer syndrome in the real world.
    • Ow SGW, Ong PY, Lee SC.
    • PLoS One. 2019 Mar 15;14(3):e0213746. doi: 10.1371/journal.pone.0213746. eCollection 2019.
    • Gaps in information about breast cancer risk and prevention impact African American women.
    • [No author given]
    • FORCE. XRAYS. 2019 Mar 14.

    Related:

    Original research:

    Layers of information: interacting constraints on breast cancer risk-management by high-risk African American women.

    • Impact of Implementing B-RSTTM to Screen for Hereditary Breast and Ovarian Cancer on Risk Perception and Genetic Counseling Uptake Among Women in an Academic Safety Net Hospital.
    • Wernke K, Bellcross C, Gabram S, Ali N, Stanislaw C.
    • Clin Breast Cancer. 2019 Mar 11. pii: S1526-8209(18)30730-4. doi: 10.1016/j.clbc.2019.02.014. [Epub ahead of print]
    • RE: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.
    • Peshkin BN, Isaacs C, Schwartz MD.
    • J Natl Cancer Inst. 2019 Mar 5. pii: djz028. doi: 10.1093/jnci/djz028. [Epub ahead of print]

    Related:

    Letter, reply:

    Response to Peshkin, Isaacs, and Schwartz.

    Original research:

    Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.

    • Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    • Quek RGW, Mardekian J.
    • Adv Ther. 2019 Mar;36(3):708-720. doi: 10.1007/s12325-018-0867-x. Epub 2019 Jan 17.
    • BRCA mutation testing for ovarian cancer in the context of available targeted therapy: Survey and consensus of Hong Kong specialists.
    • Kwong A, Cheng KD, Hsue CV, Hui SK, Leung CR, Leung KA, Ngan KR, Soong SI.
    • Asia Pac J Clin Oncol. 2019 Mar;15 Suppl 2:20-31. doi: 10.1111/ajco.13116. Epub 2019 Mar 6.
    • Genetic testing and insurance in Australia.
    • Otlowski M, Barlow-Stewart K, Lacaze P, Tiller J.
    • Aust J Gen Pract. 2019 Mar;48(3):96-99.
    • Painting a portrait: Analysis of national health survey data for cancer genetic counseling.
    • Stamp MH, Gordon OK, Childers CP, Childers KK.
    • Cancer Med. 2019 Mar;8(3):1306-1314. doi: 10.1002/cam4.1864. Epub 2019 Feb 7.
    • Author response to "a response to 'personalised medicine and population health: breast and ovarian cancer'".
    • Narod SA.
    • Hum Genet. 2019 Mar;138(3):291-292. doi: 10.1007/s00439-019-01981-2. Epub 2019 Feb 21.
    • Letter, Reply

    Related:

    Letter, Commentary:

    A response to "Personalised medicine and population health: breast and ovarian cancer".

    Review:

    Personalised medicine and population health: breast and ovarian cancer.

    • Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
    • Giri VN, Hegarty SE, Hyatt C, O'Leary E, Garcia J, Knudsen KE, Kelly WK, Gomella LG.
    • Prostate. 2019 Mar;79(4):333-339. doi: 10.1002/pros.23739. Epub 2018 Nov 18.
    • Patterns of referral and uptake of BReast CAncer (BRCA) gene testing of eligible women with ovarian cancer in New Zealand.
    • Fraser K, Tan AL, Innes C, Stephens R, Tristram A, Petrich S, Lintott C, Sykes PH, Gamet K, Christian A, Simcock B.
    • N Z Med J. 2019 Feb 22;132(1490):26-35.
    • Psychosocial, attitudinal, and demographic correlates of cancer-related germline genetic testing in the 2017 Health Information National Trends Survey.
    • Roberts MC, Turbitt E, Klein WMP.
    • J Community Genet. 2019 Feb 20. doi: 10.1007/s12687-018-00405-4. [Epub ahead of print]
    • Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice.
    • Fulton AJ, Lamarca A, Nuttall C, McCallum L, Pihlak R, O'Reilly D, Lalloo F, McNamara MG, Hubner RA, Clancy T, Valle JW.
    • World J Gastrointest Oncol. 2019 Feb 15;11(2):102-116. doi: 10.4251/wjgo.v11.i2.102.
    • Consensus Guideline on Genetic Testing for Hereditary Breast Cancer.
    • Manahan ER, Sebastian M, Hughes KS, Boughey JC, Kuerer HM, Euhus DM, Robson ME, Boolbol SK, Arun BK, Taylor WA.
    • American Society of Breast Surgeons. 2019 Feb 10.

    Related:

    Press: ASBrS Calls for Genetic Testing for All Breast Cancer Patients. (Medscape Oncology)

    News: Breast surgeons recommend genetic testing for all breast cancer patients. (FORCE. XRAYS.)

    • The cost of cancer care and impact of financial hardship on treatment.
    • [No author given]
    • FORCE. XRAYS. 2019 Feb 8.

    Related:

    Original research:

    BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.

    News: Labs, Advocacy Groups Push Back on Medicare Policy Shift on NGS Testing for Hereditary Cancer Risk. (GenomeWeb)

    News: Pricey Precision Medicine Often Financially Toxic For Cancer Patients. (Kaiser Health News)

    • Trends in BRCA Test Utilization in an Integrated Health System, 2005-2015.
    • Knerr S, Bowles EJA, Leppig KA, Buist DSM, Gao H, Wernli KJ.
    • J Natl Cancer Inst. 2019 Feb 8. doi: 10.1093/jnci/djz008. [Epub ahead of print]

    Related:

    Editorial:

    Persistent underutilization of BRCA1/2 testing suggest the need for new approaches to genetic testing delivery.

    • Genetic Service Delivery Models: Exploring Approaches to Care for Families With Hereditary Cancer Risk.
    • Pierle JM, Mahon SM.
    • Clin J Oncol Nurs. 2019 Feb 1;23(1):60-67. doi: 10.1188/19.CJON.60-67.
    • Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study®.
    • Silver MI, Klein W, Samimi G, Minasian L, Loud J, Roberts MC.
    • Breast Cancer Res Treat. 2019 Feb;173(3):719-726. doi: 10.1007/s10549-018-5035-0. Epub 2018 Nov 9.
    • A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of BRCA1/2.
    • Best AF, Tucker MA, Frone MN, Greene MH, Peters JA, Katki HA.
    • Cancer Epidemiol Biomarkers Prev. 2019 Feb;28(2):293-302. doi: 10.1158/1055-9965.EPI-18-0584. Epub 2019 Jan 28.
    • Genetic Testing Across Young Hispanic and Non-Hispanic White Breast Cancer Survivors: Facilitators, Barriers, and Awareness of the Genetic Information Nondiscrimination Act.
    • Cragun D, Weidner A, Kechik J, Pal T.
    • Genet Test Mol Biomarkers. 2019 Feb;23(2):75-83. doi: 10.1089/gtmb.2018.0253. Epub 2019 Jan 24.
    • Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic.
    • Bednar EM, Sun CC, Camacho B, Terrell J, Rieber AG, Ramondetta LM, Freedman RS, Lu KH.
    • Gynecol Oncol. 2019 Feb;152(2):328-333. doi: 10.1016/j.ygyno.2018.12.001. Epub 2018 Dec 8.
    • Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop.
    • Nikolaidis C, Ming C, Pedrazzani C, van der Horst T, Kaiser-Grolimund A, Ademi Z, Bührer-Landolt R, Bürki N, Caiata-Zufferey M, Champion V, Chappuis PO, Kohler C, Erlanger TE, Graffeo R, Hampel H, Heinimann K, Heinzelmann-Schwarz V, Kurzeder C, Monnerat C, Northouse LL, Pagani O, Probst-Hensch N, Rabaglio M, Schoenau E, Sijbrands EJG, Taborelli M, Urech C, Viassolo V, Wieser S, Katapodi MC; for the CASCADE Consortium.
    • Public Health Genomics. 2019 Jan 29:1-12. doi: 10.1159/000496495. [Epub ahead of print]
    • Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom.
    • Autier P.
    • JAMA Oncol. 2019 Jan 17. doi: 10.1001/jamaoncol.2018.6501. [Epub ahead of print]
    • Letter, Comment

    Related:

    Letter, Reply:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom-Reply.

    Original research:

    Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.

    • Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.
    • Caswell-Jin JL, Zimmer AD, Stedden W, Kingham KE, Zhou AY, Kurian AW.
    • J Natl Cancer Inst. 2019 Jan 1;111(1):95-98. doi: 10.1093/jnci/djy147.

    Related:

    Letter, comment:

    RE: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative.

    Letter, reply:

    Response to Peshkin, Isaacs, and Schwartz.

    • [Knowledge and attitude among general practitioners in Andalusia (Spain) on the identification of subjects at high risk of breast and colorectal cancer].
    • Sánchez Pérez MR, Sánchez Pérez MJ, Lorente Acosta JA, Bayo Lozano E, Mancera Romero J.
    • Semergen. 2019 Jan - Feb;45(1):6-14. doi: 10.1016/j.semerg.2018.07.006. Epub 2018 Oct 24.
    • High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study.
    • Nilsson MP, Nilsson ED, Borg Å, Brandberg Y, Silfverberg B, Loman N.
    • Breast Cancer Res Treat. 2019 Jan;173(2):313-318. doi: 10.1007/s10549-018-5000-y. Epub 2018 Oct 11.
    • European Breast Cancer Council manifesto 2018: Genetic risk prediction testing in breast cancer.
    • Rutgers E, Balmana J, Beishon M, Benn K, Evans DG, Mansel R, Pharoah P, Perry Skinner V, Stoppa-Lyonnet D, Travado L, Wyld L.
    • Eur J Cancer. 2019 Jan;106:45-53. doi: 10.1016/j.ejca.2018.09.019. Epub 2018 Nov 22.
    • The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
    • Menko FH, Ter Stege JA, van der Kolk LE, Jeanson KN, Schats W, Moha DA, Bleiker EMA.
    • Fam Cancer. 2019 Jan;18(1):127-135. doi: 10.1007/s10689-018-0089-z.
    • Review
    • Written pretest information and germline BRCA1/2 pathogenic variant testing in unselected breast cancer patients: predictors of testing uptake.
    • Nilsson MP, Nilsson ED, Silfverberg B, Borg Å, Loman N.
    • Genet Med. 2019 Jan;21(1):89-96. doi: 10.1038/s41436-018-0021-9. Epub 2018 Jun 6.
    • Challenges in the identification of inherited risk of ovarian cancer: where should we go from here?
    • Norquist BM.
    • Gynecol Oncol. 2019 Jan;152(1):3-6. doi: 10.1016/j.ygyno.2018.12.003. Epub 2018 Dec 8.
    • Inequities in genetic testing for hereditary breast cancer: implications for public health practice.
    • Sayani A.
    • J Community Genet. 2019 Jan;10(1):35-39. doi: 10.1007/s12687-018-0370-8. Epub 2018 May 20.
    • Evaluating and improving the implementation of a community-based hereditary cancer screening program.
    • Greenberg S, Yashar BM, Pearlman M, Duquette D, Milliron K, Marvin M.
    • J Community Genet. 2019 Jan;10(1):51-60. doi: 10.1007/s12687-018-0357-5. Epub 2018 Mar 5.
    • BRCA Testing Dichotomy in Saudi Arabia.
    • Abusanad A.
    • J Glob Oncol. 2019 Jan;(5):1-2. doi: 10.1200/JGO.18.00188.
    • Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing.
    • Clark DF, Maxwell KN, Powers J, Lieberman DB, Ebrahimzadeh J, Long JM, McKenna D, Shah P, Bradbury A, Morrissette JJD, Nathanson KL, Domchek SM.
    • JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00076. Epub 2019 Aug 19.
    • Layers of information: interacting constraints on breast cancer risk-management by high-risk African American women.
    • Padamsee TJ, Meadows R, Hils M.
    • Ethn Health. 2018 Dec 27:1-24. doi: 10.1080/13557858.2018.1562053. [Epub ahead of print]

    Related:

    Research news: Gaps in information about breast cancer risk and prevention impact African American women (FORCE. XRAYS.)

    • Cancer communication research in the era of genomics and precision medicine: a scoping review.
    • Kaphingst KA, Peterson E, Zhao J, Gaysynsky A, Elrick A, Hong SJ, Krakow M, Pokharel M, Ratcliff CL, Klein WMP, Khoury MJ, Chou WS.
    • Genet Med. 2018 Dec 21. doi: 10.1038/s41436-018-0402-0. [Epub ahead of print]
    • Review
    • Use and Patient-Reported Outcomes of Clinical Multigene Panel Testing for Cancer Susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study.
    • Hall MJ, Patrick-Miller LJ, Egleston BL, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long JM, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS, Bradbury AR.
    • JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00199. Epub 2018 Dec 18.
    • Response to "Male Patients With Breast Cancer: Addressing Needs Using an Educational Task Force".
    • Mahon SM.
    • Clin J Oncol Nurs. 2018 Dec 1;22(6):610. doi: 10.1188/18.CJON.610.

    Related:

    Original Research: Male Patients With Breast Cancer: Addressing Needs Using an Educational Task Force. (Clinical Journal of Oncology Nursing)

    • Impact of Appointment Waiting Time on Attendance Rates at a Clinical Cancer Genetics Service.
    • Shaw T, Metras J, Ting ZAL, Courtney E, Li ST, Ngeow J.
    • J Genet Couns. 2018 Dec;27(6):1473-1481. doi: 10.1007/s10897-018-0259-z. Epub 2018 May 24.
    • Creation and Implementation of an Environmental Scan to Assess Cancer Genetics Services at Three Oncology Care Settings.
    • Bednar EM, Walsh MT Jr, Baker E, Muse KI, Oakley HD, Krukenberg RC, Dresbold CS, Jenkinson SB, Eppolito AL, Teed KB, Klein MH, Morman NA, Bowdish EC, Russ P, Wise EE, Cooper JN, Method MW, Henson JW, Grainger AV, Arun BK, Lu KH.
    • J Genet Couns. 2018 Dec;27(6):1482-1496. doi: 10.1007/s10897-018-0262-4. Epub 2018 May 24.
    • The influence of Malay cultural beliefs on breast cancer screening and genetic testing: A focus group study.
    • Shaw T, Ishak D, Lie D, Menon S, Courtney E, Li ST, Ngeow J.
    • Psychooncology. 2018 Dec;27(12):2855-2861. doi: 10.1002/pon.4902. Epub 2018 Oct 16.
    • Next-Generation Service Delivery: A Scoping Review of Patient Outcomes Associated with Alternative Models of Genetic Counseling and Genetic Testing for Hereditary Cancer.
    • McCuaig JM, Armel SR, Care M, Volenik A, Kim RH, Metcalfe KA.
    • Cancers (Basel). 2018 Nov 13;10(11). pii: E435. doi: 10.3390/cancers10110435.
    • Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?
    • Hall ET, Parikh D, Caswell-Jin JL, Gupta T, Mills MA, Kingham KE, Koff R, Ford JM, Kurian AW.
    • JCO Precis Oncol. [2018 Nov 8];2:1-10. doi: 10.1200/PO.18.00167.
    • Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.
    • Pashayan N, Morris S, Gilbert FJ, Pharoah PDP.
    • JAMA Oncol. 2018 Nov 1;4(11):1504-1510. doi: 10.1001/jamaoncol.2018.1901.

    Related:

    Editorial:

    Implementation Challenges for Risk-Stratified Screening in the Era of Precision Medicine.

    Audio Interview: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening. (JAMA Oncology)

    Press: Breast Cancer Screening Only for Women at Higher Risk. (Medscape)

    Letter, Comment:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom

    Letter, Reply:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom—Reply.

    • Familial communication and cascade testing among relatives of BRCA population screening participants.
    • Lieberman S, Lahad A, Tomer A, Koka S, BenUziyahu M, Raz A, Levy-Lahad E.
    • Genet Med. 2018 Nov;20(11):1446-1454. doi: 10.1038/gim.2018.26. Epub 2018 Mar 29.
    • Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting.
    • DeFrancesco MS, Waldman RN, Pearlstone MM, Karanik D, Bernhisel R, Logan J, Alico L, Adkins RT.
    • Obstet Gynecol. 2018 Nov;132(5):1121-1129. doi: 10.1097/AOG.0000000000002916.
    • Knowledge regarding and patterns of genetic testing in patients newly diagnosed with breast cancer participating in the iCanDecide trial.
    • Gornick MC, Kurian AW, An LC, Fagerlin A, Jagsi R, Katz SJ, Hawley ST.
    • Cancer. 2018 Oct 15;124(20):4000-4009. doi: 10.1002/cncr.31731. Epub 2018 Oct 5.
    • Surgeon attitude impacts rate of genetic testing after a breast cancer diagnosis.
    • [No author given]
    • FORCE. XRAYS. 2018 Oct 6.

    Related:

    Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer.

    • Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer.
    • Katz SJ, Bondarenko I, Ward KC, Hamilton AS, Morrow M, Kurian AW, Hofer TP.
    • JAMA Surg. 2018 Oct 1;153(10):909-916. doi: 10.1001/jamasurg.2018.2001.

    Related:

    Commentary:

    Consideration of Population-Based BRCA Testing as a Strategy to Reduce Disparities in Genetic Counseling Referrals: The Importance of Stating (and Proving) the Obvious.

    Research News: Association of Attending Surgeon With Variation in the Receipt of Genetic Testing After Diagnosis of Breast Cancer. (FORCE, XRAYS)

    Research News: Surgeon Attitudes May Influence Genetic Testing for Patients With Breast Cancer. (Cancer Therapy Advisor)

    • Comparison of gynecologic cancer risk factors, incidence and mortality trends between South Korea and Israel, 1999-2013.
    • Michaan N, Park SY, Won YJ, Lim MC.
    • Jpn J Clin Oncol. 2018 Oct 1;48(10):884-891. doi: 10.1093/jjco/hyy111.
    • Promoting guideline-based cancer genetic risk assessment for hereditary breast and ovarian cancer in ethnically and geographically diverse cancer survivors: Rationale and design of a 3-arm randomized controlled trial.
    • Kinney AY, Howell R, Ruckman R, McDougall JA, Boyce TW, Vicuña B, Lee JH, Guest DD, Rycroft R, Valverde PA, Gallegos KM, Meisner A, Wiggins CL, Stroup A, Paddock LE, Walters ST.
    • Contemp Clin Trials. 2018 Oct;73:123-135. doi: 10.1016/j.cct.2018.09.005. Epub 2018 Sep 18.
    • Mutations in context: implications of BRCA testing in diverse populations.
    • Felix GES, Zheng Y, Olopade OI.
    • Fam Cancer. 2018 Oct;17(4):471-483. doi: 10.1007/s10689-017-0038-2.
    • Personalised medicine and population health: breast and ovarian cancer.
    • Narod SA.
    • Hum Genet. 2018 Oct;137(10):769-778. doi: 10.1007/s00439-018-1944-6. Epub 2018 Oct 17.
    • Review

    Related:

    Letter, Commentary:

    A response to "Personalised medicine and population health: breast and ovarian cancer".

    Letter, Reply:

    Author response to “a response to ‘personalised medicine and population health: breast and ovarian cancer’”.

    • Changing landscape of hereditary breast and ovarian cancer germline genetic testing in Australia.
    • Petelin L, James PA, Trainer AH.
    • Intern Med J. 2018 Oct;48(10):1269-1272. doi: 10.1111/imj.14058.
    • Commentary, Review
    • Provider's Perceptions of Barriers and Facilitators for Latinas to Participate in Genetic Cancer Risk Assessment for Hereditary Breast and Ovarian Cancer.
    • Hurtado-de-Mendoza A, Graves K, Gómez-Trillos S, Anderson L, Campos C, Evans C, Stearns S, Zhu Q, Gonzalez N, Sheppard VB.
    • Healthcare (Basel). 2018 Sep 17;6(3). pii: E116. doi: 10.3390/healthcare6030116.
    • A feasibility study of breast cancer genetic risk assessment in a federally qualified health center.
    • Hoskins KF, Tejeda S, Vijayasiri G, Chukwudozie IB, Remo MH, Shah HA, Abraham IE, Balay LE, Maga TK, Searles ER, Korah VJ, Biggers A, Stolley MR, Warnecke RB.
    • Cancer. 2018 Sep 15;124(18):3733-3741. doi: 10.1002/cncr.31635. Epub 2018 Oct 15.
    • Risk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effect.
    • Liede A, Cai M, Crouter TF, Niepel D, Callaghan F, Evans DG.
    • Breast Cancer Res Treat. 2018 Sep;171(2):435-442. doi: 10.1007/s10549-018-4824-9. Epub 2018 May 28.
    • Proposed outcomes measures for state public health genomic programs.
    • Doyle DL, Clyne M, Rodriguez JL, Cragun DL, Senier L, Hurst G, Chan K, Chambers DA.
    • Genet Med. 2018 Sep;20(9):995-1003. doi: 10.1038/gim.2017.229. Epub 2018 Jan 4.

    Related:

    Original research:

    Implementing Cancer Genomics in State Health Agencies: Mapping Activities to an Implementation Science Outcome Framework.

    • Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing.
    • Chadwell SE, He H, Knapke S, Lewis J, Sisson R, Hopper J.
    • J Genet Couns. 2018 Sep;27(5):1210-1219. doi: 10.1007/s10897-018-0241-9. Epub 2018 Mar 17.
    • Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.
    • McCuaig JM, Stockley TL, Shaw P, Fung-Kee-Fung M, Altman AD, Bentley J, Bernardini MQ, Cormier B, Hirte H, Kieser K, MacMillan A, Meschino WS, Panabaker K, Perrier R, Provencher D, Schrader KA, Serfas K, Tomiak E, Wong N, Young SS, Gotlieb WH, Hoskins P, Kim RH; BRCA TtoT Community of Practice.
    • J Med Genet. 2018 Sep;55(9):571-577. doi: 10.1136/jmedgenet-2018-105472. Epub 2018 Jul 24.
    • Establishment of the Alabama Hereditary Cancer Cohort - strategies for the inclusion of underrepresented populations in cancer genetics research.
    • Bishop MR, Shah A, Shively M, Huskey ALW, Omeler SM, Bilgili EP, Jackson E, Daniell K, Stallworth E, Spina S, Shepp K, Bergstresser S, Davis A, Dean H, Gibson J, Johnson B, Merner ND.
    • Mol Genet Genomic Med. 2018 Sep;6(5):766-778. doi: 10.1002/mgg3.443. Epub 2018 Jul 1.
    • BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.
    • Gross AL, Blot WJ, Visvanathan K.
    • JAMA. 2018 Aug 14;320(6):597-598. doi: 10.1001/jama.2018.8258.
    • Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.
    • Silverman TB, Vanegas A, Marte A, Mata J, Sin M, Ramirez JCR, Tsai WY, Crew KD, Kukafka R.
    • BMC Health Serv Res. 2018 Aug 13;18(1):633. doi: 10.1186/s12913-018-3442-x.
    • MAGENTA Study Aims to Find Best Genetic Counseling Method for Online Cancer Risk Testing.
    • Ray T.
    • Precision Oncology News. Disease Areas. Cancer. 2018 Aug 4.
    • Research news

    Related:

    Identifier: NCT02993068: Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible). (ClinicalTrials.gov)

    • Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    • Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, Li Y, Hawley ST, Morrow M, Jagsi R, Katz SJ.
    • JAMA Oncol. 2018 Aug 1;4(8):1066-1072. doi: 10.1001/jamaoncol.2018.0644.

    Related:

    Press: Multigene Sequencing Rapidly Replacing BRCA Tests. (Medscape Oncology)

    Letter, Comment:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer.

    Letter, Reply:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer-Reply.

    • Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists.
    • Murciano-Goroff YR, McCarthy AM, Bristol MN, Groeneveld P, Domchek SM, Motanya UN, Armstrong K.
    • Breast Cancer Res Treat. 2018 Aug;171(1):173-180. doi: 10.1007/s10549-018-4810-2. Epub 2018 May 8.
    • Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients.
    • Schwartz MD, Peshkin BN, Isaacs C, Willey S, Valdimarsdottir HB, Nusbaum R, Hooker G, O'Neill S, Jandorf L, Kelly SP, Heinzmann J, Zidell A, Khoury K.
    • Breast Cancer Res Treat. 2018 Aug;170(3):517-524. doi: 10.1007/s10549-018-4773-3. Epub 2018 Apr 2.
    • Beyond BRCA: A Case Series Examining the Advent of Multigene Panel Testing.
    • Reap L, Ahsan S, Saleh M.
    • Clin Breast Cancer. 2018 Aug;18(4):e431-e439. doi: 10.1016/j.clbc.2018.03.015. Epub 2018 Apr 6.
    • Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.
    • Hoskins PJ.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):472-483. doi: 10.1016/j.clon.2018.04.004. Epub 2018 May 5.
    • Review
    • Engagement with Genetic Information and Uptake of Genetic Testing: the Role of Trust and Personal Cancer History.
    • Roberts MC, Taber JM, Klein WM.
    • J Cancer Educ. 2018 Aug;33(4):893-900. doi: 10.1007/s13187-016-1160-9.
    • Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit.
    • Lobo M, López-Tarruella S, Luque S, Lizarraga S, Flores-Sánchez C, Bueno O, Solera J, Jerez Y, Del Val RG, Palomero MI, Cebollero M, Echavarría I, Torres G, Martín M, Márquez-Rodas I.
    • J Genet Couns. 2018 Aug;27(4):854-862. doi: 10.1007/s10897-017-0187-3. Epub 2017 Dec 15.
    • Breast Cancer Genetics Knowledge and Testing Intentions among Nigerian Professional Women.
    • Ngene SO, Adedokun B, Adejumo P, Olopade O.
    • J Genet Couns. 2018 Aug;27(4):863-873. doi: 10.1007/s10897-017-0194-4. Epub 2017 Dec 19.
    • Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population.
    • Manchanda R, Blyuss O, Gaba F, Gordeev VS, Jacobs C, Burnell M, Gan C, Taylor R, Turnbull C, Legood R, Zaikin A, Antoniou AC, Menon U, Jacobs I.
    • J Med Genet. 2018 Aug;55(8):538-545. doi: 10.1136/jmedgenet-2017-105195. Epub 2018 Apr 5.
    • Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers.
    • Chan GHJ, Ong PY, Low JJH, Kong HL, Ow SGW, Tan DSP, Lim YW, Lim SE, Lee SC.
    • Oncotarget. 2018 Jul 17;9(55):30649-30660. doi: 10.18632/oncotarget.25769. eCollection 2018 Jul 17.
    • A qualitative study of barriers to genetic counseling and potential for mobile technology education among women with ovarian cancer.
    • Vogel RI, Niendorf K, Lee H, Petzel S, Lee HY, Geller MA.
    • Hered Cancer Clin Pract. 2018 Jul 4;16:13. doi: 10.1186/s13053-018-0095-z. eCollection 2018.
    • Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
    • Long J, Evans TG, Bailey D, Lewis MH, Gower-Thomas K, Murray A.
    • Breast J. 2018 Jul;24(4):580-585. doi: 10.1111/tbj.12978. Epub 2017 Dec 29.
    • Psychological outcomes and surgical decisions after genetic testing in women newly diagnosed with breast cancer with and without a family history.
    • Meiser B, Quinn VF, Mitchell G, Tucker K, Watts KJ, Rahman B, Peate M, Saunders C, Geelhoed E, Gleeson M, Barlow-Stewart K, Field M, Harris M, Antill YC, Susman R, Bowen MT, Mills L, Kirk J; TFGT Collaborative Group.
    • Eur J Hum Genet. 2018 Jul;26(7):972-983. doi: 10.1038/s41431-017-0057-3. Epub 2018 Mar 30.
    • Increased access to TP53 analysis through breast cancer multi-gene panels: clinical considerations.
    • Azzollini J, Mariani M, Peissel B, Manoukian S.
    • Fam Cancer. 2018 Jul;17(3):317-319. doi: 10.1007/s10689-017-0020-z.

    Related:

    Next generation sequencing is informing phenotype: a TP53 example.

    • A comparison of cancer risk assessment and testing outcomes in patients from underserved vs. tertiary care settings.
    • Rana HQ, Cochrane SR, Hiller E, Akindele RN, Nibecker CM, Svoboda LA, Cronin AM, Garber JE, Lathan CS.
    • J Community Genet. 2018 Jul;9(3):233-241. doi: 10.1007/s12687-017-0347-z. Epub 2017 Nov 18.
    • Clinical Cancer Genetics in a Lower-Middle Income Country: Considerations for Policymaking.
    • Ginsburg O, Narod SA.
    • J Glob Oncol. 2018 Jul;(4):1-3. doi: 10.1200/JGO.18.00081.

    Related:

    Knowledge of Genetic Counseling Among Patients With Breast Cancer and Their Relatives at a Nigerian Teaching Hospital.

    • Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing.
    • Gill J, Obley AJ, Prasad V.
    • JAMA. 2018 Jun 19;319(23):2377-2378. doi: 10.1001/jama.2018.5330.
    • Commentary
    • 5-year BRCA SCOTUS Anniversary.
    • [No author given]
    • My Gene Counsel. 2018 Jun 13.
    • National Distribution of Cancer Genetic Testing in the United States: Evidence for a Gender Disparity in Hereditary Breast and Ovarian Cancer.
    • Childers KK, Maggard-Gibbons M, Macinko J, Childers CP.
    • JAMA Oncol. 2018 Jun 1;4(6):876-879. doi: 10.1001/jamaoncol.2018.0340.
    • Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening.
    • Denu RA.
    • JAMA Oncol. 2018 Jun 1;4(6):883. doi: 10.1001/jamaoncol.2017.5906.

    Related:

    Original Research:

    Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas.

    Letter, Reply:

    Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply.

    • Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.
    • Uyar D, Neary J, Monroe A, Nugent M, Simpson P, Geurts JL.
    • Gynecol Oncol. 2018 Jun;149(3):565-569. doi: 10.1016/j.ygyno.2018.03.059. Epub 2018 Apr 10.
    • [To know or not to know, that is the question - screening for BRCA].
    • Johannsson OT.
    • Laeknabladid. 2018 Jun;104(6):281. doi: 10.17992/lbl.2018.06.187.
    • [Views of Icelandic women towards genetic counseling - and testing of BRCA2 mutations].
    • Jonsdottir T, Valdimarsdottir H, Tryggvadottir L, Lund SH, Thordardottir M, Magnusson MK, Valdimarsdottir U.
    • Laeknabladid. 2018 Jun;104(6):289-296. doi: 10.17992/lbl.2018.06.189.
    • Our genes, our selves: hereditary breast cancer and biological citizenship in Norway.
    • Møller P, Hovig E.
    • Med Health Care Philos. 2018 Jun;21(2):239-242. doi: 10.1007/s11019-017-9803-0.

    Related:

    Our genes, our selves: hereditary breast cancer and biological citizenship in Norway.

    Commentary, Reply:

    Scientific supremacy as an obstacle to establishing and sustaining interdisciplinary dialogue across knowledge paradigms in health medicine.

    • Pervasive genetic testing.
    • Thiruchelvam PTR, Fisher CS, Leff DR, Domchek SM.
    • Lancet. 2018 May 26;391(10135):2089-2091. doi: 10.1016/S0140-6736(18)30997-8. Epub 2018 May 24.
    • Comment
    • Genetics of breast cancer in African populations: a literature review.
    • Abbad A, Baba H, Dehbi H, Elmessaoudi-Idrissi M, Elyazghi Z, Abidi O, Radouani F.
    • Glob Health Epidemiol Genom. 2018 May 11;3:e8. doi: 10.1017/gheg.2018.8. eCollection 2018.
    • Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
    • Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, Van Le L, Ghamande S, González-Santiago S, Bover I, Graña Suárez B, Green A, Huot-Marchand P, Bourhis Y, Karve S, Blakeley C.
    • J Clin Oncol. 2018 May 1;36(13):1300-1307. doi: 10.1200/JCO.2017.76.2781. Epub 2018 Mar 20.
    • Accuracy of self-reported family history of cancer, mutation status and tumor characteristics in patients with early onset breast cancer.
    • Augustinsson A, Ellberg C, Kristoffersson U, Borg Å, Olsson H.
    • Acta Oncol. 2018 May;57(5):595-603. doi: 10.1080/0284186X.2017.1404635. Epub 2017 Nov 22.
    • Impact of an embedded genetic counselor on breast cancer treatment.
    • Pederson HJ, Hussain N, Noss R, Yanda C, O'Rourke C, Eng C, Grobmyer SR.
    • Breast Cancer Res Treat. 2018 May;169(1):43-46. doi: 10.1007/s10549-017-4643-4. Epub 2018 Jan 18.
    • Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    • Barrington DA, Champion ML, Boitano TKL, Walters-Haygood CL, Farmer MB, Alvarez RD, Estes JM, Leath CA 3rd.
    • Gynecol Oncol. 2018 May;149(2):337-340. doi: 10.1016/j.ygyno.2018.02.014. Epub 2018 Mar 2.
    • Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer.
    • Barcenas CH, Shafaee MN, Sinha AK, Raghavendra A, Saigal B, Murthy RK, Woodson AH, Arun B.
    • J Natl Compr Canc Netw. 2018 May;16(5):518-524. doi: 10.6004/jnccn.2018.7002.
    • Hereditary Cancer Genetic Testing in Community-Based Obstetrics and Gynecology Settings.
    • Obstet Gynecol. 2018 May;131(5):119s. doi: 10.1097/01.AOG.0000533506.01865.a1.
    • Risk Screening for Hereditary Cancer During Obstetrical Care: Barriers to Testing and Health Disparities.
    • Lua LL, Jackson D, Foggia M, Rosenbaum A.
    • Obstet Gynecol. 2018 May;131(5):148s. doi: 10.1097/01.AOG.0000533083.79347.8c.
    • Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
    • Shaw J, Bulsara C, Cohen PA, Gryta M, Nichols CB, Schofield L, O'Sullivan S, Pachter N, Hardcastle SJ.
    • Patient Educ Couns. 2018 May;101(5):938-944. doi: 10.1016/j.pec.2017.12.011. Epub 2017 Dec 12.
    • Challenges in recruiting African-American women for a breast cancer genetics study.
    • Compadre AJ, Simonson ME, Gray K, Runnells G, Kadlubar S, Zorn KK.
    • Hered Cancer Clin Pract. 2018 Apr 24;16:8. doi: 10.1186/s13053-018-0091-3. eCollection 2018.
    • Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer.
    • Katz SJ, Ward KC, Hamilton AS, Mcleod MC, Wallner LP, Morrow M, Jagsi R, Hawley ST, Kurian AW.
    • J Clin Oncol. 2018 Apr 20;36(12):1218-1224. doi: 10.1200/JCO.2017.76.2369. Epub 2018 Mar 12.

    Related:

    Press: Many Breast Cancer Patients Not Receiving Genetic Evaluation. (Medscape)

    • Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer.
    • Bradbury AR, Patrick-Miller L, Egleston BL, Maxwell KN, DiGiovanni L, Brower J, Fetzer D, Bennett Gaieski J, Brandt A, McKenna D, Long J, Powers J, Stopfer JE, Nathanson KL, Domchek SM.
    • JCO Precis Oncol. 2018;2. doi: 10.1200/po.17.00250. Epub 2018 Apr 16.
    • Trends in utilization and costs of BRCA testing among women aged 18-64 years in the United States, 2003-2014.
    • Chen Z, Kolor K, Grosse SD, Rodriguez JL, Lynch JA, Green RF, Dotson WD, Bowen MS, Khoury MJ.
    • Genet Med. 2018 Apr;20(4):428-434. doi: 10.1038/gim.2017.118. Epub 2017 Sep 21.
    • Disparities in genetics assessment for women with ovarian cancer: Can we do better?
    • Manrriquez E, Chapman JS, Mak J, Blanco AM, Chen LM.
    • Gynecol Oncol. 2018 Apr;149(1):84-88. doi: 10.1016/j.ygyno.2017.10.034.
    • Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
    • Swanson CL, Kumar A, Maharaj JM, Kemppainen JL, Thomas BC, Weinhold MR, Slaby KM, Mara KC, Wick MJ, Bakkum-Gamez JN.
    • Gynecol Oncol. 2018 Apr;149(1):121-126. doi: 10.1016/j.ygyno.2018.01.033. Epub 2018 Feb 3.
    • Impact of Multigene Panel Testing on Surgical Decision Making in Breast Cancer Patients.
    • Pederson HJ, Gopalakrishnan D, Noss R, Yanda C, Eng C, Grobmyer SR.
    • J Am Coll Surg. 2018 Apr;226(4):560-565. doi: 10.1016/j.jamcollsurg.2017.12.037. Epub 2018 Jan 31.
    • Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.
    • Arai M, Yokoyama S, Watanabe C, Yoshida R, Kita M, Okawa M, Sakurai A, Sekine M, Yotsumoto J, Nomura H, Akama Y, Inuzuka M, Nomizu T, Enomoto T, Nakamura S.
    • J Hum Genet. 2018 Apr;63(4):447-457. doi: 10.1038/s10038-017-0355-1. Epub 2017 Nov 8.
    • Germline BRCA mutation in male carriers-ripe for precision oncology?
    • Leão RRN, Price AJ, James Hamilton R.
    • Prostate Cancer Prostatic Dis. 2018 Apr;21(1):48-56. doi: 10.1038/s41391-017-0018-5. Epub 2017 Dec 14.
    • Review
    • The Right Not to Know: When Ignorance Is Bliss but Deadly.
    • Clausen AM.
    • Global Health NOW. 2018 Mar 20.

    Related:

    Commentary: The right not to know when not knowing is dangerous. (FORCE. XRAYS.)

    • FDA approves breast cancer test kits: how useful are they?
    • [No author given]
    • FORCE. XRAYS. 2018 Mar 19.

    Related:

    FDA News Release: FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes (U.S. Food & Drug Administration)

    Press: Oncology Community Sees Potential for Patient Harm in FDA OK of 23andMe BRCA Test (GenomeWeb)

    Press: FDA Authorizes 23andMe DTC Test Report for Three BRCA Mutations (GenomeWeb)

    • Medical Strategy or Marketing Strategy?
    • Resta R.
    • The DNA Exchange. 2018 Mar 18.
    • Factors Influencing Clinical Follow-Up for Individuals with a Personal History of Breast and/or Ovarian Cancer and Previous Uninformative BRCA1 and BRCA2 Testing.
    • Chadwell SE, He H, Knapke S, Lewis J, Sisson R, Hopper J.
    • J Genet Couns. 2018 Mar 17. doi: 10.1007/s10897-018-0241-9. [Epub ahead of print]
    • Impact of a genetic counseling requirement prior to genetic testing.
    • Stenehjem DD, Au T, Sainski AM, Bauer H, Brown K, Lancaster J, Stevens V, Brixner DI.
    • BMC Health Serv Res. 2018 Mar 7;18(1):165. doi: 10.1186/s12913-018-2957-5.
    • First DTC Test for Some BRCA Mutations Authorized by FDA.
    • Nelson R.
    • Medscape. Medscape Medical News. 2018 Mar 7.
    • FDA authorizes, with special controls, direct-to-consumer test that reports three mutations in the BRCA breast cancer genes.
    • [No author given]
    • U.S. Food & Drug Administration. FDA News Release. 2018 Mar 6.

    Related:

    Blog post, News: NSGC Responds to U.S. Food and Drug Administration Approval of Direct-to-Consumer Cancer Test that Reports Three BRCA Mutations (NSGC Blog)

    News: FDA approves breast cancer test kits: how useful are they? (FORCE. XRAYS)

    • A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    • Hanley GE, McAlpine JN, Miller D, Huntsman D, Schrader KA, Blake Gilks C, Mitchell G.
    • BMC Cancer. 2018 Mar 5;18(1):254. doi: 10.1186/s12885-018-4153-8.
    • Genetic assessment wait time indicators in the High Risk Ontario Breast Screening Program.
    • Eisen A, Blackmore KM, Meschino WS, Muradali D, Carroll JC, Majpruz V, Warner E, Rabeneck L, Chiarelli AM.
    • Mol Genet Genomic Med. 2018 Mar;6(2):213-223. doi: 10.1002/mgg3.359. Epub 2018 Jan 25.
    • Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices.
    • Toland AE, Forman A, Couch FJ, Culver JO, Eccles DM, Foulkes WD, Hogervorst FBL, Houdayer C, Levy-Lahad E, Monteiro AN, Neuhausen SL, Plon SE, Sharan SK, Spurdle AB, Szabo C, Brody LC; BIC Steering Committee.
    • NPJ Genom Med. 2018 Feb 15;3:7. doi: 10.1038/s41525-018-0046-7. eCollection 2018.
    • Adaptation of Genetic Counseling According to an Individual's Literacy Regarding Genomics.
    • Nakamura S, Narimatsu H.
    • J Clin Oncol. 2018 Feb 10;36(5):516-517. doi: 10.1200/JCO.2017.76.3300. Epub 2018 Jan 2.
    • Letter, Comment

    Related:

    National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.

    Letter, Reply:

    Reply to S. Nakamura et al and S. Narod et al.

    • Population-Based Genetic Testing for BRCA1 and BRCA2.
    • Narod S, Akbari MR.
    • J Clin Oncol. 2018 Feb 10;36(5):517. doi: 10.1200/JCO.2017.75.8490. Epub 2018 Jan 2.
    • Letter

    Related:

    Editorial:

    Genetic Testing: What Problem Are We Trying to Solve?

    National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.

    Letter, Comment:

    Reply to S. Nakamura et al and S. Narod et al.

    • Genetic Testing: Multiple Problems to Solve.
    • Ramos E, Haidle JL.
    • J Clin Oncol. 2018 Feb 10;36(5):518-519. doi: 10.1200/JCO.2017.76.0942. Epub 2018 Jan 2.

    Related:

    Editorial:

    Genetic Testing: What Problem Are We Trying to Solve?

    Letter, Reply:

    Reply to E. Ramos et al.

    • Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation.
    • Hull LE, Haas JS, Simon SR.
    • Am J Prev Med. 2018 Feb;54(2):221-228. doi: 10.1016/j.amepre.2017.10.015. Epub 2017 Dec 11.
    • BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
    • Nilsson MP, Törngren T, Henriksson K, Kristoffersson U, Kvist A, Silfverberg B, Borg Å, Loman N.
    • Breast Cancer Res Treat. 2018 Feb;168(1):117-126. doi: 10.1007/s10549-017-4584-y. Epub 2017 Nov 21.
    • Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach.
    • Moss HA, Samimi G, Havrilesky LJ, Sherman ME, Myers ER.
    • Genet Epidemiol. 2018 Feb;42(1):117-122. doi: 10.1002/gepi.22095. Epub 2017 Nov 30.
    • Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.
    • Caswell-Jin JL, Gupta T, Hall E, Petrovchich IM, Mills MA, Kingham KE, Koff R, Chun NM, Levonian P, Lebensohn AP, Ford JM, Kurian AW.
    • Genet Med. 2018 Feb;20(2):234-239. doi: 10.1038/gim.2017.96. Epub 2017 Jul 27.
    • FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices.
    • Buchtel KM, Vogel Postula KJ, Weiss S, Williams C, Pineda M, Weissman SM.
    • J Genet Couns. 2018 Feb;27(1):131-139. doi: 10.1007/s10897-017-0130-7. Epub 2017 Aug 5.
    • Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.
    • Liang MI, Wong DH, Walsh CS, Farias-Eisner R, Cohen JG.
    • J Genet Couns. 2018 Feb;27(1):177-186. doi: 10.1007/s10897-017-0135-2. Epub 2017 Aug 7.
    • "I've just never gotten around to doing it": Men's approaches to managing BRCA-related cancer risks.
    • Rauscher EA, Dean M.
    • Patient Educ Couns. 2018 Feb;101(2):340-345. doi: 10.1016/j.pec.2017.07.015. Epub 2017 Jul 23.
    • Examination of the Patient-Focused Impact of Cancer Telegenetics Among a Rural Population: Comparison with Traditional In-Person Services.
    • Solomons NM, Lamb AE, Lucas FL, McDonald EF, Miesfeldt S.
    • Telemed J E Health. 2018 Feb;24(2):130-138. doi: 10.1089/tmj.2017.0073. Epub 2017 Jul 21.
    • Men seeking counselling in a Breast Cancer Risk Evaluation Clinic.
    • Freitas AC1, Opinião A, Fragoso S, Nunes H, Santos M, Clara A, Bento S, Luis A, Silva J, Moura C, Filipe B, Machado P, Santos S, André S, Rodrigues P, Parreira J, Vaz F.
    • Ecancermedicalscience. 2018 Jan 30;12:804. doi: 10.3332/ecancer.2018.804. eCollection 2018.
    • Communication of cancer-related genetic and genomic information: A landscape analysis of reviews.
    • Peterson EB, Chou WS, Gaysynsky A, Krakow M, Elrick A, Khoury MJ, Kaphingst KA.
    • Transl Behav Med. 2018 Jan 29;8(1):59-70. doi: 10.1093/tbm/ibx063.
    • The risk of unjustified BRCA testing after the "Angelina Jolie effect": how can we save (laboratory) medicine from the Internet?
    • Lippi G.
    • Clin Chem Lab Med. 2018 Jan 26;56(2):e33-e35. doi: 10.1515/cclm-2017-0551.
    • Letter
    • Improving attendance to genetic counselling services for gynaecological oncology patients.
    • Pokharel HP, Hacker NF, Andrews L.
    • Gynecol Oncol Res Pract. 2018 Jan 10;5:2. doi: 10.1186/s40661-018-0059-z. eCollection 2018.
    • Evaluation of a 27-gene inherited cancer panel across 630 consecutive patients referred for testing in a clinical diagnostic laboratory.
    • Gardner SA, Weymouth KS, Kelly WS, Bogdanova E, Chen W, Lupu D, Suhl J, Zeng Q, Geigenmüller U, Boles D, Okamoto PM, McDowell G, Hayden MA, Nagan N.
    • Hered Cancer Clin Pract. 2018 Jan 4;16:1. doi: 10.1186/s13053-017-0083-8. eCollection 2018.
    • Genetic Testing for Hereditary Breast Cancer: The Decision to Decline.
    • White VB, Walsh KK, Foss KS, Amacker-North L, Lenarcic S, McNeely L, White RL Jr..
    • Am Surg. 2018 Jan 1;84(1):154-160.
    • Your Genes: One Size Doesn't Fit All.
    • Freivogel ME, Cohen SA.
    • J Natl Compr Canc Netw. 2018 Jan 1;16(1):2-3. doi: 10.6004/jnccn.2017.7055.
    • Commentary

    Related:

    Commentary:

    Your Genes: Getting the Best Fit.

    • Comparing Outcomes of Genetic Counseling Options in Breast and Ovarian Cancer: An Integrative Review.
    • Fournier DM, Bazzell AF, Dains JE.
    • Oncol Nurs Forum. 2018 Jan 1;45(1):96-105. doi: 10.1188/18.ONF.96-105.
    • Review
    • Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer.
    • Szender JB, Kaur J, Clayback K, Hutton ML, Mikkelson J, Odunsi K, Dresbold C.
    • Int J Gynecol Cancer. 2018 Jan;28(1):26-33. doi: 10.1097/IGC.0000000000001122.
    • Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families.
    • Vicuña B, Delaney HD, Flores KG, Ballinger L, Royce M, Dayao Z, Pal T, Kinney AY.
    • J Community Genet. 2018 Jan;9(1):81-92. doi: 10.1007/s12687-017-0322-8. Epub 2017 Oct 2.
    • ACOG Committee Opinion No. 727: Cascade Testing: Testing Women for Known Hereditary Genetic Mutations Associated With Cancer.
    • [No authors listed]
    • Obstet Gynecol. 2018 Jan;131(1):e31-e34. doi: 10.1097/AOG.0000000000002457.

    Related:

    Summary:

    ACOG Committee Opinion No. 727 Summary: Cascade Testing: Testing Women For Known Hereditary Genetic Mutations Associated With Cancer.

    Press: 'Cascade Testing' Important for Hereditary Gynecologic Cancers: ACOG (Medscape/Reuters)

Continue to Older References